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ABSTRACT 
USING MARGINAL STRUCTURAL MODELS TO CONTROL FOR TIME-DEPENDENT CONFOUNDING  
AND TO DETECT EFFECT MODIFICATION IN A RANDOMIZED CONTROL TRIAL  




Elizabeth A. Lancet 
 
 
Advisor: Luisa N. Borrell, DDS, PhD 
 
 
Background: Unlike traditional regression used in the Intention to Treat (ITT) approach, Marginal 
Structural Models (MSM) can account for joint effects of baseline and subsequent treatments as well as 
the presence of time-dependent confounding influenced by prior treatment and selection bias due to 
censoring. In addition, MSMs have been theorized to be able to assist investigators in determining the 
overall benefit of a drug in the total population as they are able to provide a summary effect size across 
all strata of an effect modifier which cannot be done via tradition regression techniques.  The overall 
goal of this dissertation is to demonstrate the advantages and disadvantages of using MSM to 1) control 
for time-dependent confounding and 2) detect effect modification in a randomized controlled trial (RCT) 
with a time-varying exposure, non-adherence and missing data.  
 
Methods: The ITT analysis consisted of a logistic regression model linking the annual rate of acute 
asthma exacerbations (outcome) to assigned asthma treatment. Weights for the MSM analysis were 
derived from a pooled logistic regression assessing the probability of staying on assigned treatment 
(adherence) and, in Aim 1 and 3, of remaining uncensored for subjects at each visit by treatment arm.  
Poisson regression models using PROC GENMOD were fitted for the annual rate of acute asthma 
exacerbations (outcome) as a function of the assigned treatment using the weighted sample and a 
generalized estimating equation (GEE) with an independent correlation matrix in Aims 1 and 3.  The final 
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outcome model in Aim 2 also included a treatment covariate interaction term.  In all aims, the final 
models were fit to uncensored cases with complete data.   
 
Results: Despite the theoretical advantages of MSMs, my research found that the approach failed to 
invalidate previous ITT analyses, regardless of adherence level.  In Aim 1, the ITT analysis found a 22% 
increased risk of EPACs for theophylline compared with montelukast (RR=1.22, 95% CI: 0.82-1.86, 
p=0.35), no increased risk between theophylline and placebo (RR=0.99, 95% CI: 0.67-1.50, p=1.00), and 
an 18% decreased risk of EPACs between montelukast and placebo (RR=0.82; 95% CI: 0.55-1.21, p=0.31) 
for the ITT approach.  This was in comparison to a 24% increased risk of EPACs for theophylline 
compared with montelukast (RR=1.24, 95% CI: 0.83-1.84, p=0.28), no increased risk between 
theophylline and placebo (RR=1.01, 95% CI: 0.70-1.48, p=0.95), and a 17% decreased risk of EPACs 
between montelukast and placebo (RR=0.83; 95% CI: 0.57-1.19, p=0.27).  In Aim 3, despite finding a 
statistically significant difference in adherence rates between the self-reported group and the blood 
assay group over time (p=0.001), adjusted rate ratios and corresponding 95% confidence intervals 
obtained were nearly identical and in both cases non-significant.  In the self-report group, those on 
theophylline were 28% more likely to have an asthma exacerbation than those in the montelukast group 
(95% CI: 0.85-1.94, p=0.24) compared with 24% in the blood assay group (95% CI: 0.84-1.84, p=0.28).  In 
Aim 2, the MSM analysis was able to detect effect modification by race in one of the treatment groups 
(montelukast).  In the unadjusted analysis, non-whites were twice as likely to have an EPAC on 
montelukast as their white counterparts (5.75 vs. 2.66 episodes per person year, p=0.0034).  Similar 
findings were seen for increased medication use and health care visits.  Results of the MSM also 
indicated the presence of effect modification for overall EPACs, medication use and unscheduled health 
care when treated with montelukast instead of placebo.  Compared with whites, non-whites were more 
than twice as likely to suffer from an EPAC on montelukast as on placebo (RR=2.13, 95% CI: 1.08-4.46, p= 
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0.04) and almost 3 times as likely to increase medication use (RR=2.86, 95% CI: 1.10-7.42, p=0.03).  Non-
whites were over 5 times more likely to have unscheduled health care visits than whites while on 
montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02).   
 
 
Conclusions:  In theory MSMs hold much potential for further analyses of RCTs as it allows adjustment 
for time-varying exposures, time-dependent confounding and selection bias, issues more traditional 
regression based methods cannot account for.  However, it remains unclear as to whether this is the 
case in practice.  At the very least, MSMs should be conducted as a sensitivity analysis to the ITT 
approach in RCTs where there is preliminary evidence suggesting the presence of time-varying 
exposures, time-dependent confounding and/or selection bias and when MSM’s limitations can be 
reasonably ignored.  Conducting a MSM as a sensitivity analysis of the ITT can only bolster one’s 
confidence of the estimated effects of treatment on an outcome.  In terms of effect modification, more 
research is needed to determine the most appropriate way to calculate inverse probability treatment 
weights propensity scores as there is no consensus in the literature on how best to calculate the 
propensity scores required for weighting and achieve accurate subgroup results.   
 
Keywords: clinical trials, intention to treat, marginal structure models, inverse probability weighting, 
causal inference  
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Chapter 1. Introduction to Marginal Structural Models  
 
Marginal structural models (MSM) are a class of statistical models commonly used to estimate causal 
effects in observational and non-experimental studies due to their ability to account for time-dependent 
confounding as well as selection bias.1–3  In essence, MSMs measure all prognostic factors (confounders 
and/or mediators) that may affect either adherence to an exposure or loss to follow up (attrition) in an 
attempt to eliminate all back door pathways that may bias the association between the exposure and the 
outcome.1–6    
 
Formally, MSMs relates any possible exposure and censoring history, up to time t, to the corresponding 
counterfactual outcome at time t.7–11  In other words, these models allow for the estimation of all 
potential outcome-exposure combinations for each study visit, despite the fact that only one response for 
a given exposure per visit will be observed in the data, with the rest “counter to the facts”.  This is possible 
because it is assumed that the average causal effect of treatment is dependent on whether the choice of 
an exposure at a particular time point is affected by the presence of time-dependent confounding.  If all 
time-dependent confounders are eliminated then it can be assumed that all subjects had adhered to their 
assigned treatment and therefore, the exposure is said to have a causal effect on the outcome, i.e. there is 
a difference in the counterfactual outcomes under two or more treatment regimes.2–4,11  As MSMs 
describe the marginal causal expectation of a potential outcome as a function of a specified treatment 
regimen, the observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) will equal the unknown counterfactual 
risk ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).   
 
The parameters of a MSM are estimated using inverse probability weighting (IPW) which 
calculates weights based on the inverse of the predicted joint probabilities (i.e. propensity score values) of 
an individual’s treatment and censoring history conditional on their observed set of covariates.1–6,12  In 
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other words, instead of modeling the relationship between a covariate and the outcome as is done in 
traditional regression, IPW models the relationship between covariates and missingness with that of the 
putative cause, i.e. exposure.  This ensures that the reweighted population is a representative sample 
from the original study population in which each participant completed follow-up, all measured covariates 
are balanced across exposure groups and all mediators are removed from the causal pathway.  Once 
confounding is “eliminated”, a standard repeated measure model can then be fitted for the outcome as a 
function of the treatment history using the weights and a robust ‘sandwich’ variance estimator.2,4,6,8,10,13–16   
 
Another potential benefit of marginal structural models is the purported ease in which effect modification 
can be detected by the simple addition of a treatment covariate product term to the final logistic model 
weighted by the inverse probability weights.2,9,12  Most importantly, unlike traditional regression models, 
MSMs can provide a summary effect size across all strata of the effect modifier that assists investigators in 
determining the overall benefit of a drug in the total population.    
 
When assessing effect modification using MSMs, it is assumed that the causal effect of treatment on an 
outcome is dependent on whether the choice of a treatment option at a particular time point is affected 
by the presence of time-dependent confounding (L) for every level of the effect modifier (M).  While 
technically no longer a true marginal structural model because the causal effect is now conditional on M, it 
is generally accepted that as long as all time-dependent confounders are eliminated, stratum-specific 
associational risk ratios can be interpreted as a stratum-specific causal effect of treatment, i.e. there is a 
difference in the counterfactual outcomes under two or more treatment regimes in each level of M.6,9,12,17  
Therefore, there is conditional exchangeability given L and as such, the observed risk difference (Pr[Y =1 
│A=1, M=m] - Pr[Y =1 │A=0, M=m]) or risk ratio (Pr[Y =1 │A=1, M=m] / Pr[Y =1 │A=0, M=m]) will equal the 
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unknown counterfactual risk difference (Pr[Ya=1 =1 | M=m] – Pr[Ya=0 =1 | M=m]) or risk ratio (Pr[Ya=1 =1 | 
M=m] / Pr[Ya=0 =1 | M=m]), respectively.   
 
Summary and gaps in Current Literature  
Confounding 
Despite the theoretical advantages of MSMs in assessing the average causal effect of a time varying 
exposure on a target outcome, the approach has rarely been used in the analysis of randomized clinical 
trials (RCTs).  This is mainly due to the perceived superiority of the intention to treat (ITT) analysis to 
estimate average causal effects.  In an ITT, the analysis is focused on estimating the size of the difference 
in predefined outcomes between intervention groups.  Subjects are analyzed according to their assigned 
randomized treatment group, regardless of their adherence to assignment, subsequent withdrawal from 
treatment or deviation from the protocol.  With complete adherence and no loss to follow, the ITT 
analysis not only preserves baseline randomization, i.e. exchangeability, but it maintains an adequate 
sample size and addresses the pragmatic hypotheses about the clinical utility of treatment.18–21  In these 
ideal RCTs, association is causation i.e. the observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) equals the 
unknown counterfactual risk ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).   
 
Unfortunately RCTs are not infallible, with many suffering from the presence of non-adherence and 
missing data.  As the proportion of subjects who deviate from the trial increases, the more the trial begins 
to resemble a prospective observational study with baseline randomization - along with associated biases 
not traditionally found in RCTs.3–5,9  For example, non-adherence to treatment can cause confounding if 
prognostic factors that affect treatment decisions are unequally distributed across groups, while loss to 




An added complication of longitudinal research is that treatment selection and/or covariates may take on 
different values at different points in time.  In fact, research has indicated that adherence to assigned 
treatments and staying in a trial depends more on a subjects’ evolving covariate histories than on baseline 
randomization.18–20,22   If these evolving covariates happen to cause the outcome and/or bring about 
changes in treatment selection at points post randomization then time dependent confounding occurs.5,23  
Time dependent confounding is a problem as 1) the confounder may also simultaneously become a 
mediator between the current exposure and outcome and 2) selection bias may occur if levels of 
nonadherence or censorship are dependent on covariates affected by prior treatment selection.   
 
In both situations, traditional linear regression models used in the ITT approach may cause estimates to be 
biased towards the null as 1) the analysis included every subject assigned a treatment at baseline despite 
their true outcome2,5,18,24 and 2) these models cannot adjust for intermediate variables or the cumulative 
effect of treatment on the outcome.2,7,14,25,26   While a conservative effect estimate is always preferred to 
an exaggerated result, there is still a possibility that a Type II error will occur, causing investigators to 
wrongly claim no difference between treatments.2,6  
 
Of the few studies that have compared ITT to MSM in the estimation of average causal effects in RCTs with 
imperfect adherence and follow up, most have found that the latter approach resulted in slightly less 
biased estimates, albeit similar interpretation of findings.27,28,29  One notable exception was that of Toh et 
al. who reanalyzed the original ITT data analysis from the Women’s Health Initiative trial examining 
whether the use of continuous hormone therapy increased the risk of breast cancer.27  While overall 
inferences were grossly similar, the risk of breast cancer was more than two-fold higher in women with 
continuous hormone use when using MSM (HR: 1.68; 95% CI: 1.24-2.28) compared to ITT (HR: 1.25; 95% 
CI: 1.01-1.54).  The authors concluded that the change in magnitude was most likely due to an increase in 
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the proportion of women not adhering to the protocol over time, leading to differential loss-to-follow-up.  
In fact, the original authors confirmed that 40% of women had stopped taking at least 80% of their 
assigned treatment by the 6th year of follow up, a finding that was not taken into account in the ITT 
analysis.30   The other studies who compared ITT to MSM were much shorter in duration and had much 
lower levels of non-adherence and lost to follow up.28,29 
 
This begs the question as to whether a threshold exists as to the level of non-adherence and/or censorship 
most appropriate for the use of MSM compared with ITT.  Unfortunately, there are no known studies that 
have looked into this - most likely due to the complexities of measuring adherence in RCTs.  First, there is 
not a standard definition of what constitutes adherence.27,31–34  Adherence can be thought of as an all or 
nothing response – always vs. never taking the assigned therapy – or as a continuum in which patients can 
be adherent or non-adherent only part of the time, i.e. discontinuing therapy prematurely, deviating from 
instructions but still taking the medication.  Second, there is no standard method of assessing adherence 
in clinical trials and usually only one method is used per trial.31,32,34–36 
 
Effect Modification 
There are even fewer instances in the literature where MSMs have been used to detect effect 
modification and none have occurred in RCTs.  Findings from observational studies have indicated that 
MSMs do lead to similar estimates when compared with traditional regression models.2,12,37–41  For 
example, Chiba et al analyzed data from the Western Collaborative Group observational cohort study and 
found similar incidence in coronary heart disease after examining the interaction of personality behavior 
and smoking using MSM and standard log linear regression (IRR: 0.69 vs. 0.66).12    
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Overview of the dissertation 
The overall goal of this dissertation is to demonstrate the advantages and disadvantages of using MSMs to 
1) control for time-dependent confounding and 2) detect effect modification in a RCT with a time-varying 
exposure, non-adherence and missing data.  
 
Specific aims  
The following specific aims were addressed: 
 
AIM 1: To demonstrate the advantages and disadvantages of using MSMs to check the validity of an ITT 
analysis in a RCT with a time-varying exposure, non-adherence and missing data assessing treatment 
effectiveness on asthma control. 
 
AIM 2: To demonstrate the advantages and disadvantages of using MSMs to detect effect modification by race 
in a RCT with a time-varying exposure, non-adherence and missing data assessing treatment 
effectiveness on asthma control.  
 
AIM 3: To demonstrate whether the use of different adherence metrics has any effect on the direction and 
magnitude of the causal effect of asthma treatments on the rate of episodes of poor asthma 
control using MSMs in a RCT with a time-varying exposure, non-adherence and missing data 
assessing treatment effectiveness on asthma control.    
 
Organization of the dissertation 
Following this introduction, the dissertation contains four additional chapters.  Chapter 2 assesses 
confounder control using MSMs as stated in Aim 1 while Chapter 3 evaluates whether MSMs can detect 
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effect modification (Aim 2).  Chapter 4 is similar to that of Aim 1 as it assesses confounder control using 
MSMs; however, it goes further by examining whether different metrics of adherence has any effect on 
the outcome.  Chapter 5 summarizes findings from Aims 1-3, discusses the strengths and limitations of all 
the analyses and concludes with policy implications and directions for future research. 
 
Data source 
All three aims of this dissertation use data from the Low Dose Theophylline as Add-On Therapy in the 
Treatment of Asthma (LODO) trial, conducted by the American Lung Association Asthma Clinical Research 
Centers (ACRC).42   The ACRC is a network of clinical centers throughout the country dedicated to 
improving asthma outcomes in diverse populations.  Between 1999 and 2015, the network completed 
over ten trials that had a direct impact on the lives of asthma participants and the cost of their care, 
recruiting more than 5,000 participants with asthma.43    All data collected from the clinical sites are 
managed and analyzed by a Data Coordinating Center at Johns Hopkins University.  An overview of ACRC 
studies is reported elsewhere.44  Since 2015, the ACRC was renamed as the Airways Clinical Research 
Centers and its mission was expanded to include other obstructive lung disease such as COPD.  This 
change in focus is not relevant to this paper and when discussing the ACRC, it will refer to the network as 
it was between 1999 and 2015. 
 
Study population  
LODO was the ACRCs second trial that began in 2002 and ran throughout 2003.  It aimed to evaluate 
whether low-dose theophylline was as effective as an add-on therapy in treating asthmatics compared 
with 1) anti-leukotriene antagonist montelukast and 2) placebo.  To be eligible for the study, participants 
had to be over the age of 15 years, have physician-diagnosed asthma, have been prescribed daily asthma 
medication for at least a year, have an FEV1 of 50% or more of predicted values and have a score of 1.5 or 
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greater on the Asthma Control Questionnaire.  Potential participants who smoked or used oral 
corticosteroids, leukotriene antagonists or theophylline with four weeks preceding enrollment or had 
other significant illness were ineligible to participate. In total 488 patients were randomized and 
participated in the study. 
 
Study design 
LODO was a multicenter, randomized, double-blind, parallel design and placebo-controlled trial. 
After a one to two week run-in, eligible participants were randomized in a stratified permuted block 
method in a 1:1:1 allocation ratio to 300mg/day theophylline (n=160) or 10mg/day montelukast (n=164) 
or placebo (n=164) – in addition to their existing asthma therapy.  Participants were followed for six 
months (24 weeks), attended three follow-up visits (one, three and six months after randomization) and 
were contacted by phone periodically in between visits to ensure the participant was not experiencing any 
problems associated with study participation.  Data collected through diaries included sociodemographic 
characteristics, recorded peak expiratory flow rates, medical history and asthma symptoms. Medication 
adherence was assessed three ways – by 1) diary cards; 2) visit patient care questionnaires and 3) the 
collection of plasma montelukast or theophylline concentrations at one and six months.   
 
Primary Data Analysis Results 
LODO achieved a sample size that had 80% power to detect a 15% difference in the proportion of patients 
experiencing one or more asthma exacerbations between active treatment groups and placebo, assuming 
that 50% of the placebo group had an episode of poor asthma control (EPAC).  Poisson regression models 
with Huber-White variance estimates were used to calculate event rates of EPACs.  Linear and logistic 
regression models with generalized estimating equations (GEE) were used to evaluate differences among 




Despite initial hypotheses that adding low dose theophylline to the treatment of persistently symptomatic 
patients would decrease the rate of asthma exacerbations when compared with placebo add-on 
treatment, ACRC investigators found no difference in EPAC rates between the three treatment groups; 
theophylline 4.9 (95% CI: 3.6-6.7); montelukast 4.0 (95% CI: 3.0-5.4) and placebo 4.9 (95% CI: 3.8-6.4).42   
 
Follow up throughout the 24 week study remained strong with 95% of patients completing diary cards and 
94% completing follow-up spirometry.  However, adherence to therapy faltered throughout the study 
period.  Overall, self-reported adherence to the study drugs was 84% for theophylline and 88% for both 
montelukast and placebo yet plasma drug concentrations indicated that actual adherence to the study 
drugs was even lower at 79% and 71% at 4-weeks for theophylline and montelukast, respectively, and at 
60% in both groups at week 24.   
 
Outcomes 
The primary outcome for all dissertation aims mirrored that of the original ITT analysis - the annual rate of 
acute asthma exacerbations (events/person/time).  This was defined as having at least one of the 
following episodes of poor asthma control (EPACs):    
 
• 30% drop in peak flow for 2 consecutive days; or 
• Increase of 2 or more used of rescue medication (4 puffs MDI, 2 nebulizer uses); or 
• New course of oral steroids for asthma; or 




This composite outcome measure was used to reflect the several dimensions of good asthma control, 
including physiology, symptoms and health care use.  It should be noted that EPACs is not a standardized 
composite measure of asthma control and this definition was created by the ACRC for this and other trials.   
 
Statistical analysis 
Inverse Probability Weighting Models  
Pooled logistic regression models were fitted separately for the probability of staying on assigned 
treatment (adherence) and, in Aim 1 and 3, of remaining uncensored for subjects at each visit by 
treatment arm. The dataset for these models was discretized into one observation per subject per visit so 
that 1) time could be fit as a class variable to allow a separate intercept for each time and 2) lagged 
variables for previous treatment and confounder histories would be comparable between subjects.  
Stabilized treatment weights were created by dividing the baseline probability of selecting a treatment 
(numerator in equation 1) by the probability of selecting treatment given prior treatment history and 
potential confounders up to time t (denominator in equation 1).  Calculation of the censored probabilities 
mirrored that of treatment weights but had to be offset by one visit as censoring looked forward i.e. ‘did 
the subject return for a following visit?’ compared with ‘what was the treatment at the previous visit?’ 
(equation 2).  Each covariate was entered in the pooled logistic models as a main effect only. 
 
Resulting predicted probabilities were then used to construct the final stabilized treatment and censoring 
weights for each subject at each visit.  For the Inverse Probability Treatment Weights, the pooled logistic 
regression models provided the estimated probability of remaining on assigned treatment, so the next 
step was to subtract the propensity score by 1 to get the probability of not staying on assigned treatment 
for those who were non-adherent.  Once all subjects had a stabilized weight for each visit, a final stabilized 
weight per participant was obtained by multiplying the estimated probability of their observed treatment 
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at each visit cumulatively over time, i.e. the first score was left as is, and for all others, the scores at the 
current visit was multiplied by the score of the previous visit.  For the Inverse Probability Censoring 
Weights, the estimated probabilities of being uncensored for each visit were multiplied cumulatively over 
time.  The final Inverse Probability Weight for each subject was the product of the treatment selection 
weights and the censoring weights.  
 
Outcome Models 
Poisson regression models using PROC GENMOD were fitted for the annual rate of acute asthma 
exacerbations (outcome) as a function of the assigned treatment using the weighted sample and a 
generalized estimating equation (GEE) with an independent correlation matrix in Aims 1 and 3.  The final 
outcome model in Aim 2 also included a treatment covariate interaction term.  In all aims, the final models 
were fit to uncensored cases with complete data.   
 
All data management procedures were conducted with SAS 9.4 (SAS Institute, Cary, NC).45  
 
Applications of findings 
Information obtained from ITT analyses can be important information for policy makers and health planners, 
but patients and clinicians usually prefer to know what are the benefits and risk of receiving a treatment rather 
than being assigned to one.  When analyzing clinical trial data that resemble a prospective observational study, 
using an approach like MSMs may provide more clinically relevant information due to its ability to 
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Chapter 2: Using Marginal Structural Models to check the validity of 
Intention to Treat analysis in the presence of non-adherence and missing 
data 
 
Background: The intention to treat (ITT) analysis is the cornerstone statistical method used to analyze 
data from randomized controlled trials (RCT).  However, in the presence of non-adherence and missing 
data, results of the ITT analysis may be biased as it is measuring the effect of assignment rather than the 
effect of treatment. The purpose of this study is to demonstrate the advantages and disadvantages of 
using MSMs to check the validity of ITT analyses in the presence of non-adherence and missing data.  A 
RCT of treatment of asthma is used as working model. 
 
Methods: The ITT analysis consisted of a logistic regression model linking the annual rate of acute asthma 
exacerbations (outcome) to assigned asthma treatment. Weights for the MSM analysis were derived from 
a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of 
remaining uncensored for subjects at each visit by treatment arm.  The weighted sample was then pooled 
into a MSM analysis using a Poisson generalized estimating equation (GEE) with an independent 
correlation matrix. 
 
Results: The adjusted rate ratio, and corresponding 95% confidence intervals, obtained from the MSM 
were nearly identical to that of the ITT analysis, indicating that adherence and censoring were not a 
significant problem in these data and that the baseline randomization held throughout the trial. 
 
Conclusions:  MSMs allow adjustment of the ITT analysis for time-varying confounding and selection bias 
due to censoring, issues more traditional regression based methods cannot account for.  MSMs should be 
conducted as a sensitivity analysis to the ITT approach in RCTs when time-varying non-adherence is 
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suspected or data are missing. Concordance between the ITT and the MSM analysis indicates that 
adherence and censoring may not invalidate the ITT analysis. 
 
Keywords: clinical trials, intention to treat, marginal structure models, inverse probability weighting, 






Randomized controlled trials (RCT) commonly use the Intention to Treat (ITT) approach to provide unbiased 
comparisons among treatment groups.  When there is full compliance and no loss to follow up, this analytical 
approach will maintain the prognostic balance generated from the original randomization, allowing for causal 
inference.1,2  Unfortunately, most clinical trials will have some levels of non-adherence and missing data, 
making them more like longitudinal studies with baseline randomization and causing results from an ITT 
analysis to be biased towards the null and  to cause a Type II error in which investigators will claim no 
difference in treatment when there might actually be an important difference.2–4 
 
Marginal Structured Models (MSM) have been increasingly used to estimate causal effects in 
observational studies, replicating measures most commonly reported in RCTs.1,3,5 In essence, MSM 
measure all post randomization prognostic factors (confounders and/or mediators) that may affect either 
adherence to treatment choices or loss to follow up (attrition) in an attempt to eliminate all back door 
pathways that may bias the association between the treatment and the outcome, making the baseline 
randomization once again valid.1,3–7  The parameters of a MSM are estimated using inverse probability 
weighting (IPW).  IPW first calculates the inverse of the predicted joint probabilities (i.e. propensity score 
values) of an individual’s treatment and censoring history, conditional on their observed set of covariates.  
These propensity scores are then weighted such that the reweighted data are balanced on the exposure of 
interest at each point in time during the follow-up.  A final weighted model is then fitted using these 
weights with only a function of exposure history predicting the outcome of interest, together with a 
robust ‘sandwich’ variance estimator. 
 
In this paper, I utilize MSMs to check the validity of ITT analyses in the presence of a time-varying 
treatment, non-adherence and missing data.  This is a secondary data analysis of the American Lung 
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Association Asthma Clinical Research Centers (ACRC) Low Dose Theophylline as Add-On Therapy in the 
Treatment of Asthma (LODO) trial.8  LODO evaluated the effectiveness of low dose theophylline, a drug 
known for its narrow therapeutic window and severe interactions with various drugs, in maintaining 
asthma control in mild to moderately severe asthmatics compared with the widely used anti-leukotriene 
antagonist montelukast (Singulair) and placebo, respectively.  The ITT analysis published by the ACRC 
found no difference between treatment groups when assessing Episodes of Poor Asthma Control (EPACs), 
despite initial hypotheses  that adding low dose theophylline to the treatment of persistently symptomatic 
participants would decrease the rate of asthma exacerbations when compared with placebo and would be 
equally effective as the more popular and expensive drug, montelukast.  While study participants were 
randomized to treatment initially, noncompliance and censorship occurred in each of the follow up 
periods.  As the decision to terminate treatments or drop out of the study is a nonrandomized event, 
influenced by both subject attributes and previous treatment, it was assumed that time dependent 
confounding may have caused the results of the ITT to be biased towards the null. 
   
Intention-To-Treat Approach 
In epidemiology, randomized controlled trials (RCT) are considered the most rigorous study design for 
assessing the efficacy and/or safety of medicine.9–12   This is due to several important methodological 
features such as randomization, blinding and the intention to treat (ITT) analysis, all of which theoretically 
exert control over most threats to internal validity.   
 
The act of randomization minimizes the likelihood of prognostic differences between treatment groups 
preventing selection bias and confounding on baseline participant characteristics commonly found among 
other study designs. Baseline randomization ensures that not only are the treatment groups 
exchangeable, i.e. the risk of the outcome in one group would have been the same in the second group if 
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all subjects received the same treatment, but that any differences seen between the groups occurred by 
chance.11  Blinding, on the other hand, minimizes the likelihood of differential treatment or assessments of 
outcomes preventing performance and ascertainment bias after randomization.9,10  The concealment of 
intervention group allocations from both participants and study investigators, in theory, ensures that all 
study subjects will be treated equally except for the experimental treatment. 
 
Yet, many believe that the simplicity of the ITT analysis is the real reason behind the RCT's perceived 
superiority.  Under ideal conditions, the ITT analysis not only preserves baseline randomization but it 
maintains an adequate sample size and addresses the pragmatic hypotheses about the clinical utility of 
treatment.9,10,12,13  In an ITT, the analysis is focused on estimating the size of the difference in predefined 
outcomes between intervention groups.  Subjects are analyzed according to their assigned randomized 
treatment group, regardless of their adherence to assignment, subsequent withdrawal from treatment or 
deviation from the protocol. By including noncompliant participants and dropouts in the final study 
population, power is maintained, minimizing the chance of a Type II error – the failure to reject a false null 
hypothesis.  The ITT also avoids overoptimistic estimates of the efficacy of an intervention resulting from 
the removal of non-compliers by accepting that noncompliance and protocol deviations are likely to occur 
in actual clinical practice.  As such, one can claim that with full compliance and no loss to follow up, the 
results of the ITT will be unbiased estimates of the treatment effects, as the analysis will maintain the 
prognostic balance generated from the original randomization.1,2,6,13  In these ideal RCTs, association is 
causation i.e. the observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) equals the unknown counterfactual 
risk ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).   
 
Unfortunately, the presence of non-adherence and missing data are all too common in RCTs and as the 
proportion of subjects who deviate from the trial increases, the more the trial begins to resemble a 
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prospective observational study - along with all its associated biases not traditionally found in RCTs.4–6,11  
For example, non-adherence can cause confounding if prognostic factors that affect treatment decisions 
are unequally distributed across groups, while loss to follow-up may cause attrition bias if prognostic 
factors affect decisions to stay in the study.  Furthermore, research has indicated that subsequent values 
of received treatment depend more on evolving covariate histories than on baseline randomization, which 
may affect the level of non-adherence and loss to follow up, increasing the likelihood of cross 
contamination, confounding and selection bias.9,12–14 
   
By avoiding the issue of post-randomization exchangeability, estimates from the ITT analysis may be 
biased towards the null because the analysis included every subject assigned a treatment at baseline 
despite their true outcome i.e. “once randomized, always analyzed”.2–4,13  While a conservative effect 
estimate is always preferred to an exaggerated result, there is still a possibility that a Type II error will 
occur, causing investigators to wrongly claim no difference between treatments.3,7  Furthermore, 
traditional regression models used in an ITT analysis may fail to adjust appropriately when there are time 
dependent covariates that act simultaneously as confounders and intermediate variables.3,15–18  This 
‘circular’ relationship can result in conditional associations or selection bias, where none existed at 
baseline, and may lead to an underestimate the impact of the cumulative effect of treatment on 
outcome.  In any event, association can no longer be considered causation as exchangeability is not met, 
i.e. Pr [Y =1 │A=1] / Pr [Y =1 │A=0] ≠ Pr [Ya=1 =1] / Pr [Ya=0 =1], and estimates will be biased.    
 
Marginal Structural Models  
Marginal structural models (MSM) can be used to estimate effects of time-varying treatment selection in 
the presence of time-dependent confounding and censoring in longitudinal studies.3,6,15,19–21  A concern 
with estimating effects that span more than one time point is that  it is assumed that a subjects’ behavior 
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and subsequently the distribution of risk factors will change with time.  For example, if participants who 
do not comply with treatment or who are censored differ from those who comply or are still being 
followed, then imbalances with respect to the risk factors by treatment group (confounding) can occur 
and this imbalance can fluctuate over time.  Furthermore, in the presence of time-dependent 
confounding, a confounder may be simultaneously a mediator between the current exposure and 
outcome.  If reasons for nonadherence or censorship are due to covariates that have been affected by 
prior treatment, selection bias will occur and estimates from traditional regression models will be biased 
as they cannot adjust for intermediate variables.  Unlike conditional regression approaches, MSMs 
account for both the joint effects of baseline and subsequent treatments and for the presence of time-
dependent confounding influenced by prior treatment, by modeling exposures at each follow up and the 
final outcome.3,6,15,21 
 
Formally, MSM is a regression model for longitudinal data that relates any possible exposure and 
censoring history, up to time t, to the corresponding counterfactual outcome at time t.11,17,19,22,23  In other 
words, these models allow for the estimation of all potential outcome-treatment combinations for each 
study visit, despite the fact that only one response for a given treatment level per visit will be observed in 
the data, with the rest “counter to the facts”.  This is possible because it is assumed that the average 
causal effect of treatment is dependent on whether the choice of a treatment option at a particular time 
point is affected by the presence of time-dependent confounding.  If all time-dependent confounders are 
eliminated then it can be assumed that all subjects had adhered to their assigned treatment and 
therefore, the exposure is said to have a causal effect on the outcome, i.e. there is a difference in the 
counterfactual outcomes under two or more treatment regimes.3,5,6,23  As MSMs describes the marginal 
causal expectation of a potential outcome as a function of a specified treatment regimen, the 
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observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) will once again equal the unknown counterfactual risk 
ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).   
 
MSM parameters are estimated using inverse probability weighting (IPW).  IPW adjusts for post-
randomization confounding and selection bias due to 1) non-adherence, 2) mediators and 3) loss to follow 
up by creating a pseudo-population where the time-varying treatment is independent of stable and time-
varying covariates that preceded it, at every time point allowing for causal treatment comparisons using 
standard repeated measure models.3,6,7,18–22,24  Instead of modeling the relationship between a covariate 
and the outcome as is done in the ITT approach, IPW models the relationship between covariates and 
missingness with that of the exposure. 
 
Conducting an MSM-IPW analysis is a two-step process.  The first step is to estimate each subject’s 
probability of 1) having their own treatment history and 2) having their own censoring history at each 
time-point and then use these to derive Inverse Probability Treatment (IPT-) and Inverse Probability 
Censoring (IPC-) weights.  The second step is to estimate the treatment-outcome association in 
a conventional regression model for repeated measures that is weighted by the product of IPT- and IPC- 
weights.   
 
Weights can be are either non-stabilized or stabilized.  The former is estimated by taking the reciprocal of 
the probabilities of receiving treatment given the covariates (1/p for those treated and 1-1/p for those 
untreated), while the latter adds a numerator representing the overall probability of being treated for 
those who were treated and of not being treated for those who were not treated using baseline covariates 
only.  As the numerator and denominator in stabilized weighting will share common factors, the weights 
will be less variable, the sample size will be close to that of the original population and there will be less 
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chance of Type 1 errors.3,7,24  Therefore, stabilized weights increase statistical efficiency attains better 
coverage of confidence intervals and is recommended when using IPW to fit a marginal structural model.  
For the purposes of the following analysis, I will be referring to stabilized inverse probability weights.  
 
Treatment Weights 
Confounding due to non-adherence in RCTs is eliminated through the application of an inverse-
probability-of-treatment weighting (IPTW).1,4,11  IPTWs adjust for imbalances in the characteristics of the 
treated and untreated participants.  It is fit by building a predictive model for receiving the treatment of 
interest given past treatment and prognostic factor history at each time point and then obtaining a single 
weight per subject by multiplying the current treatment weight with that of the treatment weights from 
the previous time points.  Most researchers do this in one step by fitting pooled logistic regression 
treatment models with time as a class variable to allow a separate intercept for each time.  The resulting 
predicted probabilities (i.e. propensity scores) are used to construct the stabilized weights for each subject 
at each time point during follow-up.  The treatment weights are defined as: 
 
𝑆𝑆𝑆𝑆(𝑡𝑡) =  ∏ 𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝑉𝑉] 
𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝐿𝐿(𝑘𝑘),𝑉𝑉]
𝑡𝑡
𝑘𝑘=0  Equation 1 
 
The denominator of the model represents the probability that the subject received their own treatment 
history (ƒAk), given all prior treatments (Ak-1) and covariate histories (L) until the last visit (k) for all possible 
treatments (R). The numerator acts as a stabilizing factor to reduce the variance of the estimates and 
represents the overall probability of being treated for those who were treated and of not being treated for 
those who were not treated.  When analyzing RCTs with baseline randomization, the value of A at time 0 






To account for attrition bias due to loss to follow up, one may also calculate inverse-probability-of-
censoring weights (IPCW) following the same steps above.11,25  The only difference is that each study 
subject is assigned a weight that is the inverse probability of remaining in the trial for the entire duration 
i.e. uncensored.  The censoring weights are defined as:  
 
𝑆𝑆𝑆𝑆(𝑐𝑐) =  ∏ 𝑓𝑓[𝐶𝐶(𝑘𝑘+1)=0|𝐶𝐶(𝑘𝑘)=0,𝐴𝐴(𝑘𝑘) ] 
𝑓𝑓[𝐶𝐶(𝑘𝑘+1)=0|𝐶𝐶(𝑘𝑘)=0,𝐴𝐴(𝑘𝑘),𝐿𝐿(𝑘𝑘)]
𝑡𝑡
𝑘𝑘=0   Equation 2 
 
where the denominator depicts the probability that the subject remained in the trial given their treatment 
(Ak) and covariate histories (L) until the last visit (k) in each treatment group (R) and the numerator, the 
overall probablity of remaining uncensored per treatment.  The stabilized weights do not eliminate 
censoring in the pseudo-population, they make censoring occur at random with respect to the measured 
covariates.  Complete cases with similar characteristics to those of censored cases are weighted to 
represent those who were lost.   Just as with treatment, when analyzing RCTs with baseline 
randomization, the value of C at time 0 will be 0 as there is no loss to follow up.6,17,22 
 
Treatment-Outcome Model 
When both non-adherence and loss to follow-up are present, the weights from both models (treatment 
and censoring) are multiplied together to form one stabilized weight per participant.  The simulated 
pseudo-population now represents a sample from the actual randomized study population in which each 
participant completed follow up, all measured covariates are balanced across exposure groups, and all 
mediators are removed from the causal pathway.  It is the balance across exposure groups, i.e. 
exchangeability, which allows for unbiased estimates of treatment effects in RCTs without nonadherence 
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and censoring.  Once balance is established, the average causal effect of treatment on the outcome can be 
unbiasedly estimated in a conventional regression model that does not include the measured confounders 
as covariates.  
 
Assumptions 
There are several assumptions that must be met when fitting a MSM. First is the assumption of no 
unmeasured confounders, i.e. conditional exchangeability or sequential randomization.  This assumption 
requires that all covariates which are associated with treatment assignment, outcomes or censorship are 
adjusted for at each visit, enabling treatment selection to once again be random as it was at baseline.5,6,24  
If unobserved confounders are present, then treatment groups will no longer be exchangeable and 
residual bias in the treatment-outcome association can remain.  Therefore, it is important, although not 
empirically verifiable, to ensure that all possible confounders which affect treatment selection and 
outcome are added to the models.     
 
The second assumption of positivity assumes that the conditional probability of receiving either treatment 
and of remaining under complete follow-up will be greater than zero.  Positivity is guaranteed in 
randomized control trials because, by design, there will be individuals assigned to each level of the studied 
treatment and therefore, there is no possibility of a structural violation of positivity.5,11,24 However, 
depending on the sample size and the number of confounders, there can be instances where, at one or 
more levels of the confounders, no one happens to be observed at one or more levels of the exposure 
(zero cells).  These random violations of probability occur by chance and can be corrected by using 




The third is the unverifiable assumption that one is using the correct weighting and analysis models.  Any 
parametric model may be mis-specified by the omission of unmeasured confounders, non-linear terms or 
interactive relationships.  If misspecification occurs, residual bias in the treatment-outcome association 
can remain or, in some cases, even increase.5,18  Sensitivity analyses to test the listed structural model 
specifications above must be done to determine whether the stabilized weights have a mean of 1.0 and a 
minimum and maximum that is not very extreme.  
 
Lastly, it is assumed that all missing data will be missing at random (MAR).  The MAR assumption states 
that conditional on some set of variables that are fully observed, the probability of missing outcome or 
exposure is independent of all variables in the model.20,22,26 
 
Methods 
Study population   
The American Lung Association Airway Clinical Research Centers (ACRC) is a network of clinical centers 
throughout the country dedicated to improving asthma outcomes in diverse populations (figure 2.1).  
Between 1999 and 2015, the network completed over ten trials that had a direct impact on the lives of 
asthma participants and the cost of their care, recruiting more than 5,000 participants with asthma.27  As a 
multicenter network, the ACRC is well poised to conduct comparative effectiveness research due to its 
ability to enroll large numbers of participants from diverse populations from different regions of the 
United States to ensure that the research findings has external generalizability and are relevant to large 
groups of participants.27  All data collected from the clinical sites is managed and analyzed by a Data 
Coordinating Center at Johns Hopkins University.  An overview of ACRC studies is reported elsewhere.28  
Since 2015, the ACRC was renamed as the Airways Clinical Research Centers and its mission was expanded 
to include other obstructive lung disease such as COPD.  This change in focus is not relevant to this paper 
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and when discussing the ACRC, it will refer to the network as it was between 1999 and 2015. 
 
Study Design  
The Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial was the ACRCs 
second trial that began in 2002 and ran throughout 2003.  It was a multicenter, randomized, double-blind, 
parallel design, placebo-controlled trial evaluating whether low-dose theophylline was as effective as an 
add-on therapy in treating asthmatics compared with 1) montelukast and 2) placebo in 488 participants 
with poor asthma control.  
 
To be eligible for the study, participants had to be over the age of 15 years, have physician-diagnosed 
asthma, have been prescribed daily asthma medication for at least a year, have an FEV1 of 50% or more of 
predicted values and have a score of 1.5 or greater on the Asthma Control Questionnaire.  Potential 
participants who smoked or used oral corticosteroids, leukotriene antagonists or theophylline with four 
weeks preceding enrollment or had other significant illness were ineligible to participate.  
 
After a one to two week run-in, eligible participants were randomized in a stratified permuted block 
method in a 1:1:1 allocation ratio to 300mg/day theophylline (n=160) or 10mg/day montelukast (n=164) 
or placebo (n=164) – in addition to their existing asthma therapy.  Participants were followed for six 
months (24 weeks), attended three follow-up visits (one, three and six months after randomization) and 
were contacted by phone periodically in between visits to ensure the participant was not experiencing any 





The outcome of interest in the LODO trial was the annual rate of acute asthma exacerbations 
(events/person/time) defined as having at least one of the following episodes of poor asthma control 
(EPACs):    
 
• 30% drop in peak flow for 2 consecutive days; or 
• Increase of 2 or more used of rescue medication (4 puffs MDI, 2 nebulizer uses); or 
• New course of oral steroids for asthma; or 
• Unscheduled health care for asthma symptoms 
 
This composite outcome measure was used to reflect the several dimensions of good asthma control, 
including physiology, symptoms and health care use.  It should be noted that EPACs is not a standardized 
composite measure of asthma control and this definition was created by the ACRC for this and other trials.   
 
Treatment Groups 
In the original ITT analyses, participants were randomized in equal allocation ratio to one of three 
treatment groups:  
 
• Theophylline (Theo-Dur®) 300 mg/capsule  
• Montelukast (Singulair®) 10 mg/capsule  
• Placebo capsule 
 
Subjects were instructed to ingest 1 capsule daily following their evening meal.  All treatments were 
masked by opaque capsules.  After randomization, the remainder of the study was observation in the 
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sense that participants could discontinue study medication.  
 
As such, for the IPW analysis treatment groups consisted of all those who were compliant with their 
respective assigned treatments at each visit compared to those who were not compliant for each arm of 
the original randomization.  This allowed for a participant’s propensity for adherence to vary as 
circumstances changed over the course of the study.  Adherence information was obtained from 
questionnaires given by study investigators at the 1, 3 and 6 month clinical visits.  A person was 
considered to be adherent to assigned treatment if they reported, at the time of their clinic visit, being on 
study treatment with no interruptions since the last clinic visit or if they were currently on study 
treatment but had temporarily discontinued since last visit.  All other cases were considered to be non-
adherent.   
 
In total, 174 participants did not adhere to their assigned study treatment at 218 visits.  Twenty three 
participants were non-adherent with assigned medication at 1 month – 11, 8, and 4 in the theophylline, 
montelukast and placebo groups, respectively.  Twelve were non-adherent at three months – 6, 4 and 2 in 
the theophylline, montelukast and placebo groups, respectively.  At the six month visit, an additional 139 
participants did not adhere to the study medication – 45 in the theophylline group, 49 in the montelukast 
group and 45 in the placebo group.   
 
Potential Time-Dependent Confounders 
A number of covariates were considered as potential time-dependent confounders. It was assumed that 
these variables were measured prior to deciding whether or not to continue with their assigned treatment 




Variables that were collected only at baseline and remained static throughout the trial included age 
(defined as a continuous variable), sex (male, female) and race (white, black or other).    
 
Covariates considered potential time-vary confounders included: 
 
• Lung function test volumes such as forced expiratory volume (FEV1), forced vital capacity (FVC) 
and ambulatory peak flow (PF) which objectively measure airway obstruction or the ability of the 
lungs to perform in asthmatic participants.29,30  Volumes were interpreted as percentages of 
predicted values based on Hankinson et al. well-established reference equations for healthy 
subjects of similar demographic characteristics (height, age, sex, race and weight).  A detailed 
description on how percent predicted values based on normal lung function are calculated has 
been previously published.31,32  
 
• Average Asthma Symptom Utility Index (ASUI) is a 10-item self-administered questionnaire 
assessing asthma symptoms.  It was scored from 0 to 1, with 0 indicating severe symptoms for at 
least one week to 1 signifying no symptoms in the two week period.33  The items are then 
weighted according to participant preferences and scored based on a multi-attribute utility 
function of ASUI= 1.200 x (S1 Cough * S2 Wheeze * S3 Shortness of Breath * S4 Awake At Night * 
S5 Medical Side Effects) - 0.200. A detailed description of the ASUI has been previously published 
elsewhere.33 
 
• Medication use was defined as a binary measure.  Participants were asked if they had used any of 
the following medications since their last visit: inhaled corticosteroids, inhaled long-acting beta-
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agonists, inhaled short-acting beta-agonists, inhaled anticholinergic, combination drugs such as 
Advair.   
 
• Adverse effects were also defined as a binary measure.  Participants were asked if they had any of 
the following adverse effects since their last visit – nausea, vomiting, poor appetite, heartburn, 
headache, insomnia, anxiety, tremor, heart palpitations and skin rash.   
 
• Use of health care services was also defined since their last visit.  Starting with the 1 month visit, 
participants were asked if they visited with their doctor or were hospitalized since their last study 
visit.  
 
All potential time-varying confounders came from participant diary cards except for FEV1 and FVC 
measures which were collected through spirometry at each visit.  It was assumed that these covariates 
fully encompass the clinician’s and participant’s perspective of asthma and therefore, was considered 
good predictors of the outcome (asthma exacerbation), treatment adherence and censorship.  For 
example, a lower than normal FEV1 is associated with severity of asthma symptoms, increased asthma 
attacks, reduced quality of life and the likelihood of both hospitalizations and respiratory failure all of 
which have been shown to affect whether a participant stays on their assigned treatment.30  In addition, 
since clinical trials are longitudinal studies, current spirometry measures are in part a result of previous 
treatment, mediating the association between treatment and asthma control.  A similar case can be made 
for all of the other potential time-varying confounders mentioned above.  
 
Figure 2.3 shows a possible directed acyclic graph34 that represents the relationships between the time-
varying treatments (generally a time-varying variable as each day you may take it or not take it) and the 
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above covariates with the outcome, assuming no unmeasured confounding. L(0) denotes baseline 
demographic characteristics along with baseline FEV1.  It was assumed that there was no effect of L(0) on 
A(0), because of randomization and full initial compliance.  Therefore, confounding is assumed to occur 
only after A(0) (baseline).  A(1), A(2) and A(3) represent treatments actually received, irrespective of 
randomization, at follow up times 1, 2, and 3.  L(1), L(2) and L(3) denote the current levels of the time 
varying covariates - pulmonary function measures, asthma symptoms, medications and adverse effects at 
follow-up visits 1, 2, and 3.  C(1), C(2), and C(3) account for lost to follow-up which occurred due to past 
treatment history and confounder levels.  Lastly, Y denotes the annual rate of asthma exacerbations 
indicating poor asthma control.   
 
Overall, there are 10 possible outcomes (arrows into Y) for each subject, representing all possible 
combinations of treatments for the four time periods, of which only one is observed.  However, once all 
confounding paths are blocked, only the causal paths (green arrows into Y) remain.  
 
Missing Data  
Thirty-one participants (6% of participant visits) had missing covariate estimates for one or more 
confounders despite attending visits and providing exposure and outcome data.  Missing covariate data 
were imputed using the mean value for the treatment and time period groups.  These cases were retained 
for all analyses.  
 
Data were censored at the time of the first missed visit, i.e. exposure, or in cases where the outcome was 
missing.  Research has indicated that censored at first missed visit is generally the least biased across all 
missingness mechanisms.15,20,35  Twenty-eight cases were lost to follow-up after the baseline visit – 13 
from the theophylline group, 5 from montelukast and 10 from the placebo group - leaving 460 cases with 
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complete data at the six week visit.  Another 33 participants had been lost to follow-up after the six-week 
visit – 10 from theophylline, 14 from montelukast and 9 from placebo – leaving 427 cases with complete 
data at the three month visit.  At the six month visit, another 24 were censored – 10 from the 
theophylline, 5 from montelukast and 9 from placebo – leaving 403 cases with complete data at the six 
month and final visit.   
 
Statistical Analysis  
Intention-to-Treat – Outcome Model 
The original ITT analyses were replicated using data on 488 participants randomized at baseline.  Poisson 
regression models with Huber-White variance estimates were used to calculate event rates of EPACs.  
Logistic regression models with generalized estimating equations (GEE) to evaluate differences among 
treatment groups. 
 
Marginal Structural Models 
1) Inverse Probability Weighting  
Pooled logistic regression models were fitted separately for the probability of staying on assigned 
treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment 
arm.  The dataset for these models was discretized into one observation per subject per visit so that 1) 
time could be fit as a class variable to allow a separate intercept for each time and 2) lagged variables for 
previous treatment and confounder histories would be comparable between subjects.  Stabilized 
treatment weights were created by dividing the baseline probability of selecting a treatment (numerator 
in equation 1) by the probability of selecting treatment given prior treatment history and potential 
confounders up to time t (denominator in equation 1).  The calculation of censored probabilities mimicked 
that of treatment adherence weights but was offset by one visit as censoring looked forward i.e. ‘did the 
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subject return for a following visit?’ compared to ‘what was the treatment at the previous visit?’ (equation 
2).  Each covariate was entered in the pooled logistic models as a main effect only. 
 
Resulting predicted probabilities were then used to construct the final stabilized treatment and censoring 
weights for each subject at each visit.  For the Inverse Probability Treatment Weights, the pooled logistic 
regression models provided the estimated probability of remaining on assigned treatment, so the next 
step was to subtract the propensity score by 1 to get the probability of not staying on assigned treatment 
for those who were non-adherent.  Once all subjects had a stabilized weight for each visit, a final stabilized 
weight per participant was obtained by multiplying the estimated probability of their observed treatment 
at each visit cumulatively over time, i.e. the first score was left as is, and for all others, the scores at the 
current visit was multiplied by the score of the previous visit.  For the Inverse Probability Censoring 
Weights, the estimated probabilities of being uncensored for each visit were multiplied cumulatively over 
time.  The final Inverse Probability Weight for each subject was the product of the treatment selection 
weights and the censoring weights.  
 
To determine whether the final stabilized weights resulted in balanced data, distribution plots were 
created to assess central tendency and skewness between the original and weighted data sets. 
 
2) Outcome Model 
A poisson regression model using PROC GENMOD were fitted for the annual rate of acute asthma 
exacerbations (outcome) as a function of the assigned treatment using the weighted sample and a 
generalized estimating equation (GEE) with an independent correlation matrix.  The use of GEE accounted 




The final model were fit to all uncensored cases with complete data (N=403).  Final analyses of treatment 
effects on asthma control were conducted for three groups – theophylline vs. montelukast, theophylline 
vs. placebo and montelukast vs. placebo. 
 




Baseline characteristics of the 488 subjects randomized to the LODO study is shown in table 2.1. Assigned 
treatment groups were balanced with respect to demographics and baseline asthma characteristics.  
Participants tended to be middle-aged, predominantly female and white.  On average, participants’ pre-
bronchodilator FEV1 was slightly below that of a normal population indicating mild asthma severity.  Post-
bronchodilator lung function continued to be mildly reduced on average compared to a normal 
population.  Around 9% of participants were prescribed daily asthma medication, but did not use it.  The 
majority of subjects either took short acting beta-agonists, inhaled corticosteroids or a combination of 
medications.   
  
Table 2.2 shows participant characteristics over the follow-up period.  After randomization, study 
discontinuation was similar across the treatment groups.  At four weeks, the theophylline group tended to 
be slightly sicker than the montelukast group (significant findings were found for ASUI score, inhaled 
corticosteroids, nausea) and placebo group (significant findings for insomnia).  By the 3 month follow up 





Inverse Probability Weights 
The model for the denominator of the weights is the most important component for determining the 
predicted probabilities.  Covariates with negative coefficients predict those individuals who would be 
more likely to be non-adherent and be censored.24  For the inverse probability treatment weights, 
previous treatment was strongest predictor of present treatment in all treatment groups (-5.70 for 
theophylline, -4.96 for montelukast and -18.17 for placebo).  None of the other time-varying covariates 
were strong predictors of treatment changes – suggesting bias in treatment selection over time may not 
be particularly strong in these data (see Appendix 2.A, 2.B, 2.C).    
 
For the inverse probability censoring weights, most of the covariates in the MSM model were not 
associated with censoring.  The exceptions were pre-bronchodilator percent predicted FEV1 (-0.64, 
p=0.03), ASUI score (1.70, p=0.03), being black (-0.54, p=0.04) and age (0.03, p=0.003).  Similarly to the 
treatment weights, this indicates that selection bias may not be particularly strong in these data (see 
Appendix 2.D). 
 
The mean of the final stabilized weights (treatment x censoring) was 0.995 and ranged from 0.4 to 4.3, 
indicating that the model was correctly specified.  Furthermore, the sum of the weights in the pseudo 
population was 1785 which was identical to the number of visits with complete data in the original 
sample.  Figure 2.4 shows the distribution overlap of the stabilized weights for all groups over time.   
The distribution of treatment groups (theophylline vs. montelukast, theophylline vs. placebo and 
montelukast vs. placebo) was examined through plotting the stabilized weights in the treated and 
untreated groups over time both in the original and in the weighted data sets.  The central tendency of the 
covariate values coincided between groups indicating that balance was achieved; however, there was no 
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difference in central tendency measures between the original and weighted data sets.  The distribution 
plots for the weighted data sets are shown in figures 2.5a, b, and c. 
 
Outcome Models 
Table 2.3 summarizes the outcome using poisson binominal regression models, looking at asthma control 
rates using EPAC composite events as well as each component individually due to treatment effects.  
 
The results of the ITT analysis found no significant treatment effect on overall asthma exacerbation rates 
among all three groups: theophylline vs. montelukast (RR=1.22, 95% CI: 0.82-1.86, p=0.35); theophylline 
vs. placebo (RR=0.99, 95% CI: 0.67-1.50, p=1.00) and montelukast vs. placebo (RR=0.82; 95% CI: 0.55-1.21, 
p=0.31).  However, montelukast was significantly less likely to cause drops in peak flow than in the 
placebo group (RR = 0.44 p-value= 0.01).    
 
The effect estimates obtained from the MSM, using no further adjustments other than the stabilized 
weights, were nearly identical to that of the ITT analysis, indicating that adherence and censoring was not 
a significant problem in this data and that the baseline randomization held throughout the trial.  This 
result was expected as the inverse probability weights were not particularly variable, and therefore, would 
not dramatically change the results of the ITT Poisson regression.   
 
Discussion 
A marginal structural model for repeated measures was used to estimate the causal effect of treatment on 
asthma control in the LODO trial of the ALA-ACRC.  This method was used as it was assumed that, due to 
non-adherence and censoring over time, there may have been time-dependent confounding and selection 
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bias that could not have been appropriately adjusted for by standard statistical methods used in an ITT 
analysis. 
 
Although non-adherence and censoring occurred over time in the LODO trial, the results of the MSM did 
not change the findings of the original ITT analysis.  After adjustment, the theophylline group had a 24% 
and a 1% increased risk of having episodes of poor asthma control compared with the montelukast and 
placebo groups, respectively, while the montelukast group had 0.57 times the risk of the outcome than 
those in the placebo group.  None of these findings were significant and were nearly identical to the ITT 
estimates.   
 
Concordance between the ITT and the MSM analyses may indicate that non-adherence and censorship will 
not invalidate ITT analyses but more research on potential adherence thresholds is warranted.  Previously 
published studies that have found improved efficiency, albeit similar interpretations, using MSM 
compared to ITT did so in RCTs with significantly longer follow up periods and higher rates of censorship 
and non-adherence.40,41  For example, Toh et al. reanalyzed data from the Women’s Health Initiative trial 
examining whether the use of hormone therapy increased the risk of breast cancer over a 6 year period in 
a sample of roughly 600 patients using IPW compared to ITT.41  The MSM approach found the risk of 
breast cancer to be more than two-fold higher in women with continuous hormone use(HR: 1.68; 95% CI: 
1.24-2.28) compared to the original ITT analysis by Rossouw et al. (HR: 1.25; 95% CI: 1.01-1.54).42  
Although these differences led to grossly similar inference, it is  apparent that the change in magnitude 
was most likely due to an increase in the proportion of women not adhering to the protocol over time, 
leading to differential loss-to-follow-up.  In fact, the original authors confirmed that about 40% of women 
had stopped taking at least 80% of their assigned treatment by the 6th year of follow up, a finding that was 




In contrast, the LODO study had a follow up time of six months and self-reported adherence was 84% for 
theophylline and 88% for both montelukast and placebo while only 6% of study participants were 
censored.  The length of the LODO trial and the good clinical practices exercised by the ALA-ACRC 
prevented the presence of non-adherence and differential loss-to-follow up, which limited the ability to 
show a difference between ITT and MSM approaches.   Results of this study are comparable to other trials 
that had similar proportions of noncompliance and censorship.43,44   
 
These results should be considered in the context of the following limitations.  First, MSMs requires the 
untestable assumption of no unmeasured confounding; i.e. that subjects are exchangeable, conditional on 
the measured variables.5,11,16,40  It is assumed that all the most important confounders were identified 
using the expert knowledge of the ALA-ACRC investigators and were then appropriately measured and 
included in the analysis.  However, it can never be verified that all joint predictors of exposure and 
outcome were added to the models. 
  
Second, due to the small sample size and the number of potential confounders added to the MSM models, 
finite-sample bias occurred leading to the presence of random zeros in a few of the exposure-covariate 
groups.  Therefore, one cannot assume that the positivity assumption was met in this study.  However, 
random zeros are essentially guaranteed because of the infinite number of possible values and a more 
valid assessment of positivity includes looking at extreme values, mean of weights and values of exposure-
covariate groups adjacent to those with zero.5   Overall, the mean stabilized weight in this study was 0.995 
and the sample did not have very extreme values.  Also, as seen in figures 2.5a, b, and c, many if not all of 




Lastly, it is assumed that the models used in this analysis are correctly specified. To explore the robustness 
of the models, linear and quadratic terms of continuous variables were tested to restrict the possible 
values of the propensity scores such that on a logit scale the conditional relation between the continuous  
covariates and the risk of treatment can be represented by a parabolic curve, and each covariate 
contributions to the risk is independent of that of the other covariates.22  No significant changes to the 
outcome were noted.  Additionally models were fitted with different groupings of covariates.  For 
example, models were fitted for individual side effects and medications alone, for composite measures of 
side effects and medications and for both composite and individual grouping.  Again, there were no 
significant changes to the outcome.  Finally, the fact that the mean of the final stabilized weight was close 
to 1 and that the MSM and ITT results were near identical, gives strength to the assumption that the MSM 
was not mis-specified.  Unfortunately, the assumption of a correctly specified model can never be proven. 
 
However, since none of these limitations can be reasonably assumed to be consequential in the current 
working model and since time-varying non-adherence was suspected and data were missing, it is 
reassuring to see that both the ITT and MSM approaches yielded consistent results.  This only bolsters 




In my analysis, fitting MSMs using IPW did not change the ITT analysis outcomes, validating the original 
findings of the study.  It is possible that these findings could have been due to the relatively low rates of 
non-adherence and censorship over the six months LODO was conducted.  In a longer RCT with baseline 
randomization, it is assumed that there would be higher rates of non-adherence and censorship and that 
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MSMs could serve as an alternative, and maybe more efficient, method to ITT in elucidating causal 
interpretations.  
 
In any event, it is my recommendation that MSMs be used, at a minimum, as a sensitivity analysis to the 
ITT approach in RCTs when time-varying non-adherence is suspected or data are missing and when MSM’s 
limitations can be reasonably ignored.  Concordance between the ITT and the MSM analysis may indicate 
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Figure 2.2. Schema of the Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma 
(LODO) trial (ACRC, 2002-2003) 
 
 
V1/Run-In: Potentially eligible patients were followed for a 1-2 week run-in period  
V2/M0: Patients who successfully completed the run-in and agreed to be randomized were assigned to 
one of the three treatments shown 
V3: 1 month follow up visit 
V4: 3 month follow up visit 
V5: 6 month follow up visit 




Figure 2.3. Structural relationships over time between treatments and asthma control in the Low Dose 
Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial (ACRC, 2002-2003)1
 
1 Created through Daggity software: Johannes Testor, Juliane Hardt, and Sven Knuppel.  Daggitty: A graphical tool 
for analyzing causal diagrams.  Epidemiology, 22(5): 745, 2011 
-A0, A1, A2, A3 represent observed cumulative treatment exposure to either Theophylline, Montelukast or 
Placebo from baseline randomization (A0), 1 month (A1), 3 months (A2) and 6 months (A3). 
-L1, L2, L3 denote measured confounders (pulmonary function measures, asthma symptoms, medications and 
adverse effects) that may be associated with A(k),respectively. L(0) denotes baseline demographic characteristics 
along with baseline FEV1.  It was assumed that there was no effect of L(0) on A(0), because of randomization and 
full initial compliance.   
-C1, C2, C3 reflects loss to follow up at 1 month (C1), 3 months (C2) and 6 months (C3). 
-Y indicates the outcome of annual rate of asthma exacerbations indicating poor asthma control.   If all possible 
























Table 2.1. Baseline Characteristics of the 488 LODO Participants by Treatment Assignment 
  Theophylline Montelukast Placebo p-value 1 
  
      
Number of patients 160 164 164 --- 
  
      
          
  
      
Demographics          
  
      
Age, mean ± SD 41.5 ± 14.7 39.8 ± 15.0 40.0 ± 14.6 0.56 
  
      
Male, % 25.0 28.1 25.6 0.80 
  
      
White, % 60.0 62.2 59.8 0.88 
  
      
Black, % 31.3 25.6 30.5 0.48 
  
      
Other Race, % 8.8 12.2 9.8 0.57 
  
      
          
  
      
Asthma Symptoms, mean ± SD         
  
      
ASUI Average Score 0.66 ± 0.15 0.68 ± 0.15 0.70 ± 0.15 0.16 
  
      
          
  
      
Pulmonary Function, mean ± SD         
  
      
Pre-BD FEV1, % predicted* 78.3 ± 16.5 77.5 ± 17.5 80.3 ± 16.2 0.32 
  
      
Pre-BD FVC, % predicted* 87.2 ± 14.8 87.1 ± 16.9 88.5 ± 14.8 0.65 
  
      
Post-BD FEV1, % predicted* 84.4 ± 15.6 83.7 ± 17.1 86.8 ± 15.2 0.18 
  
      
Post-BD FVC, % predicted* 91.8 ± 15.7 91.6 ± 16.0 91.7 ± 14.1 1.00 
  
      
Peak Flow, % predicted* 83.4 ± 20.3 83.0 ± 20.3 80.6 ± 19.3 0.39 
  
      
FEV1 Bronchodilator % change 9.2 ± 12.6 9.3 ± 11.7 8.9 ± 10.3 0.94 
  
      
FVC Bronchodilator % change 5.9 ± 10.3 6.6 ± 13.8 3.8 ± 7.2 0.06 
  
      
          
  
      
Daily Asthma Treatments, %         
  
      
Using asthma medication daily 90.0 92.7 93.3 0.51 
  
      
Inhaled anticholinergic 2.5 4.9 3.7 0.52 
  
      
Inhaled long-acting -agonist 22.5 22.6 18.3 0.56 
  
      
Inhaled short-acting -agonist 58.1 60.4 56.7 0.79 
  
      
Combination drugs 37.5 40.2 36.6 0.78 
  
      
Inhaled Corticosteroids 39.4 34.8 39.0 0.63 
  
      
*Predicted values of Hankinson and colleagues.   
   
      




Table 2.2. Time-Varying Characteristics of LODO Participants by Treatment Assignment over LODO Follow Up Periods 1,2    
 
            
 
Time 1 (4 Weeks)  
N=460 
Time 2 (3 Month) 
N=427 
Time 3 (6 Month) 
N=410  
  T M P p T M P p T M P p 
Number of patients 147 159 154 -- 137 145 145 -- 131 141 138 -- 
                          
Asthma Symptoms, mean ± SD                         
ASUI Average Score 0.73 ± 0.17 0.78 ± 0.15 0.74 ± 0.15 0.02a 0.76 ± 0.15 0.78 ± 0.20 0.79 ± 0.16 0.38 0.74 ± 0.15 0.78 ± 0.15 0.81 ± 0.17 0.66 
Pulmonary Function, mean ± SD                         
Pre-BD FEV1, % predicted* 80.1 ± 16.0 78.8 ± 17.8 79.7 ± 16.4 0.79 79.6 ± 15.8 78.6 ± 18.6 78.9 ± 15.8 0.86 80.7 ± 18.3 79.8 ± 17.9 78.3 ± 15.7 0.49 
Pre-BD FVC, % predicted* 88.7 ± 15.4 88.7 ± 16.4 87.9 ± 15.7 0.87 88.7 ± 16.8 87.8 ± 16.6 87.5 ± 14.5 0.79 90.2 ± 17.3 89.2 ± 19.3 87.1 ± 14.5 0.28 
Post-BD FEV1, % predicted* 86.1 ± 15.6 84.1 ± 17.4 85.6 ± 15.9 0.54 85.5 ± 15.4 83.8 ± 18.2 85.2 ± 15.2 0.63 85.6 ± 15.8 84.7 ± 17.5 84.6 ± 15.1 0.85 
Post-BD FVC, % predicted* 93.0 ± 16.5 92.4 ± 19.4 91.5 ± 13.9 0.67 92.2 ± 17.4 90.9 ± 16.7 91.0 ± 13.7 0.78 92.6 ± 16.2 91.6 ± 16.7 90.4 ± 14.5 0.50 
Peak Flow, % predicted* 86.1 ± 18.8 84.1 ± 18.7 82.4 ± 18.4 0.22 84.7 ± 17.0 84.5 ± 19.7 81.5 ± 20.5 0.31 85.4 ± 17.4 85.9 ± 18.0 82.6 ± 19.6 0.30 
FEV1 Bronchodilator % change 8.4 ± 10.3 7.7 ± 11.0 8.9 ± 12.2 0.63 8.7 ± 12.9 7.6 ± 11.2  9.0 ± 9.3 0.54 7.7 ± 12.7 7.1 ± 10.4 9.0 ± 10.3 0.29 
FVC Bronchodilator % change 5.3 ± 8.5 4.6 ± 11.3 5.0 ± 10.6 0.82 4.5 ± 9.70 4.1 ± 9.0 4.8 ± 9.9 0.83 3.5 ± 9.4 3.6 ± 8.9 4.1 ± 7.9 0.79 
Daily Asthma Treatments, %             .           
Using asthma medication daily 88.8 88.4 88.4 0.99 87.8 89.3 88.3 0.91 85.8 85.6 89.1 0.61 
Inhaled anticholinergic 2.5 3.7 4.9 0.52 2.0 3.8 2.6 0.64 2.1 2.7 3.4 0.80 
Inhaled long-acting -agonist 17.5 19.5 15.9 0.68 19.7 18.2 16.2 0.73 19.9 20.6 13.6 0.23 
Inhaled short-acting -agonist 51.3 48.2 50.0 0.86 48.3 42.1 46.8 0.53 43.3 36.3 45.6 0.25 
Combination drugs 38.8 38.4 35.4 0.79 37.4 40.9 37.0 0.74 37.6 42.5 40.8 0.69 
Inhaled Corticosteroids 38.8 28.1 34.2 0.12b 39.5 30.2 33.1 0.22 36.2 30.8 29.3 0.42 
Adverse Effects %                         
Nausea 14.4 6.1 7.9 0.03c 3.4 6.3 5.2 0.51 1.4 5.5 4.8 0.17 
Vomiting 2.5 1.8 4.3 0.39 1.4 2.5 2.6 0.71 1.4 1.4 0.7 0.80 
Poor Appetite 3.8 2.4 4.3 0.65 6.1 2.5 2.0 0.10 4.3 4.8 4.8 0.97 
Heartburn 8.1 8.5 10.4 0.75 9.5 6.3 5.2 0.31 7.8 11.6 11.6 0.48 
Headache 21.9 20.1 22.6 0.86 19.7 20.8 13.6 0.21 17.7 17.8 22.5 0.51 
Insomnia 23.8 18.3 14.0 0.08d 17.7 12.6 15.6 0.46 22.7 16.4 16.3 0.28 
Anxiety 11.9 6.1 10.4 0.18 8.8 8.2 5.8 0.58 10.6 11.0 10.9 1.00 
Tremor 2.5 1.2 2.4 0.65 2.7 0.6 2.6 0.33 4.3 1.4 3.4 0.34 
Heart Palpitations 3.1 1.8 3.1 0.72 4.1 3.1 2.6 0.77 3.6 2.7 5.4 0.47 
Skin Rash 2.5 1.8 4.3 0.39 3.4 3.1 3.9 0.93 3.6 6.9 4.8 0.43 
Use of Healthcare Services, %                         
Hospitalization 1.9 1.2 0.0 0.23 2.0 4.4 2.60 0.45 2.8 2.7 3.4 0.94 
Doctor Visits 15.0 13.4 14.6 0.91 16.3 25.8 18.8 0.10 
e 23.4 28.8 23.8 0.51 
*Predicted values of Hankinson and colleagues.           
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T=Theophylline, M=Montelukast, P=Placebo 
1 P values for continuous variables from ANOVA.  Significant results p<=0.05 level were further tested with Bonferroni to determine which group was significantly 
different than the others. 
2 P values for categorical variables were obtained from Pearson Chi-Square test.  As Pearson Chi-Square tests only for interactions among groups, any significance 
level less than 0.15 was then reanalyzed in binary groups - Theophylline vs. Montelukast, Montelukast vs. Placebo and Theophylline vs. Placebo - to determine 
significant differences between groups. 
a) Patients taking Theophylline have significantly lower ASUI scores, indicating poorer asthma control than those taking 
Montelukast.    
b) Patients taking Theophylline were significantly more likely to be taking inhaled corticosteroids (ICS) than those taking 
Montelukast (p=0.04).    
c) Patients taking Theophylline were significantly more like to be nauseous than patients in the Montelukast 
(p=0.01).       
d) Patients taking Theophylline were significantly more like to have insomnia than patients taking placebo 
(p=0.03).      
e) Patients taking Montelukast were significantly more like to report visiting the doctor than patients in the 
Theophylline (p=0.04)      
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Figure 2.4. Distribution Overlap of the Stabilized Inverse Probability Weights for all Treatment Groups By Time Period  
  
-Stabilized Inverse Probability Weights (SW) in each time period showed a mean (◊) and median (─) close to 1 indicating 
that the model was correctly specified.  Overall, the mean of the SW was 0.995 and ranged from 0.4–4.3. 
-Time Period 0: Baseline with 488 participants; Time Period 1: 1 month with 460 participants; Time Period 2: 3 months 
with 427 participants; Time Period 3: 6 months with 410 participants 
 
Figure 2.5a. Distribution of Stabilized Inverse Probability Weights in the Treated (Theophylline) and Untreated 
(Montelukast) Groups 
 
-Stabilized Inverse Probability Weights (SW) in the theophylline and montelukast groups had means of 1 and followed a 




Figure 2.5b. Distribution of Stabilized Inverse Probability Weights in the Treated (Theophylline) and Untreated 
(Placebo) Groups 
 
-Stabilized Inverse Probability Weights (SW) in the theophylline and placebo groups had means of 1 and followed a 
similar distribution indicating balance between both groups. 
 
Figure 2.5c. Distribution of Stabilized Inverse Probability Weights in the Treated (Montelukast) and Untreated 
(Placebo) Groups 
--- 
-Stabilized Inverse Probability Weights (SW) in the montelukast and placebo groups had means of 1 and followed a 




Table 2.3. Estimated Effects of Treatment on Episodes of Poor Asthma Control (EPACs) in the LODO Trial, 2002-
20031 
   
          
  Treatment Groups Intention to Treat RR 
Inverse Probability Weights 
(SWA*SWC) RR 
  T M P T vs. M T vs. P M vs. P T vs. M T vs. P M vs. P 
Number of patients 150 160 154             
Asthma EPACs                   
    Events, n 269 236 293             
    Rate, events/person-year 4.9 4.0 4.9 1.22 0.99 0.82 1.24 1.01 0.83 
    95% CI 3.6-6.7 3.0-5.4 3.8-6.4 0.82-1.86 0.67-1.50 0.55-1.21 0.83-1.84 0.70-1.48 0.57-1.19 
    p-value -- -- -- 0.35 1.00 0.31 0.28 0.95 0.27 
Peak flow, 30% drop                   
    Events, n 75 43 100             
    Rate, events/person-year 1.3 0.7 1.6 1.85 0.81 0.44 1.94 0.78 0.40 
    95% CI 0.8-2.2 0.5-1.1 1.0-2.5 0.96-3.54 0.42-1.59 0.24-0.81 0.99-3.78 0.40-1.52 0.22-0.73 
    p-value -- -- -- 0.07 0.55 0.01* 0.05 0.44    0.00 * 
Increased medication use                   
    Events, n 198 179 200             
    Rate, events/person-year 3.5 3.0 3.3 1.16 1.07 0.92 1.19 1.15 0.97 
    95% CI 2.4-5.0 2.2-4.2 2.4-4.5 0.71-1.90 0.66-1.73 0.58-1.45 0.72-1.95 0.71-1.85 0.61-1.53 
    p-value -- -- -- 0.55 0.79 0.72 0.50 0.60 0.85 
New use of oral 
corticosteroids                   
    Events, n 30 32 34             
    Rate, events/person-year 0.5 0.5 0.5 0.99 0.96 0.97 1.03 1.14 1.10 
    95% CI 0.4-0.7 0.3-0.8 0.3-0.8 0.56-1.75 0.53-1.73 0.51-1.84 0.58-1.79 0.67-1.94 0.62-2.01 
    p-value -- -- -- 0.97 0.89 0.93 0.91 0.63 0.74 
Unscheduled health care                   
    Events, n 41 34 41             
    Rate, events/person-year 0.7 0.5 0.6 1.27 1.09 0.85 1.28 1.32 1.03 
    95% CI 0.5-1.0 0.4-0.8 0.4-1.2 0.72-2.24 0.54-2.19 0.42-1.75 0.73-2.27 0.72-2.41 0.56-1.89 
    p-value -- -- -- 0.40 0.81 0.67 0.40 0.37 0.92 
1 p values for treatment effects on rates of episodes of poor asthma control are based on negative binominal regression with robust variance 




Chapter 3: Using Marginal Structural Models to Determine Whether Race 
is an Effect Modifier in Analyzing Treatment Effects on Asthma Control 
 
Background:  Marginal Structural Models (MSMs) have been commonly used to control for confounding in 
longitudinal studies with time-varying treatments and time-dependent covariates, yet their use in detecting 
effect modification, while plausible, has been limited in practice.  The purpose of this paper is to 
demonstrate the use of MSMs for detecting effect modification by race in a randomized controlled trial 
(RCT) assessing treatment effectiveness on asthma control.  
 
Methods: MSMs using inverse probability treatment weighting (IPTW) on the full cohort were 
implemented.  Pooled logistic regression models were first fitted to assess the probability of staying on 
assigned treatment (adherence) for all subjects at each visit by treatment arm to control for 
confounding.  A final pooled logistic regression model was fitted for the annual rate of acute asthma 
exacerbations (outcome) as a function of the IPTWs, assigned treatment and an interaction term 
between treatment and race using a Poisson generalized estimating equation (GEE) with an 
independent correlation matrix to assess effect modification by race in the relationship between 
treatment and asthma control.   
 
Results:  IPTWs were first computed for both the full cohort and by strata; however, when examining 
balance between treatment groups by race, it was determined that the non-white group was not of 
sufficient size to obtain meaningful estimates.  As such weights for the full cohort were used to detect 
effect modification.  Effect modification by race was seen on the multiplicative scale only when 
comparing montelukast to placebo for overall episodes of poor asthma control (EPACs), increased 
medication use and unscheduled health care visits.  Compared with whites, non-whites were more than 
twice as likely to suffer from EPACs on montelukast as on placebo (RR=2.13, 95% CI: 1.08-4.46, p= 0.04) 
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and almost 3 times as likely to increase medication use (RR=2.86, 95% CI: 1.10-7.42, p=0.03).  Non-
whites were over 5 times more likely to have unscheduled health care visits than whites while on 
montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02).  
 
Conclusions:  Race modified the relationship between montelukast and most of the asthma control 
outcomes.  While MSMs can be used in the detection of effect modification, more research is needed to 
determine the most appropriate way to calculate inverse probability treatment weights propensity 
scores as there is no consensus in the literature on how best to calculate the propensity scores required 
for weighting and achieve accurate subgroup results.   
 
Keywords: marginal structure models, effect modification, inverse probability weighting, clinical trials, 





In certain situations, average causal effects may differ within subgroups compared to the entire 
population.  Understanding whether the effect of a treatment (or exposure) is different in groups of 
patients with different characteristics can assist clinically in determining who would benefit most, or 
least, from a particular treatment.1,2  Unfortunately, designing a clinical trial to study time-varying 
treatment effects in relevant subgroups is a costly and time consuming endeavor and therefore, analytic 
methods to assess effect modification are needed.   
 
Marginal Structural Models (MSMs), which have been commonly used to eliminate confounding in 
longitudinal studies with time dependent covariates, have been posited to be able to detect whether a 
pre-treatment fixed covariate modifies the causal effect of a time varying treatment on an outcome at 
the same time as adjusting for post-randomization confounding in a clinical trial.2–4  In essence, MSMs 
first estimate inverse probability weights (IPW) to determine joint probabilities, i.e. propensity score 
values, of an individual’s treatment and censoring history, conditional on their observed set of 
covariates.  This theoretically eliminates all back door pathways (post randomization confounding in 
clinical trials) that may bias the association between the treatment and the outcome, making the 
baseline randomization once again valid.3–9  Once confounding is “eliminated”, a final weighted model is 
then fitted for the outcome as a function of the treatment history and a treatment-covariate interaction 
term for the computation of a causal effect of treatment within levels of a covariate that may potentially 
act as an effect modifier in the association between exposure and outcome.3   
 
While the use of MSMs to adjust for confounding in longitudinal studies is increasing common, there are 
only a few instances in the literature that use MSMs to assess for effect modification.  To add to the 
literature, I utilize MSMs to assess whether race modifies the causal effect of asthma treatments on the 
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rate of episodes of poor asthma control (EPACS) in a 6 month randomized control trial that was not 
initially designed to do so.   
 
Race was chosen as a potential effect modifier for two reasons.  First, research has indicated that certain 
racial and ethnic groups fare significantly worse than whites when assessing asthma control.10–17  For 
example, one study found that African Americans were three times more likely than whites to visit an 
emergency room for an exacerbation (18.3% vs. 6.1%)18while another study found that Hispanics were 
60% more likely than non-Hispanic whites to have poorly-controlled asthma.4  Lastly, a few studies have  
indicated that certain first-line asthma treatments  were not as effective in improving asthma control in 
African Americans and Puerto Ricans in comparison with other racial and ethnic subgroups.19–23  
 
Second, this is a secondary data analysis of the American Lung Association Airway Clinical Research 
Centers (ACRC) Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial24.  
The ACRC has been extremely successful in enrolling large numbers of patients from diverse 
populations. 25,26  As such, the opportunity presented itself to examine whether race was an effect 
modifier in the estimation of the causal effect of theophylline, montelukast and placebo on the annual 
rate of EPACs using a MSM while also accounting for potential time-dependent confounding that could 
have occurred due to post randomization confounding.  While the original results of the LODO study 
found a null average casual effect between asthma treatment and episodes of poor asthma control, I 
postulate that these estimates may differ when stratified by race using a MSM.  
 
Effect Modification 
Effect modification, i.e. heterogeneity of effect, occurs when the magnitude of the effect of the primary 
exposure on an outcome differs within levels of a third variable.1,2,4,27,28  Unlike confounders, effect 
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modifiers are not associated with the exposure nor can they be descendants of either exposure or 
outcome.  They are natural occurrences that can be viewed as another independent cause of the 
outcome of interest.  Therefore, failure to consider potential effect modification and estimating only the 
individual contribution of an exposure to an outcome may result in erroneous conclusions.  
 
The most common way of identifying effect modification is to examine the association between an 
exposure and outcome separately for each level of the third variable, i.e. stratification.  If the causal 
effect happens to be different between the two strata, then there is evidence of effect modification.  
The type of effect modification found is dependent on the measure of association (i.e. risk difference, 
risk ratio) being used.  When the causal risk difference varies across strata (M), then effect modification 
is present on the additive scale (equation 1)  
 
Pr[Ya=1=1|M=m] - Pr[Ya=0=1|M=m]          Equation 1. 
 
while the use of the causal risk ratio indicates that effect modification exists on the multiplicative scale 
(equation 2). 
 
Pr[Ya=1=1|M=m] / Pr[Ya=0=1|M=m]              Equation 2. 
 
Furthermore, effect modification can be classified as being qualitative or quantitative in nature.  The 
former is present when the direction of the effect differs across the strata, i.e. when 1) there is an 
association in one subgroup but no association in the other or 2) there is an increased risk in one 
subgroup but decreased risk in the other.   In contrast, quantitative effect modification exists when the 
direction is the same across strata but the strength of the association differs.  When qualitative effect 
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modification occurs it will be present on both the additive and multiplicative scale.  However, 
quantitative effect modification can occur on both scales or only on one.  Regardless of type, if effect 
modification exists, the crude effect measure will be between the estimates of the stratum-specific 
estimates. 
 
The clinical motivation behind the assessment of effect modification is to identify whether the effect of 
a treatment (or exposure) is different in groups of patients with different characteristics to determine 
who would benefit most, or least, from a particular treatment.1,2  Ultimately, understanding effect 
modification may allow individualized preventive medical advice before diagnosis, in addition to 
personalized medical treatment after a disease diagnosis or susceptibility to a particular disease has 
been determined.  
 
Marginal Structural Models  
A concern with estimating effects from longitudinal data is the assumption that a subjects’ behavior and 
subsequently the distribution of risk factors will change with time.  Unlike traditional regression models, 
Marginal Structural Models (MSMs) can account for both the joint effects of baseline and subsequent 
treatments and for the presence of time-dependent confounding which may be influenced by prior 
treatment (mediators), by modeling exposures at each follow up and the final outcome.3,6,29,30  Formally, 
an MSM relates any possible exposure (A), up to time t, to the corresponding counterfactual outcome 
(Y) at time t to measure overall population impact.2,31–34    In other words, these models allow for the 
estimation of all potential outcome-treatment combinations for each study visit, despite the fact that 
only one response for a given treatment level per visit will be observed in the data, with the rest 




Less commonly, MSMs have been used to detect whether the causal effect of a time-varying treatment 
on an outcome is modified by a pre-treatment fixed covariate (M).3,4,35–39 When assessing effect 
modification using MSMs, it is assumed that the causal effect of treatment on an outcome is dependent 
on whether the choice of a treatment option at a particular time point is affected by the presence of 
time-dependent confounding (L) for every level of M.  While technically no longer a true marginal 
structural model because the causal effect is now conditional on M, it is generally accepted that as long 
as all time-dependent confounders are eliminated, stratum-specific associational risk ratios can be 
interpreted as a stratum-specific causal effect of treatment, i.e. there is a difference in the 
counterfactual outcomes under two or more treatment regimes in each level of M.2,4,9,27  Therefore, 
there is conditional exchangeability given L and as such, the observed risk difference (Pr[Y =1 │A=1, 
M=m] - Pr[Y =1 │A=0, M=m]) or risk ratio (Pr[Y =1 │A=1, M=m] / Pr[Y =1 │A=0, M=m]) will equal the 
unknown counterfactual risk difference (Pr[Ya=1 =1 | M=m] – Pr[Ya=0 =1 | M=m]) or risk ratio (Pr[Ya=1 =1 | 
M=m] / Pr[Ya=0 =1 | M=m]), respectively.   
 
MSM parameters are estimated through the application of an inverse-probability-of-treatment 
weighting (IPTW).2,7,8  IPTWs adjusts for post-randomization confounding due to 1) non-adherence and 
2) mediators by creating a pseudo-population where the time-varying treatment is independent of 
stable and time-varying covariates that preceded it, allowing for causal treatment comparisons using 
standard repeated measure models.3,9,30,32,33,40–42  Instead of modeling the relationship between a 
covariate and the outcome as is done in traditional regression, IPTW models the probability of receiving 
the treatment given past treatment and prognostic factor history at each time point.  Most researchers 
do this in one step by fitting pooled logistic regression treatment models with time as a class variable to 
allow a separate intercept for each time point.  The resulting predicted probabilities (i.e. propensity 
scores) are used to construct the stabilized weights for the entire study population at each time point 
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during follow-up.  A single weight per subject is then obtained by multiplying the current treatment 
weight with that of the treatment weights from the previous time points.   
 
Weights can be either non-stabilized or stabilized.  The former is estimated by taking the reciprocal of 
the probabilities of receiving treatment given the covariates (1/p for those treated and 1-1/p for those 
untreated), while the latter adds a numerator representing the overall probability of being treated for 
those who were treated and of not being treated for those who were not treated.  As the numerator 
and denominator in stabilized weighting will share common factors, the weights will be less variable, the 
sample size will be close to that of the original population and there will be less chance of Type 1 
errors.3,9,42  Therefore, stabilized weights increase statistical efficiency attains better coverage of 
confidence intervals and is recommended when using IPTW to fit a marginal structural model.  For the 
purposes of the following analysis, I will be referring to stabilized inverse probability weights. 
 
Stabilized treatment weights are defined as: 
 
𝑆𝑆𝑆𝑆(𝑡𝑡) =  ∏ 𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝑉𝑉] 
𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝐿𝐿(𝑘𝑘)]
𝑡𝑡
𝑘𝑘=0  Equation 3. 
 
The denominator of the model represents the probability that the subject received their own treatment 
history (ƒAk), given all prior treatments (Ak-1) and all baseline and time-varying covariate histories (L) 
until the last visit (k) for all possible treatments. The numerator acts as a stabilizing factor to reduce the 
variance of the estimates and represents the overall probability of being treated for those who were 
treated and of not being treated for those who were not treated using baseline covariates only (V) 
which includes the potential effect modifier (M).  When analyzing RCTs with baseline randomization, the 
value of A at time 0 will be each participant’s assigned treatment and since there is no confounding the 
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stabilized weight will be 1.6,31,33   
 
Once the IPTWs are calculated and balance between treatment groups is established, both the detection 
of effect modification and the average causal effect of treatment on the outcome can be unbiasedly 
estimated in a conventional regression model for repeated measures.  This is done by fitting the 
outcome as a function of the stabilized weights and an interaction term between treatment history and 
the potential effect modifier in all complete cases.2–4  If the interaction term is significant at the 0.05 
level, multiplicative effect modification exists and stratum specific conditional estimates should be 
reported.   
 
Assumptions 
There are several assumptions that must be met when fitting a MSM to assess either confounding or 
effect modification. First is the assumption of no unmeasured confounders, i.e. conditional 
exchangeability or sequential randomization.  This assumption requires that all covariates which are 
associated with treatment assignment, outcomes or censorship are adjusted for at each visit, causing 
treatment selection to once again be random as it was at baseline.5,6,42  If unobserved confounders are 
present, then treatment groups will no longer be exchangeable and residual bias in the treatment-
outcome association can remain.  Therefore, it is important, although not empirically verifiable, to 
ensure that all possible confounders which affect treatment selection and outcome are added to the 
models.     
 
The second assumption of positivity assumes that the conditional probability of receiving either 
treatment and of remaining under complete follow-up will be greater than zero.  Positivity is guaranteed 
in randomized control trials because, by design, there will be individuals assigned to each level of the 
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studied treatment and therefore, there is no possibility of a structural violation of positivity.2,5,42 
However, depending on the sample size and the number of confounders, there can be instances where, 
at one or more levels of the confounders, no one happens to be observed at one or more levels of the 
exposure (zero cells).  These random violations of probability occur by chance and can be corrected by 
using parametric models or combining adjacent subgroups with cells greater than zero.2,42 
 
The third is the unverifiable assumption that one is using the correct weighting and analysis models.  
Any parametric model may be mis-specified by the omission of unmeasured confounders, non-linear 
terms or interactive relationships.  If misspecification occurs, residual bias in the treatment-outcome 
association can remain or, in some cases, even increase.5,41  Sensitivity analyses to test the listed 
structural model specifications above must be done to determine whether the stabilized weights have a 
mean of 1.0 and a minimum and maximum that is not very extreme.  
 
Lastly, it is assumed that all missing data will be missing at random (MAR).  The MAR assumption states 
that conditional on some set of variables that are fully observed, the probability of missing outcome or 
exposure is independent of all variables in the model.33,40,43 
 
The Importance of Looking at Race as an Effect Modifier in the LODO trial 
In the ACRC LODO trial, the investigators tested the effectiveness of low dose theophylline, a drug 
known for its narrow therapeutic window and severe interactions with various drugs, in maintaining 
asthma control in mild to moderately severe asthmatics compared to the widely used anti-leukotriene 
antagonist montelukast (Singulair) and placebo, respectively.  Results of the LODO study found no 
difference in EPAC rates between theophylline and montelukast (1.22; 95% CI=0.82-1.86; p=.35) as well 




Maintaining asthma control was defined as the rate of episodes of poor asthma control assessed 
by spirometry measures, ambulatory peak flow monitoring, participant-reported symptoms and the use of 
rescue or reliever medications or health care services.  Not only do these measures predict asthma control, 
they have also been shown to predict subsequent treatment adherence and be affected by prior treatment.  
For example, a lower than normal FEV1 is associated with severity of asthma symptoms, increased asthma 
attacks, reduced quality of life and the likelihood of both hospitalizations and respiratory failure all of which 
have been shown to affect whether a participant stays on their assigned treatment.44  In addition, since 
clinical trials are longitudinal studies, current spirometry measures are in part a result of previous treatment, 
mediating the association between treatment and asthma control.  A similar case can be made for all of the 
other potential time-varying confounders mentioned above. As the decision to terminate treatments is a 
nonrandomized event, influenced by both subject attributes and previous treatment, it was assumed that 
time dependent confounding may have caused the results of the ITT to be biased towards the null.   
 
Similarly, the above measures have been shown to differ within and between racial and ethnic 
subgroups.  Increasing evidence has supported the notion that racial and ethnic disparities for asthma 
outcomes and trial participation come about when biases in the health care system interface with 
individual and societal traits10,11,45–48  First, physicians may have unintentional biases and stereotypical 
beliefs about minority populations that influence medical decision-making, leading to under treatment, 
inadequate levels of self-management education and excess asthma morbidity and mortality.11,46,48–50 
For example, Okelo et al. found that physicians frequently underestimate the severity of disease in black 
compared with whites (65% vs. 59%, p=0.05).50  Studies have also shown that physicians are more likely 
to believe that their African American and Hispanic patients would be less capable of adhering to 
doctor’s orders than their white counterparts leading to non-representation in clinical trials and/or the 
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potential for information bias.51,52  Unfortunately, the stereotyping of minorities is not a new 
phenomenon as anecdotes as far back as the early twentieth century have indicated the medical 
community’s prejudice against ‘groups that could not be assimilated into a complex, white civilization’.53 
 
Consequently, poor interactions with physicians have lead patients to distrust their provider and the 
health care system in general which affects participation and adherence in clinical trials.17,54–56  A 
number of studies have found that minorities, particularly African Americans, distrust healthcare 
institutions and providers, in general, due to past experiences of racism within the medical community 
such as in the case of Tuskegee, where doctors purposely withheld syphilis treatment from poor black 
men for more than 20 years post penicillin.46,53,57  It has been estimated that 25% of African Americans 
have a high level of distrust in physicians, but this is most likely an underestimate.58  Furthermore, 
adherence to prescribed medications may become sub-optimal when patients do not trust their 
clinicians or believe that the medications prescribed are actually ineffective or unneeded.  For example, 
studies have found that asthma medication use in inner-city minority populations is over reliant on 
symptom-driven management rather than daily use of controller medications to treat the underlying 
disease.56,59  Riekert et al found that even when providers practiced according to the guidelines, at least 
a third of the patients did not take their controller medications, with children managing symptoms of 
asthma with short-term beta-agonists instead of controller medications (70% vs. 45%).56   
 
Lastly, racial and ethnic differences have been shown to exist in regards to certain treatment response 
and effects.60  Albuterol is the most commonly prescribed short-acting bronchodilator (SABA) asthma 
medication in the US and is likely to be the only medication used to treat airflow obstruction due to 
asthma regardless of severity among minority populations.  However, a number of studies have found 
that the drug may not be as effective in Puerto Ricans and African Americans as it is in whites and 
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Mexicans.20,61–64  In addition, inhale corticosteroids (ICS), which have been recommended by National 
Asthma guidelines as a first-line therapy for the treatment of chronic asthma,65 has been consistently 
shown to reduce airway responsiveness, diminish symptoms and prevent exacerbations over time.  
However, there is substantial inter-individual variability in response to ICS and there is evidence that 
these first-line treatments are not as effective in improving asthma control in African Americans in 
comparison with other racial and ethnic subgroups.20,21,66–68  One study found that ICS, improved the 
change in FEV1 after albuterol administration in Mexican Americans (21.7%, P=.01) and Puerto Ricans 
(18.5%, P=.02) but not in African Americans (3.0%, P=.73).21   Unfortunately, information on the 
pharmacokinetics of theophylline or montelukast by race is not known.   
 
Understanding the complex etiologies of asthma as they relate to diverse populations will become 
increasingly important from the perspective of public health.  Over the next four decades, the U.S. will 
experience significant demographic shifts with minority or multiple race populations becoming the 
majority.  First, having knowledge about beneficial, or non-successful, treatment options in diverse 
research participants would improve the generalizability of research findings and provide clinical 
guidance in asthma management for minority patients.69  Second, diversity in clinical research is a 
prerequisite for equity and elimination of disparities.46,69–71  The inclusion of minority groups in trials will 
not only improve patients’ knowledge and sense of empowerment, but over time will lead to better 
health advocacy, study participation and health outcomes.  In fact, one study found that when patients 
are empowered by their physicians, inner city families are highly motivated to comply with medical 
regimens and asthma action plans.56    
 
Knowing that the ACRC has been successful in enrolling large numbers, the opportunity presented itself to 
examine whether race was an effect modifier in the estimation of the causal effect of theophylline, 
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montelukast and placebo on the annual rate of EPACs using a MSM while also accounting for potential time-
dependent confounding that could have occurred due to post randomization confounding.   
 
Figure 3.1 shows a possible directed acyclic graph72 that represents the relationships between the time-
varying treatments (generally a time-varying variable as each day you may take it or not take it) and the 
above covariates with the outcome stratified by an effect modifier, assuming no unmeasured confounding.  
L(0) denotes baseline demographic characteristics along with baseline FEV1.  It was assumed that there was 
no effect of L(0) on A(0), because of randomization and full initial compliance.  Therefore, confounding is 
assumed to occur only after A(0) (baseline).  A(1), A(2) and A(3) represents treatments actually received, 
irrespective of randomization, at follow up times 1, 2, and 3.  L(1), L(2) and L(3) denotes the current levels of 
the time varying covariates - pulmonary function measures, asthma symptoms, medications and adverse 
effects at follow-up visits 1, 2, and 3.  C(1), C(2), and C(3) accounts for lost to follow-up which occurred due 
to past treatment history and confounder levels.  M represents the effect modifier - race.  Lastly, Y denotes 
the annual rate of asthma exacerbations indicating poor asthma control.   
 
While the DAG implies that both A and M affect Y, it does not indicate whether effect modification exists 
or if it does, how M modifies the effect of A on Y.2  Overall, there are 10 possible outcomes (arrows into 
Y) for each subject representing all possible combinations of treatments for the four time periods, of 
which only one is observed.  However, once all confounding paths are blocked, only the causal paths 
(green arrows into Y) remain.  
 
Methods 
Study population   
The American Lung Association Airway Clinical Research Centers (ACRC) is a network of clinical centers 
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throughout the country dedicated to improving asthma outcomes in diverse populations.  Between 1999 
and 2015, the network completed over ten trials that had a direct impact on the lives of asthma 
participants and the cost of their care, recruiting  more than 5,000 participants with asthma with 
average study populations consisting of 40% non-Hispanic white, 40% African American and 20% 
Hispanic.26  As a multicenter network, the ACRC is well poised to conduct comparative effectiveness 
research due to its ability to enroll large numbers of participants from diverse populations from 
different regions of the USA to ensure that the research findings had external generalizability and were 
relevant to large groups of participants.26  All data collected from the clinical sites is managed and 
analyzed by a Data Coordinating Center at Johns Hopkins University.  An overview of ACRC studies has 
been reported elsewhere.25  Since 2015, the ACRC mission was expanded to include other obstructive 
lung disease such as COPD.  This change in focus is not relevant to this paper and when discussing the 
ACRC, it will refer to the network as it was between 1999 and 2015. 
 
Study Design  
The Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial was the ACRCs 
second trial that began in 2002 and ran throughout 2003.  It was a multicenter, randomized, double-
blind, parallel design, placebo-controlled trial evaluating whether low-dose theophylline was as effective 
as an add-on therapy in treating asthmatics compared with 1) montelukast and 2) placebo in 488 
participants with poor asthma control.  
 
To be eligible for the study, participants had to be over the age of 15 years, had physician-diagnosed 
asthma, been prescribed daily asthma medication for at least a year, had an FEV1 of 50% or more of 
predicted values and had a score of 1.5 or greater on the Asthma Control Questionnaire.  Participants 
who smoked or used oral corticosteroids, leukotriene antagonists or theophylline with four weeks 
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preceding enrollment or had other significant illness were ineligible to participate.  
 
After a one to two week run-in, eligible participants were randomized in a stratified permuted block 
method in a 1:1:1 allocation ratio to 300mg/day theophylline (n=160) to 10mg/day montelukast (n=164) 
to placebo (n=164) – in addition to their existing asthma therapy.  Participants were followed for six 
months (24 weeks), attended three follow-up visits (one, three and six months after randomization) and 
were contacted by phone periodically in between visits to ensure the participant was not experiencing 
any problems associated with study participation (figure 3.2). 
 
Primary Outcome 
The outcome of interest in the LODO trial was the annual rate of acute asthma exacerbations 
(events/person/time) defined as having at least one of the following episodes of poor asthma control 
(EPACs):    
 
• 30% drop in peak flow for 2 consecutive days; or 
• Increase of 2 or more used of rescue medication (4 puffs MDI, 2 nebulizer uses); or 
• New course of oral steroids for asthma; or 
• Unscheduled health care for asthma symptoms 
 
This composite outcome measure was used to reflect the several dimensions of good asthma control 
including physiology, symptoms and health care use.  It should be noted that EPACs is not a standardized 
composite measure of asthma control and was created by the ACRC investigators.  This measure has 
been used as the primary outcome for many of their trials in order to achieve its mission to provided 
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In the original ITT analyses, participants were randomized in equal allocation ratio to one of three 
treatment groups:  
 
• Theophylline (Theo-Dur®) 300 mg/capsule  
• Montelukast (Singulair®) 10 mg/capsule  
• Placebo capsule 
 
Subjects were instructed to ingest 1 capsule daily following their evening meal.  All treatments were 
masked by opaque capsules.  After randomization, the remainder of the study was observation in the 
sense that participants could discontinue study medication.  
 
As such, for the IPW analysis treatment groups consisted of all those who were compliant with their 
respective assigned treatments at each visit compared to those who were not compliant for each arm of 
the original randomization.  This allowed for a participant’s propensity for adherence to vary as 
circumstances changed over the course of the study.  Adherence information was obtained from diary 
cards participants provided to study investigators at the 1, 3 and 6 month clinical visits.  A person was 
considered to be adherent to assigned treatment if they reported being on study treatment with no 
interruptions since the last clinic visit or if they were currently on study treatment but had temporarily 
discontinued since last visit.  All other cases were considered to be non-adherent.  In total, 174 
participants did not adhere to their assigned study treatment in 218 visits.  Twenty three participants 
73 
 
were non-adherent with assigned medication at 1 month – 11, 8, and 4 in the theophylline, montelukast 
and placebo groups, respectively.  Twelve were non-adherent at three months – 6, 4 and 2 in the 
theophylline, montelukast and placebo groups, respectively.  At the six month visit, an additional 139 
participants did not adhere to the study medication – 45 in the theophylline group, 49 in the 
montelukast group and 45 in the placebo group.   
 
Potential Effect Modifier 
Racial/ethnic group, a pretreatment covariate, was considered to be a potential effect modifier in the 
relationship between treatment and asthma control.  In the original LODO study, race/ethnicity 
consisted of the following self-reported groups: white (61%), black (29%), Hispanic (7.9%), Asian (0.4%), 
American Indian (0.2%) and Other (1.6%).24  For the preservation of positivity in my analysis, race was 
restricted to two mutually exclusive subgroups: white (61%) vs. non-white (39%).   
 
Time-Dependent Confounders 
A number of covariates were considered as potential time-dependent confounders. It was assumed that 
these variables were measured prior to deciding whether or not to continue with their assigned 
treatment or the study in general.   
 
Variables that were collected only at baseline and remained static throughout the trial included age 
(defined as a continuous variable), sex (male, female) and race (white, non-white).    
 
Covariates considered potential time-vary confounders included: 
• Pulmonary Function Test indices such as forced vital capacity (FVC), forced expiratory volume 
(FEV1); bronchodilator reversibility (BD); and ambulatory peak flow (PEF)  - interpreted as 
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percentages of predicted values based on Hankinson et al. well-established reference equations 
for healthy subjects of similar demographic characteristics (height, age, sex, race and weight).  A 
detailed description on how percent predicted values based on normal lung function are 
calculated has been previously published.73,74  
  
• Average Asthma Symptom Utility Index (ASUI) was scored from 0 to 1, with 0 indicating severe 
symptoms for at least one week to 1 signifying no symptoms in the two week period.75  The 
items are then weighted according to participant preferences and scored based on a multi-
attribute utility function of ASUI= 1.200 x (S1 Cough * S2 Wheeze * S3 Shortness of Breath * S4 
Awake At Night * S5 Medical Side Effects) - 0.200.  A detailed description of the ASUI has been 
previously published elsewhere.75  
 
• Medication use was defined as a binary measure.  Participants were asked if they had used any 
of the following medications since their last visit: inhaled corticosteroids, inhaled long-acting 
beta-agonists, inhaled short-acting beta-agonists, inhaled anticholinergic, combination drugs 
such as Advair.   
 
• Adverse effects were also defined as a binary measure.  Participants were asked if they had any 
of the following adverse effects since their last visit – nausea, vomiting, poor appetite, 
heartburn, headache, insomnia, anxiety, tremor, heart palpitations and skin rash.   
 
• Use of health care services was also defined since their last visit.  Starting with the 1 month visit, 
participants were asked if they visited with their doctor or were hospitalized since their last 




It was assumed that these covariates fully encompass the loosely associated four domains of asthma, as 
well as, both the clinician’s and participant’s perspective and therefore, was considered good predictors 
of the outcome (asthma exacerbation), treatment adherence and censorship. 
 
Missing Data  
Thirty-one participants (6% of participant visits) had missing covariate estimates for one or more 
confounders despite attending visits and providing exposure and outcome data.  Missing covariate data 
were imputed using the mean value for the treatment and time period groups.  These cases were 
retained for all analyses.  
 
Data were censored at the time of the first missed visit, i.e. exposure or in cases where the outcome was 
missing.  Research has indicated that censored at first missed visit is generally the least biased across all 
missingness mechanisms.29,40,76  Twenty-eight cases were lost to follow-up after the baseline visit – 13 
from the theophylline group, 5 from montelukast and 10 from the placebo group - leaving 460 cases 
with complete data at the six week visit.  Another 33 participants had been lost to follow-up after the 
six-week visit – 10 from theophylline, 14 from montelukast and 9 from placebo – leaving 427 cases with 
complete data at the three month visit.  At the six month visit, another 24 were censored – 10 from the 
theophylline, 5 from montelukast and 9 from placebo – leaving 403 cases with complete data at the six 
month and final visit.   
 
Statistical Analysis  
Inverse Probability Weighting Models  
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There is lack of consensus as to whether the propensity scores used to calculate the IPTWs when 
attempting to detect effect modification should be estimated on the full cohort or by strata.35–37,39  In all 
of these studies, both methods seem to provide valid subgroup analyses as long as the propensity score 
correctly reflects the underlying distribution and that the cohort and subgroups are of sufficient size.  To 
test these findings, propensity scores were computed for both the full cohort and by stratum.   
 
Pooled logistic regression models were fitted for the probability of staying on assigned treatment 
(adherence) for subjects at each visit by treatment arm in the full cohort as well as by stratum.  The 
dataset for these models was discretized into one observation per subject per visit so that 1) time could 
be fit as a class variable to allow a separate intercept for each time and 2) lagged variables for previous 
treatment and confounder histories would be comparable between subjects.   
 
Stabilized treatment weights were created by dividing the baseline probability of selecting a treatment 
(numerator in equation 1) by the probability of selecting treatment given prior treatment history and 
potential confounders up to time t (denominator in equation 1).  Each covariate was entered in the 
pooled logistic models as a main effect only. 
 
Resulting predicted probabilities were then used to construct the final stabilized treatment weights for 
each subject at each visit.  Once all subjects had a stabilized weight for each visit, a final stabilized 
weight per participant was obtained by multiplying the estimated probability of their observed 
treatment at each visit cumulatively over time, i.e. the first score was left as is, and for all others, the 
scores at the current visit was multiplied by the score of the previous visit.  To determine whether the 
final stabilized weights resulted in balanced data, distribution plots were created to assess central 




Poisson regression models using PROC GENMOD were ran for the entire population and for each level of 
M.  The full cohort model fitted the annual rate of episodes of poor asthma control (outcome) as a 
function of the assigned treatment using the final weights and an interaction term between the assigned 
treatment and potential effect modifier.  Stratum specific models were fitted using the same criteria as 
the full cohort model with the exception of the interaction term.   
 
Final models were fit to all uncensored cases with complete data (N=403) and were conducted for three 
treatment groups – theophylline vs. montelukast, theophylline vs. placebo and montelukast vs. placebo. 
Generalized estimating equations (GEE) with an independent correlation matrix were used in all models 
to account for the correlation within-subjects when estimating regression parameters to make valid 
statistical inferences from longitudinal data.77–79  All data management procedures were conducted with 
SAS 9.4 (SAS Institute, Cary, NC).80  
 
Results 
Participant Characteristics  
Table 3.1 delineates baseline characteristics and treatment assignment rates by race.  Out of the 488 
subjects randomized to the LODO study, 296 (61%) were white and 192 (39%) were non-white, with the 
majority of the latter being African American (29%) and Hispanic (8%).  Treatment groups had similar 
representation of both white and non-white subjects.  No differences between racial groups were seen 
for baseline characteristics except for the fact that whites were significantly more likely to be taking 




Table 3.2 shows participant characteristics by race over the follow-up period.  Treatment adherence 
over time was similar for racial groups.  At four weeks, white subjects had significantly lower declines in 
their FVC bronchodilator change rate and were significantly more likely to report heartburn than their 
non-white counterparts.  Non-whites displayed lower pre-bronchodilator FEV1 than whites throughout 
the trial but this difference only became significant after 3 months.  Lastly, non-whites were significantly 
more likely to report tremors at six months than their white counterparts (p-value=0.02).   
 
Table 3.3 summarizes the number and rates of EPAC composite events as well as each component 
individually due to treatment effects by race.  Event rates were similar for racial groups in both the 
theophylline and placebo groups however, in the montelukast group, nonwhites were found to have 
more EPACs overall and by episode components.  Significant differences in event rates were found 
between whites and non-whites assigned to montelukast for overall EPACs (2.66 vs. 5.75, p-
value=0.0034), increased medication use (2.15 vs. 4.60, p-value=0.0212) and unscheduled health care 
(0.33 vs. 0.93, p=0.0007). 
 
Inverse Probability Weighting Models 
Propensity scores were initially computed for the full cohort and by racial strata.  The mean stabilized 
weight in the full cohort was 0.998 and ranged from 0.04 to 4.0, indicating that the model was correctly 
specified.  Figure 3.2 shows the distribution overlap of the stabilized weights for all groups over time in 
the full cohort.  In comparison, the stratum-specific mean stabilized weights were similar to the full 
cohort for whites but ranged from 0.02 to 10 in the non-white group.  Furthermore, the non-white 
group had abnormally large standard errors and violated the positivity assumption as many exposure-
covariate groupings had zero cases.  This led to the conclusion that the non-white group was not of 
79 
 
sufficient size to obtain meaningful estimates.  As such, the full cohort was used for all subsequent 
analyses.  
 
The distribution of treatment groups (theophylline vs. montelukast, theophylline vs. placebo and 
montelukast vs. placebo) in the full cohort was examined through plotting the stabilized weights in the 
treated and untreated groups over time both in the original and in the weighted data sets.  The central 
tendency of the covariate values coincided between groups in both data sets indicating that balance was 
achieved.  The distribution plots for the weighted data sets are shown in figures 3.3a, b, and c. 
 
The denominator of the inverse probability treatment weight models for the full cohort were further 
examined to find covariates with negative coefficients as these predict which individuals would be more 
likely to be non-adherent.42  In these models, previous treatment was strongest predictor of present 
treatment in all treatment groups (-5.72 for theophylline, -4.97 for montelukast and -18.43 for placebo).  
None of the other time-varying covariates were strong predictors of treatment changes – suggesting 
bias in treatment selection over time may not be particularly strong in this data (see Appendix 3.A, 3.B, 
3.C).    
 
Outcome Models 
The results of the MSM analysis for the full cohort are found in table 3.4.  There found no significant 
treatment effect on overall asthma exacerbation rates among all three groups: theophylline vs. 
montelukast (RR=1.20, 95% CI: 0.81-1.77, p=0.36); theophylline vs. placebo (RR=1.01, 95% CI: 0.69-1.49, 
p=0.96) and montelukast vs. placebo (RR=0.84; 95% CI: 0.58-1.22, p=0.36).  However, taking 
montelukast was associated with significantly reduced drops in peak flow than for the placebo group (RR 




Effect modification by race was seen only when comparing montelukast to placebo for overall EPACs, 
increased medication use and unscheduled health care visits.  Compared with whites, non-whites were 
more than twice as likely to suffer from an EPAC on montelukast as on placebo (RR=2.13, 95% CI: 1.08-
4.46, p= 0.04) and almost 3 times as likely to increase medication use (RR=2.86, 95% CI: 1.10-7.42, 
p=0.03).  Furthermore, non-whites were over 5 times more likely to have unscheduled health care visits 
than whites while on montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02).  Lastly, 
while only borderline significant, it should be noted that compared with whites, non-whites on 
theophylline were 66% less likely to have unscheduled health care visits than those on montelukast 
(RR=0.34, 95% CI: 0.11-1.01, p=0.05). 
 
Table 3.5 shows the effects of treatment by strata for those outcomes in which effect modification by 
race was found.  The only significant finding was that whites on montelukast were significantly less likely 
to have an EPAC than those on placebo. 
 
Discussion 
This study examined the moderating impact of race on the causal effect of treatment on asthma control 
in the LODO trial of the ACRC using MSMs.  As hypothesized, qualitative effect modification on the 
multiplicative scale existed for a number of treatment-outcome associations. However, race differences 
only seemed to exist for patients on montelukast.  In the unadjusted analysis, non-whites were twice as 
likely to have an EPAC on montelukast as their white counterparts (5.75 vs. 2.66 episodes per person 
year, p=0.0034).  Similar findings were seen for increased medication use and health care visits (table 
3.3).  Results of the MSM also indicated the presence of effect modification for overall EPACs, 
medication use and unscheduled health care when treated with montelukast instead of placebo.  For 
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example, non-whites were over 5 times more likely to have unscheduled health care than whites on 
montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02) (table 3.4).  
 
These finding may be indicative of potential information bias in adherence levels, which was determined 
in this study by self-report.  Research has shown that minority groups are more likely to be over reliant 
on symptom-driven management rather than daily use of controller medications.56,81,82  One study found 
that at least a third of black patients claimed to not take their controller medications, with many 
managing symptoms of asthma with short-term beta-agonists alone.56  However, since the significant 
findings only applied to montelukast and not to theophylline, it may be more plausible that the 
difference is due to pharmacogenetics reasons.  Prior research has found that African Americans do not 
respond as well as whites to inhaled corticosteroids and albuterol.20,21  Unfortunately, there have been 
no studies to date that have examined racial differences in pharmacokinetics for montelukast.    
 
These results should be considered in the context of the following limitations.  First, MSMs requires the 
untestable assumption of no unmeasured confounding; i.e. that subjects are exchangeable, conditional 
on the measured variables.2,5,83,84  It is assumed that all the most important confounders were identified 
using the expert knowledge of the ALA-ACRC and were then appropriately measured and included in the 
analysis.  However, it can never be verified that all joint predictors of exposure and outcome were 
added to the models. 
 
Second, there is lack of consensus as to whether the propensity scores used to calculate the IPTWs 
should be estimated on the full cohort or by strata.35–37,39  It is assumed that strata-propensity scores 
would lead to better balance between treatment groups and therefore, less bias in the treatment-
outcome relationship when dealing with studies like this with rare outcome events.  However, the same 
82 
 
research indicates that weighting according to the distribution of effect modifiers observed in the full 
cohort is the ideal method when estimating a casual contrast from randomized clinical trials (or any trial 
where there is well defined inclusion and exclusion criteria and everyone has the indication under 
study).  Unfortunately, there is no guideline as to what constitutes a sufficient size for strata-specific 
propensity score models.36 
 
Even when using the full-cohort propensity scores model, finite-sample bias occurred due to the small 
overall sample size and the number of potential confounders.  This led to the presence of random zeros 
in a few of the exposure-covariate groups.  Therefore, one can assume the positivity assumption was not 
met in this study.  However, random zeros are essentially guaranteed because of the infinite number of 
possible values and a more valid assessment of positivity includes looking at extreme values, mean of 
weights and values of exposure-covariate groups adjacent to those with zero.5  Also, as seen in figures 
3.5a, b, and c, many if not all of the exposure-covariate groupings with zero were surrounded by non-
zero groups. 
 
Third, it is assumed that the models used in this analysis are correctly specified. To explore the 
robustness of the models, linear and quadratic terms of continuous variables were tested to restrict the 
possible values of the propensity scores such that on a logit scale the conditional relation between the 
continuous  covariates and the risk of treatment can be represented by a parabolic curve, and each 
covariates contributions to the risk is independent of that of the other covariates.33  No significant 
changes to the outcome were noted.  Additionally models were fitted with different groupings of 
covariates.  For example, models were fitted for individual side effects and medications alone, for 
composite measures of side effects and medications and for both composite and individual grouping.  
Again, there were no significant changes to the outcome.  Finally, the fact that the mean of the final 
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stabilized weight was close to 1 and that the MSM and ITT results were nearly identical, gives strength 
to the assumption that the MSM was not mis-specified.  Unfortunately, the assumption of a correctly 
specified model can never be proven. 
 
Lastly, while there has been plenty of research published regarding racial disparities on asthma 
morbidity and burden, it is important to note that race may not be the true causal factor but instead 
serves as a proxy or marker for one or more of the complex, multilevel and intertwined environmental 
and cultural factors thought to be associated with asthma control disparities.13,16,45,69,85,86   Related to this 
last point, the original LODO study results found that the use of inhaled corticosteroids modified the 
effect of treatment on asthma control.  Comparatively, the only  significant difference in baseline 
characteristics in this study was the fact that whites were significantly more likely to be taking inhaled 
corticosteroids than their non-white counterparts (p-value= 0.02).   Adding credence to the argument 
that race is an effect modifier by proxy and not a direct effect modifier in this study is the fact that while 
there was significance for effect modification in some treatment-outcome relationships, there was no 
significant relationship found between race and any of the asthma control outcomes (table 3.2).  Having 
an association with the outcome is a prerequisite of being an effect modifier.1,2,27,28  Unfortunately, 
effect modification by inhaled corticosteroids was not examined in this paper and it is unknown if it 
would have impacted the results of the MSM analysis.  
 
In summary, my analysis found that race modified the relationship between montelukast and most of 
the asthma control outcomes.  Unfortunately, there is little information on the appropriate method to 
and sample size for a MSM to accurately assess effect modification despite the obvious need for ways to 
combine moderation analysis with advanced causal methods and with the increasing use of MSMs to 
adjust for confounding in longitudinal data with time-varying exposures and covariates.  While this 
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analysis adds to the scarce literature, there are many limitations that may preclude confidence in the 
results including the use of race as an effect modifier and a not so large sample size for at least one of 
the stratum.  However, the fact that all significant findings were found for montelukast indicates that 
something unrelated to the MSM process is at play.  
 
Conclusion 
While MSMs have been commonly used to adjust for confounding in longitudinal studies with time-
varying exposures and time-dependent covariates, they have been rarely used for detecting effect 
modification and there is no consensus in the literature on how best to achieve accurate results.  
Despite theoretical evidence, more practical research on MSMs ability to assess effect modification is 
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Figure 3.1. Structural relationships over time between treatments and asthma control in the Low Dose 
Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial (ACRC, 2002-2003)1
 
1 Created through Daggity software: Johannes Testor, Juliane Hardt, and Sven Knuppel.  Daggitty: A 
graphical tool for analyzing causal diagrams.  Epidemiology, 22(5): 745, 2011 
-A0, A1, A2, A3 represent observed cumulative treatment exposure to either Theophylline, Montelukast 
or Placebo from baseline randomization (A0), 1 month (A1), 3 months (A2) and 6 months (A3). 
-L1, L2, L3 denote measured confounders (pulmonary function measures, asthma symptoms, 
medications and adverse effects) that may be associated with A(k),respectively. L(0) denotes baseline 
demographic characteristics along with baseline FEV1.  It was assumed that there was no effect of L(0) 
on A(0), because of randomization and full initial compliance.   
-C1, C2, C3 reflects loss to follow up at 1 month (C1), 3 months (C2) and 6 months (C3). 
-M represents the potential effect modifier, race. 
-Y indicates the outcome of annual rate of asthma exacerbations indicating poor asthma control.   If all 





Table 3.1. Baseline Characteristics of the 488 LODO Participants by Race/Ethnicity  
  White  Non-White p-value1 
Number of patients (N=488) 296 192 -- 
        
Treatment Assignment, %       
Theophylline 32.4 33.3 0.84 
Montelukast 34.5 32.3 0.62 
Placebo 33.1 34.4 0.77 
        
Demographics        
Age, mean ± SD 41.3 ± 15.3 39.1 ± 13.8 0.10 
Male, % 26.7 25.5 0.77 
        
Asthma Symptoms, mean ± SD       
ASUI Average Score, mean ± SD 0.68 ± 0.14 0.68 ± 0.17 0.93 
        
Pulmonary Function, mean ± SD       
Pre-BD FEV1, % predicted* 79.6 ± 16.0 77.3 ± 17.7 0.14 
Pre-BD FVC, % predicted* 87.3 ± 14.9 88.0 ± 16.4 0.62 
Post-BD FEV1, % predicted* 85.8 ± 15.1 83.6 ± 17.1 0.13 
Post-BD FVC, % predicted* 90.9 ± 13.4 92.8 ± 17.5 0.21 
Peak Flow, % predicted* 83.1 ± 18.1 81.1 ± 22.4 0.30 
FEV1 Bronchodilator, % change 8.9 ± 9.9 9.5 ± 13.6 0.58 
FVC Bronchodilator, % change 5.1 ± 9.8 6.0 ± 12.1 0.34 
        
Daily Asthma Treatments, %       
Using asthma medication daily 93.6 89.6 0.11 
Inhaled anticholinergic 3.0 4.7 0.35 
Inhaled long-acting b-agonist 21.0 21.4 0.91 
Inhaled short-acting b-agonist 57.4 59.9 0.59 
Combination drugs 37.8 38.5 0.88 
Inhaled Corticosteroids 41.9 31.3 0.02a 
*Predicted values of Hankinson and colleagues. 
1 P values for categorical variables from Pearson Chi-Square test or Fisher Exact test compared to 
ANOVA test for continuous categories. 





Table 3.2. Time-Varying Characteristics of LODO Participants by Race over LODO Follow Up Periods  
  
 
    
 
      Time 1 (4 Weeks) Time 2 (3 Months) Time 3 (6 Months) 
  White  Non-White p1 White  Non-White p1 White  Non-White p1 
Number of patients 296 192 -- 279 181 -- 270 164 -- 
          
Outcomes, mean ± SD                   
Any EPAC -- -- -- -- -- -- 3.78 ± 0.38    4.99  ± 0.62 0.08 
Peak flow, 30% drop -- -- -- -- -- -- 1.02 ± 0.19 1.35 ± 0.30 0.34 
Increased medication use -- -- -- -- -- -- 2.98 ± 0.38  3.61 ± 0.59 0.35 
New use of oral corticosteroids -- -- -- -- -- -- 0.47 ± 0.08 0.58 ± 0.10 0.41 
Unscheduled health care -- -- -- -- -- -- 0.61 ± 0.12 0.64 ± 0.13 0.85 
  
         On Treatment, % 
         Theophylline 29.4 32.3 0.50 28.0 29.3 0.76 17.0 21.3 0.26 
Montelukast 33.1 30.2 0.50 33.0 30.9 0.65 20.0 20.1 0.98 
Placebo 32.1 33.9 0.69 31.5 33.2 0.72 20.4 25.0 0.26 
  
         Asthma Symptoms, mean ± SD 
         ASUI Average Score 0.75 ± 0.15 0.75 ± 0.17 0.90 0.78 ± 0.16 0.76 ± 0.18 0.38 0.80 ± 0.15 0.79 ± 0.17 0.73 
  
         Pulmonary Function, mean ± SD 
         Pre-BD FEV1, % predicted* 80.6 ± 15.5 77.9 ± 18.4 0.11 80.4 ± 15.9 76.8 ± 17.9 0.03
c 81.1 ± 16.6 76.8 ± 18.3 0.02c 
Pre-BD FVC, % predicted* 88.4 ± 14.9 88.4 ± 17.5 0.98 88.2 ± 14.1 87.5 ± 18.2 0.66 88.6 ± 15.5 89.3 ± 19.7 0.72 
Post-BD FEV1, % predicted* 86.1 ± 15.0 84.0 ± 17.8 0.19 85.9 ± 15.2 83.0 ± 17.9 0.08 86.1 ± 15.1 82.9 ± 17.8 0.07 
Post-BD FVC, % predicted* 91.3 ± 13.5 93.8 ± 20.8 0.15 91.1 ± 13.8 91.8 ± 18.9 0.67 91.1 ± 14.3 92.3 ± 18.3 0.48 
Peak Flow, % predicted* 85.0 ± 17.3 82.9 ± 20.5 0.25 84.5 ± 17.5 82.0 ± 21.6 0.21 85.8 ± 18.0 82.6 ± 19.0 0.09 
FEV1 Bronchodilator % change 7.8 ± 10.6 9.15 ± 11.9 0.19 7.9 ± 10.2 9.2 ± 12.6 0.25 7.1 ± 9.3 9.4 ± 13.8 0.06 
FVC Bronchodilator % change 3.9 ± 8.4 6.5 ± 12.3 0.01a 3.8 ± 9.3 5.5 ± 9.9 0.08 3.4 ± 7.3 4.4 ± 10.8 0.30 
          
Daily Asthma Treatments, % 
         Using asthma medication daily 89.9 86.5 0.25 89.3 87.3 0.52 86.7 87.2 0.87 
Inhaled anticholinergic 3.0 4.7 0.35 3.2 2.2 0.52 3.0 2.4 0.75 
Inhaled long-acting b-agonist 17.9 17.2 0.84 18.6 17.1 0.68 17.8 18.3 0.89 
Inhaled short-acting b-agonist 49.7 50.0 0.94 44.8 47.0 0.65 39.3 45.7 0.18 
Combination drugs 37.8 37.0 0.85 38.7 38.1 0.90 40.7 39.6 0.82 
Inhaled Corticosteroids 35.1 31.3 0.37 35.5 32.0 0.45 33.7 29.3 0.34 
 
         Adverse Effects % 
         Nausea 8.8 10.4 0.55 6.1 3.3 0.18 4.1 3.7 0.83 
Vomiting 3.4 2.1 0.40 3.2 0.6 0.05 1.5 0.6 0.41 
Poor Appetite 3.0 4.2 0.51 3.9 2.8 0.50 4.1 5.5 0.50 
Heartburn 11.8 4.7 0.01b 7.2 6.6 0.82 11.9 8.0 0.19 
Headache 19.9 24.0 0.29 17.6 18.8 0.74 18.5 20.7 0.57 
Insomnia 18.9 18.2 0.85 16.1 13.8 0.50 17.0 20.7 0.34 
Anxiety 8.8 10.4 0.55 8.2 6.6 0.52 9.6 12.8 0.30 
Tremor 1.4 3.1 0.18 1.8 2.2 0.75 1.5 5.5 0.02d 
Heart Palpitations 3.0 2.1 0.52 2.5 4.4 0.26 2.6 6.1 0.07 
Skin Rash 3.4 2.1 0.40 3.9 2.8 0.50 5.2 4.9 0.89 
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Table 3.2. Time-Varying Characteristics of LODO Participants by Race over LODO Follow Up Periods  
  
 
    
 
      Time 1 (4 Weeks) Time 2 (3 Months) Time 3 (6 Months) 
  White  Non-White p1 White  Non-White p1 White  Non-White p1 
          Use of Healthcare Services, % 
         Hospitalization 0.68 1.6 0.34 2.9 3.3 0.78 2.6 3.7 0.53 
Doctor Visits 13.9 15.1 0.70 19.4 22.1 0.48 23.7 28.1 0.31 
*Predicted values of Hankinson and colleagues. 
    1 P values for categorical variables from Pearson Chi-Square test compared to t-tests for continuous variables. As Pearson Chi-Square tests  
only for interactions among groups, any significance level less than 0.15 was then reanalyzed in binary groups - Theophylline vs. Montelukast, 
Montelukast vs. Placebo and Theophylline vs. Placebo - to determine significant differences between groups. 
a) Non-white patients have significantly higher FVC Bronchodilator reversibility than white patients at time 1. 
b) Non-white patients are significantly less likely to report heartburn at time 1 than white patients. 
c) Non-white patients have significantly lower pre-bronchodilator FEV1 than whites at times 2 and 3. 
d) Non-whites are significantly more likely to report tremors at time 3 than white patients. 
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Table 3.3. Number and rate of Episodes of Poor Asthma Control (EPACs), by Treatment Group and Race, 2002-20031 
     
  
 
   
  Treatment Groups 
 
   
  Theophylline Montelukast Placebo 
 
   








   
Asthma EPACs             
 
   
    Events, n 163 106 106 130 183 110 
 
   
    Rate, events/person-year 4.35 4.91 2.66 5.75 4.59 4.50 
 
   
    95% CI 3.05-6.20 3.08-7.82 1.86-3.81 3.97-8.32 3.39-6.21 2.95-6.85 
 
   
    p-value  0.6852 0.0034* 0.9385 
 
   
              
 
   
Episode Components             
 
   
Peak flow, 30% drop             
 
   
    Events, n 53 22 25 18 46 54 
 
   
    Rate, events/person-year 1.42 1.03 0.63 0.80 1.17 2.23 
 
   
    95% CI 0.74-2.76 0.54-1.97 0.37-1.07 0.41-1.58 0.69-1.97 1.15-4.31 
 
   
    p-value  0.4946 0.5865 0.1312 
 
   
              
 
   
Increased medication use             
 
   
    Events, n 118 80 83 96 140 60 
 
   
    Rate, events/person-year 3.27 3.88 2.15 4.60 3.69 2.59 
 
   
    95% CI 2.07-5.17 2.12-7.10 1.37-3.36 2.88-7.34 2.53-5.37 1.44-4.67 
 
   
    p-value  0.6569 0.0212* 0.3214 
 
   
              
 
   
New use of oral 
corticosteroids             
 
   
    Events, n 16 14 17 15 23 11 
 
   
    Rate, events/person-year 0.43 0.65 0.43 0.66 0.58 0.45 
 
   
    95% CI 0.26-0.71 0.39-1.07 0.24-0.77 0.34-1.29 0.31-1.06 0.24-0.86 
 
   
    p-value  0.2475 0.3313 0.5844 
 
   
              
 
   
Unscheduled health care             
 
   
    Events, n 27 14 13 21 32 9 
 
   
    Rate, events/person-year 0.72 0.65 0.33 0.93 0.8 0.37 
 
   
    95% CI 0.44-1.18 0.36-1.17 0.20-0.54 0.52-1.65 0.40-1.61 0.15-0.93 
 
   
    p-value  0.7899 0.007* 0.1861 
 
   
CI= confidence interval 
       
   
1 P values were obtained from Poisson regression with robust variance.   
 
   
* Significant at the 0.05 level 
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Figure 3.2. Distribution Overlap of the Full Cohort Stabilized Inverse Probability Treatment   Weights 
(SWT) for all Treatments by Time Period and Race 
 
-Stabilized Inverse Probability Weights (SWT) in each time period showed a mean (O) and median (─) 
close to 1 indicating that the model was correctly specified.   
-Overall, the mean and median of the SW was 0.98 and 0.99, respectively, and ranged from 0.9-10.4. 
-Time Period 0: Baseline with 324 participants; Time Period 1: 1 month with 266 participants; Time 
Period 2: 3 months with 265 participants; Time Period 3: 6 months with 249 participants 
 
Figure 3.3a. Distribution of Stabilized Inverse Probability Weights in the Treated (Theophylline) and 
Untreated (Montelukast) Groups 
 
-Stabilized Inverse Probability Weights (SW) in the theophylline and montelukast groups followed a 




Figure 3.3b. Distribution of Stabilized Inverse Probability Weights in the Treated (Theophylline) and 
Untreated (Placebo) Groups  
 
-Stabilized Inverse Probability Weights (SW) in the theophylline and placebo groups followed a similar 
distribution indicating balance between both groups. 
 
Figure 3.3c. Distribution of Stabilized Inverse Probability Weights in the Treated (Montelukast) and 
Untreated (Placebo) Groups  
 
-Stabilized Inverse Probability Weights (SW) in the montelukast and placebo groups followed a similar 




Table 3.4. Effects of Treatment and Treatment Effect Modification by Race (white vs. non-white) on  
Episodes of Poor Asthma Control(EPACS), Full Cohort MSM, 2002-20031 
          
 
T vs. M T vs. P M v. P 
 
RR 95% CI P RR 95% CI P RR 95% CI P 
 
                  
Asthma EPACs                   
   Treatment  1.20 0.81-1.77 0.36 1.01 0.69-1.49 0.96 0.84 0.58-1.22 0.36 
   Treatment*Race 0.54 0.25-1.17 0.12 1.14 0.53-2.47 0.73 2.13 1.08-4.46 0.04* 
                    
Episode Components                   
Peak flow, 30% drop                   
   Treatment  1.77 0.95-3.28 0.07 0.70 0.38-1.30 0.26 0.40 0.22-0.72 0.00* 
   Treatment*Race 0.63 0.18-2.19 0.47 0.41 0.12-1.40 0.15 0.64 0.20-2.12 0.47 
                    
Increased medication use                   
   Treatment  1.14 0.70-1.88 0.60 1.19 0.72-1.97 0.50 1.04 0.65-1.68 0.87 
   Treatment*Race 0.56 0.21-1.52 0.26 1.61 0.59-4.41 0.36 2.86 1.10-7.42 0.03* 
                    
New use of oral 
corticosteroids                  
   Treatment  1.01 0.58-1.76 0.98 1.16 0.67-2.01 0.59 1.16 0.64-2.10 0.63 
   Treatment*Race 1.04 0.34-3.20 0.94 1.88 0.63-5.64 0.26 1.80 0.544-5.95 0.34 
                    
Unscheduled health care                   
   Treatment  1.23 0.71-2.12 0.46 1.47 0.75-2.86 0.26 1.19 0.62-2.31 0.60 
   Treatment*Race 0.34 0.11-1.01 0.05* 1.72 0.45-6.54 0.42 5.01 1.36-18.97 0.02* 
 
1. p values for treatment effects on rates of episodes of poor asthma control are based on Poisson regression with  
robust variance 
T=Theophylline; M=Montelukast; P=Placebo; RR=Relative Risk Ratio 
      * Significant at the 0.05 level  




Table 3.5. Effects of Treatment by Stratum for Those Outcomes in Which Effect Modification by Race 
Was Found in the Full Cohort MSM1 
  T vs. M M vs. P 
  Rate 95% CI P Rate 95% CI P 
Asthma EPACs             
         White      0.58 0.36-0.92 0.02 
         Non-White      1.23 0.70-2.17 0.48 
             
Episode Components            
Increased medication use            
         White      0.62 0.34-1.11 0.11 
         Non-White      1.76 0.83-3.73 0.14 
Unscheduled health care             
         White 1.64 0.97-2.75 0.06 0.53 0.26-1.09 0.09 





Chapter 4: Comparing Two Adherence Metrics Using Marginal Structural 
Models to Determine Treatment Effectiveness on Asthma Control 
 
 
Background: Poor adherence to treatment assignments will almost always lead to biased effect 
measures.  Adherence can be considered a time-dependent confounder as it is associated with the 
outcome and is also influenced by past and current treatment.  Marginal Structural Models (MSMs) have 
been used to estimate causal effects of time-varying treatment selection in the presence of time-
dependent confounding and censoring in longitudinal studies.  However, there is no gold standard for 
measuring adherence and it is not clear as to what constitutes an unacceptable level of adherence.  The 
purpose of this paper is to demonstrate whether the use of different adherence metrics has any effect 
on the direction and magnitude of the causal effect of asthma treatments on the rate of episodes of 
poor asthma control (EPACs) in a 6 month randomized controlled trial (RCT) that experienced non-
adherence and loss to follow up.    
 
Methods: MSMs with inverse probability weighting were implemented.  Pooled logistic regression 
models were fitted to compare the probability of staying on assigned treatment (adherence) and of 
remaining uncensored for subjects at each visit for two treatment arms (theophylline and montelukast) 
using self-reported and blood assay adherence metrics.  Final pooled logistic regression models were 
fitted for the annual rate of acute asthma exacerbations comparing treatment arms and the weighted 
sample using a Poisson generalized estimating equation (GEE) with an independent correlation matrix.  
 
Results: There were significant differences in the proportion of patients that were non-adherent 
between the self-report and blood assay adherence metrics. These differences were similar for the two 
treatments.  Still, the adjusted rate ratio, and corresponding 95% confidence intervals, comparing the 
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two treatments for specific outcomes using both MSMs were nearly identical, indicating that adherence 
and censoring was not a significant problem in these data and that exchangeability held throughout the 
trial. 
 
Conclusions:  In theory MSMs hold much potential for further analyses of randomized clinical trials as it 
allows adjustment for time-varying confounding and selection bias, issues more traditional regression 
based methods cannot account for.  However, it remains unclear as to what constitutes a substantial 
level of non-adherence or censorship for MSMs to show differing results from the traditional Intent to 
Treat (ITT) approach.  At the very least, MSMs should be conducted as a sensitivity analysis to the ITT 
approach in RCTs where there is preliminary evidence suggesting the presence of time-varying 
confounders or selection bias.  
 
Keywords: clinical trials, adherence, marginal structure models, inverse probability weighting, causal 






Marginal structural models (MSM) have been theorized to be less biased than Intention to Treat 
methods (ITT) in the estimation of causal effects of time-varying treatments in clinical trials that 
experience non-adherence and attrition.1–6   This is due to the fact that unlike ITT, MSM measure all post 
randomization prognostic factors (confounders and/or mediators) that may affect either treatment 
selection or loss to follow up in an attempt to eliminate all back door pathways that may bias the 
association between the treatment and the outcome, making the baseline randomization in the clinical 
trials once again valid.  
 
Parameters of a MSM are estimated using inverse probability weighting (IPW) which calculates weights 
based on the inverse of the predicted joint probabilities (i.e. propensity score values) of an individual’s 
treatment and censoring history conditional on their observed set of covariates.  This ensures that the 
reweighted data are balanced on the covariates at each point in time during the follow-up, making 
baseline randomization once again valid.  A final weighted model is then fitted using these weights with 
only a function of exposure history predicting the outcome of interest, together with a robust ‘sandwich’ 
variance estimator. 
 
As the direction and magnitude of the effect of “assigned” treatment depends on the adherence 
pattern, accurate measurement of patient adherence is fundamental in estimating the casual effect of a 
treatment on a disease using MSM.  However, there are many problems with this assumption.  First, 
there is not a standard definition of what constitutes adherence.7–11  Adherence can be thought of as an 
all or nothing response – always vs. never taking the assigned therapy – or as a continuum in which 
patients can be adherent or non-adherent only part of the time, i.e. discontinuing therapy prematurely, 
deviating from instructions but still taking the medication etc.  Second, there is no standard method of 
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assessing adherence in clinical trials.  Despite a wide range of options, each method has advantages and 
disadvantages and no single adherence intervention has been determined to be useful in all 
situations.7,8,11–13 
 
In this paper, I will assess whether the use of different adherence metrics (self-report vs. blood assay) in 
a MSM changes the direction and magnitude of the causal effect of asthma treatments on the rate of 
episodes of poor asthma control in a 6 month RCT that experienced non-adherence and loss to follow 
up.  This is a secondary data analysis of the American Lung Association Asthma Clinical Research Centers 
(ACRC) Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial conducted in 
2002-2003.14  The original ITT analysis published by the ACRC found no difference between treatment 
groups when assessing EPACs, despite initial assumptions and/or previous research studies indicating 
otherwise, possibly suggesting that results under the ITT approach may have been biased towards the 
null.  While the ACRC is known for having better average compliance than other clinical trial networks15, 
average adherence rates in LODO trial was 85% for self-reported diary cards versus 60% for plasma drug 
concentrations.  
 
Marginal Structural Models  
Marginal structural models (MSM) have been theorized to be less biased than Intention to Treat 
methods (ITT) in the estimation of causal effects of time-varying treatments in clinical trials that 
experience non-adherence and attrition.1–6   A concern with estimating treatment effects that span 
more than one time point is that a subjects’ behavior and subsequently the distribution of risk factors 
will assumedly change with time.  For example, if participants who do not comply with treatment or 
who are censored differ from those who comply or are still being followed, then imbalances with 
respect to the risk factors by treatment group (confounding) can occur and this imbalance can fluctuate 
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over time.  Furthermore, in the presence of time-dependent confounding, a confounder may 
simultaneously be a mediator between the current exposure and outcome.  If reasons for nonadherence 
or censorship are due to covariates that have been affected by prior treatment, selection bias will occur 
and estimates from traditional regression models will be biased as they cannot adjust for intermediate 
variables.  Unlike conditional regression approaches used in ITTs, MSMs account for both the joint 
effects of baseline and subsequent treatments and for the presence of time-dependent confounding 
influenced by prior treatment, by modeling exposures at each follow up and the final outcome.1,3,5,6 
 
Formally, MSM is a regression model for longitudinal data that relates any possible exposure and 
censoring history, up to time t, to the corresponding counterfactual outcome at time t.2,16–19  In other 
words, these models allow for the estimation of all potential outcome-treatment combinations for each 
study visit, despite the fact that only one response for a given treatment level per visit will be observed 
in the data, with the rest “counter to the facts”.  This is possible because it is assumed that the average 
causal effect of treatment is dependent on whether the choice of a treatment option at a particular time 
point is affected by the presence of time-dependent confounding.  If all time-dependent confounders 
are eliminated then it can be assumed that all subjects had adhered to their assigned treatment and 
therefore, the exposure is said to have a causal effect on the outcome, i.e. there is a difference in the 
counterfactual outcomes under two or more treatment regimes.1,6,19,20  As MSMs describes the marginal 
causal expectation of a potential outcome as a function of a specified treatment regimen, the 
observed risk ratio (Pr [Y =1 │A=1] / Pr [Y =1 │A=0]) will once again equal the unknown counterfactual 
risk ratio (Pr [Ya=1 =1] / Pr[Ya=0 =1]).   
 
MSM parameters are estimated using inverse probability weighting (IPW).  IPW adjusts for post-
randomization confounding and selection bias due to 1) non-adherence, 2) mediators and 3) loss to 
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follow up by creating a pseudo-population where the time-varying treatment is independent of stable 
and time-varying covariates that preceded it, at every time point allowing for causal treatment 
comparisons using standard repeated measure models.1,2,4–6,18,21–23  Instead of modeling the relationship 
between a covariate and the outcome as is done in traditional regression, IPW models the relationship 
between covariates and missingness with that of the putative cause. 
 
Conducting an MSM-IPW analysis is a two-step process.  The first step is to estimate each subject’s 
probability of 1) having their own treatment history and 2) having their own censoring history at each 
time-point and then use these to derive Inverse Probability Treatment (IPT-) and Inverse Probability 
Censoring (IPC-) weights.  The second step is to estimate the treatment-outcome association in 
a conventional regression model for repeated measures that is weighted by the product of IPT- and IPC- 
weights.   
 
Weights can be either non-stabilized or stabilized.  The former is estimated by taking the reciprocal of 
the probabilities of receiving treatment given the covariates (1/p for those treated and 1-1/p for those 
untreated), while the latter adds a numerator representing the overall probability of being treated for 
those who were treated and of not being treated for those who were not treated using baseline 
covariates only.  As the numerator and denominator in stabilized weighting will share common factors, 
the weights will be less variable, the sample size will be close to that of the original population and there 
will be less chance of Type 1 errors.1,22,23  Therefore, stabilized weights increase statistical efficiency 
attains better coverage of confidence intervals and is recommended when using IPW to fit a marginal 
structural model.  For the purposes of the following analysis, I will be referring to stabilized inverse 





Confounding due to non-adherence in RCTs is eliminated through the application of an inverse-
probability-of-treatment weighting (IPTW).17,24,25  IPTWs adjust for imbalances in the characteristics of 
the treated and untreated participants.  It is fit by building a predictive model for receiving the 
treatment of interest given past treatment and prognostic factor history at each time point and then 
obtaining a single weight per subject by multiplying the current treatment weight with that of the 
treatment weights from the previous time points.  Most researchers do this in one step by fitting pooled 
logistic regression treatment models with time as a class variable to allow a separate intercept for each 
time.  The resulting predicted probabilities (i.e. propensity scores) are used to construct the stabilized 
weights for each subject at each time point during follow-up.  The treatment weights are defined as: 
 
𝑆𝑆𝑆𝑆(𝑡𝑡) =  ∏ 𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝑉𝑉] 
𝑓𝑓[𝐴𝐴(𝑘𝑘)|𝐴𝐴(𝑘𝑘−1),𝐿𝐿(𝑘𝑘),𝑉𝑉]
𝑡𝑡
𝑘𝑘=0  Equation 1 
 
The denominator of the model represents the probability that the subject received their own treatment 
history (ƒAk), given all prior treatments (Ak-1) and covariate histories (L) until the last visit (k) for all 
possible treatments (R). The numerator acts as a stabilizing factor to reduce the variance of the 
estimates and represents the overall probability of being treated for those who were treated and of not 
being treated for those who were not treated.  When analyzing RCTs with baseline randomization, the 
value of A at time 0 will be each participant’s assigned treatment and since there is no confounding the 
stabilized weight will be 1.6,16,18 
 
Censoring Weights 
To account for attrition bias due to loss to follow up, one may also calculate inverse-probability-of-
censoring weights (IPCW) following the same steps above.17,26  The only difference is that each study 
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subject is assigned a weight that is the inverse probability of remaining in the trial for the entire duration 
i.e. uncensored.  The censoring weights are defined as:  
 
𝑆𝑆𝑆𝑆(𝑐𝑐) =  ∏ 𝑓𝑓[𝐶𝐶(𝑘𝑘+1)=0|𝐶𝐶(𝑘𝑘)=0,𝐴𝐴(𝑘𝑘) ] 
𝑓𝑓[𝐶𝐶(𝑘𝑘+1)=0|𝐶𝐶(𝑘𝑘)=0,𝐴𝐴(𝑘𝑘),𝐿𝐿(𝑘𝑘)]
𝑡𝑡
𝑘𝑘=0   Equation 2 
 
where the denominator depicts the probability that the subject remained in the trial given their 
treatment (Ak) and covariate histories (L) until the last visit (k) in each treatment group (R) and the 
numerator, the overall probablity of remaining uncensored per treatment.  The stabilized weights do 
not eliminate censoring in the pseudo-population, they make censoring occur at random with respect to 
the measured covariates.  Complete cases with similar characteristics to those of censored cases are 
weighted to represent those who were lost.   Just as with treatment, when analyzing RCTs with baseline 
randomization, the value of C at time 0 will be 0 as there is no loss to follow up.6,16,18 
 
Treatment-Outcome Model 
When both non-adherence and loss to follow-up are present, the weights from both models (treatment 
and censoring) are multiplied together to form one stabilized weight per participant.  The simulated 
pseudo-population now represents a sample from the actual randomized study population in which 
each participant completed follow up, all measured covariates are balanced across exposure groups, and 
all mediators are removed from the causal pathway.  It is the balance across exposure groups, i.e. 
exchangeability, which allows for unbiased estimates of treatment effects in RCTs without 
nonadherence and censoring.  Once balance is established, the average causal effect of treatment on 
the outcome can be unbiasedly estimated in a conventional regression model that does not include the 




There are several assumptions that must be met when fitting a MSM. First is the assumption of no 
unmeasured confounders, i.e. conditional exchangeability or sequential randomization.  This assumption 
requires that all covariates which are associated with treatment assignment, outcomes or censorship 
are adjusted for at each visit, enabling treatment selection to once again be random as it was at 
baseline.6,20,23  If unobserved confounders are present, then treatment groups will no longer be 
exchangeable and residual bias in the treatment-outcome association can remain.  Therefore, it is 
important, although not empirically verifiable, to ensure that all possible confounders which affect 
treatment selection and outcome are added to the models.     
 
The second assumption of positivity assumes that the conditional probability of receiving either 
treatment and of remaining under complete follow-up will be greater than zero.  Positivity is guaranteed 
in randomized control trials because, by design, there will be individuals assigned to each level of the 
studied treatment and therefore, there is no possibility of a structural violation of positivity.17,20,23 
However, depending on the sample size and the number of confounders, there can be instances where, 
at one or more levels of the confounders, no one happens to be observed at one or more levels of the 
exposure (zero cells).  These random violations of probability occur by chance and can be corrected by 
using parametric models or combining adjacent subgroups with cells greater than zero.17,23 
 
The third is the unverifiable assumption that one is using the correct weighting and analysis models.  
Any parametric model may be mis-specified by the omission of unmeasured confounders, non-linear 
terms or interactive relationships.  If misspecification occurs, residual bias in the treatment-outcome 
association can remain or, in some cases, even increase.20,21  Sensitivity analyses to test the listed 
structural model specifications above must be done to determine whether the stabilized weights have a 




Lastly, it is assumed that all missing data will be missing at random (MAR).  The MAR assumption states 
that conditional on some set of variables that are fully observed, the probability of missing outcome or 
exposure is independent of all variables in the model.4,18,27 
 
Measuring Adherence 
Adherence has been defined by the World Health Organization as “the extent to which the person’s 
behavior corresponds with agreed recommendations from a healthcare provider”.28  In most clinical 
trials, this refers to the patient taking medications as prescribed by study personnel for the entire 
duration of the trial.  Unfortunately, it has been well documented that most clinical trials suffer from 
some level of non-adherence, with adherence rates ranging from 50% to 80%.7,11,28,29   
 
Poor adherence to treatment assignments will almost always lead to biased effect measures.  First, 
adherence to therapy is always a correlate of clinical outcomes; plenty of studies have shown that trial 
participants who do not follow prescribed regimens have a poorer prognosis than subjects in the 
respective groups who do.7,11–13,25  Furthermore, in longitudinal studies with time-varying treatments, 
selection bias may occur if adherence is predicted by past treatment history.18,22,24,30,31  As such, the true 
benefit of many effective medications, including optimal dosage, may be under- or overestimated in 
studies with non-adherence.   
 
Measuring adherence in clinical trials is, therefore, important as results cannot be realistically 
interpreted without such information.  Numerous methods are available for measuring patient 
adherence to medication regimens and all are generally categorized as being subjective vs. objective or 
direct vs. indirect.7,11,12,28  All direct metrics are considered objective as they not only provide proof that 
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the drug was taken by the patient but are measured the same way regardless of situation.  Direct 
metrics include the detection of the drug or a metabolite in a biologic fluid; the detection of a biologic 
marker that is given with the drug; or with direct observation of the patient receiving the medication.  
Tests to detect the presence of the drug or drug marker can be conducted at specified intervals or 
randomly, when feasible.   
 
The majority of tools used to measure adherence in clinical trials are of the indirect type and can be 
categorized as either subjective or objective, based on whether the assessment of medication-taking 
behavior comes directly from the provider/patient or not.  These include self-reporting by the patient; 
medication measurement; use of prescription or electronic medical record review; and/or the use of 
electronic monitoring devices.  
 
Unfortunately, no one single metric has been considered the standard for measuring adherence in 
clinical trials as all have their own advantages and disadvantages. 7,11,12,32,33  The strength of all the direct 
metrics is that they provide a qualitative confirmation that the patient received a dose of medication at 
some point.  However, these metrics do not reveal patterns of adherence and are further susceptible to 
differences in patient-specific metabolic variations.  In addition, these metrics are expensive, difficult to 
perform, may be invasive for patients, and can be impractical for routine use. 
 
Of the indirect metrics, self-report methods (e.g. diaries, questionnaires, interviews) are by far the most 
widely used adherence metric in clinical trials due to its generally low cost and simplicity of 
administration.  Self-reporting tools are useful for identifying patients who are candid non-adherers, as 
well as, assessing the patient’s beliefs, attitudes and barriers to adherence.  However, due to its 
subjective nature, these metrics are susceptible to a number of reporting biases and have been deemed 
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to be unreliable for assessing adherence patterns.  For example, studies have shown that the majority of 
information collected from diaries is either completed retrospectively, which increases the risk of 
patient recall bias, or are fabricated as patients tend to over-report and/or exaggerate medication 
adherence especially in the weeks before and after a clinical visit.31,34   
 
Medical measurement, including dose counting, pill counting and canister weighing, is another common 
indirect adherence metric used in clinical trials.  These metrics are also relatively simple and low cost to 
implement but provides a more objective and valid measure of adherence than self-report.7,12  However, 
these metrics are not without their issues as patients can deliberately switch medications between 
bottles, discard pills/medicines before visits, and/or “forget” to return medications at study visits to hide 
true adherence.  One study found that up to 20% of participants in a clinical trial were guilty of 
medication dumping.31  Furthermore, medical measurement does not provide information on 
medication-taking patterns or the reasons for the non-adherence as self-reported measurement does. 
 
Pharmacy databases have been used to provide objective information on the rates of refilling 
prescriptions during the trial.  This indirect metric can be used to assess adherence patterns including 
premature discontinuation of therapy.  Pharmacy databases can also substantiate patient responses to 
self-report measures or drug levels in the body through direct metrics.  However for this metric to be 
valid, the entire prescription refill history for a patient must be housed in a centralized pharmacy 
system.  Unfortunately, issues with insurance refill limits or formularies may cause patients to seek 
study medications from more than one pharmacy.7  Another problem with using pharmacy databases is 
the unverifiable assumption that prescription refill patterns correlate to patient-medication-taking 




Lastly, electronic monitoring devices provide an objective measure of adherence by recording the times 
and dates when a bottle is opened, drops are dispensed and canisters are activated.   
Electronic monitoring has significant advantages over most of the other adherence metrics.  First, it 
provides continuous, reliable and precise measure of a patient’s adherence to the prescribed regimen 
unlike that of direct, self-reporting or pharmacy refill measures.  An electronic monitor can detect an 
abnormal medication taking pattern and can verify the number of daily doses missed in partial 
adherence situations.  Furthermore, electronic monitors require that patients open containers, dispense 
drops or activate canisters at the same time each day to guarantee same patterns of adherence, and 
therefore, discarding medication is not as simple as it is with medical measurements.  As a result, 
electronic monitors are commonly used as a reference standard for validating other adherence 
metrics.7,12  However, as with all indirect metrics, electronic monitors cannot prove that the patient 
actually took their assigned treatment or its correct dose. Patients may falsify adherence measurement 
by purposely activating the monitor but not taking the medication or invalidating the data by placing the 
medication into another container.  Furthermore, studies have shown that using an electronic monitor 
to assess medication adherence is stressful to some patients who do not like the thought of being under 
constant surveillance.  Lastly, electronic monitors are costly; they are not typically covered by insurance 
and require additional training of study staff and patients to appropriately use and care for the machine.  
Thus, these devices are not in routine use.   
 
Even with all the options available, measuring adherence remains no easy task.  There is no one metric 
that has been determined to be the gold standard for all settings.  Selection of an adherence metric 




The Case for Precise Measurement of Adherence Data In the LODO trial 
This is a secondary data analysis of the American Lung Association Asthma Clinical Research Centers 
(ACRC) Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial.14  The LODO 
trial aimed to evaluate the effectiveness of low dose theophylline, a drug known for its narrow 
therapeutic window and severe interactions with various drugs, in maintaining asthma control in mild to 
moderately severe asthmatics compared to the widely used anti-leukotriene antagonist montelukast 
(Singulair) and placebo, respectively.   
 
Due to the scientific evidence on theophylline’s significant anti-inflammatory properties at the time 
LODO was being proposed (circa 2000), it was hypothesized by ACRC investigators that adding low dose 
theophylline to the treatment of persistently symptomatic participants would decrease the rate of 
asthma exacerbations when compared with placebo and would be equally effective as the more popular 
and expensive drug, montelukast.  However, results of the ITT approach found no difference in asthma 
control between theophylline and montelukast (1.22; 95% CI=0.82-1.86; p=.35) as well as theophylline 
and placebo (0.99; 95% CI=0.67-1.50); p=1.00) using an ITT approach.14   
 
Like with most chronic diseases, non-adherence to asthma medications is extremely common in clinical 
trials.  One study found that patients tried to deceive investigators regarding their adherence to asthma 
study drugs by continuously  activating inhalers.29 Other studies, found that almost all diary information 





Suboptimal adherence has been found to not only have a direct influence on asthma outcomes but has 
been proven to be a fundamental mediator in the association between treatment and outcomes.13,31,34,36  
For example, non-adherence with study treatments cause an increase in the severity of asthma 
symptoms, increased asthma attacks, reduced quality of life and the likelihood of both hospitalizations 
and respiratory failure.31,35,36   These negative outcomes have also been shown to affect whether a 
participant stays on their assigned treatment.37  In addition, since clinical trials are longitudinal studies, 
current adherence metrics are in part a result of previous treatment, mediating the association between 
treatment and asthma control.   
 
Therefore, it is of upmost importance to distinguish poor asthma control related to nonadherence from 
that of treatment-resistant asthma when interpreting the results of a clinical trial measuring the effects 
of various asthma treatments.31,36  Unfortunately, the ITT analysis effectively ignores these factors, 
attenuating treatment effect towards the null causing a Type II error in which investigators will claim no 
difference in treatment when there might actually be an important difference.1,25,38  As the decision to 
terminate, switch or augment treatments or drop out of the study is a nonrandomized event, influenced 
by both subject attributes and previous treatment, it was assumed that time dependent confounding 
may have existed in the LODO trial and as such, it would be of benefit to reanalyze the data using a 
marginal structural model to allow for a participant’s propensity to adhere to change as circumstances 
are perceived over the course of the study. 
 
Unfortunately, there is no gold standard for adherence metrics and the use of multiple metrics in the 
same study may indicate different levels of non-adherence.  In the LODO trial, self-report adherence by 
patient diaries found adherence rates to be between 85%-90% while blood assay adherence rates were 
in the low to mid 60%.  Due to the significant differences in the proportion of adherence between these 
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two metrics, it was assumed that the causal effect of theophylline and montelukast on the annual rate 
of asthma exacerbations may differ depending on the adherence measurement used. 
 
As such, this paper assesses whether the use of different adherence metrics (self-report vs. blood assay) 
in a MSM changes the direction and magnitude of the causal effect of asthma treatments on the rate of 
episodes of poor asthma control in a 6 month RCT that experienced non-adherence and loss to follow 
up.  Figure 4.1 shows a possible directed acyclic graph39 that represents the relationships between the 
time-varying treatments (generally a time-varying variable as each day you may take it or not take it) 
and the above covariates with the outcome, assuming no unmeasured confounding. L(0) denotes 
baseline demographic characteristics along with baseline FEV1.  It was assumed that there was no effect 
of L(0) on A(0), because of randomization and full initial compliance.  Therefore, confounding is assumed 
to occur only after A(0) (baseline).  A(1), A(2) and A(3) represents treatments actually received, 
irrespective of randomization, at follow up times 1, 2, and 3.  L(1), L(2) and L(3) denotes the current 
levels of the time varying covariates – adherence, pulmonary function measures, asthma symptoms, 
medications and adverse effects at follow-up visits 1, 2, and 3.  C(1), C(2), and C(3) accounts for lost to 
follow-up which occurred due to past treatment history and confounder levels.  Lastly, Y denotes the 
annual rate of asthma exacerbations indicating poor asthma control.   
 
Overall, there are 10 possible outcomes (arrows into Y) for each subject, representing all possible 
combinations of treatments for the four time periods, of which only one is observed.  However, once all 





Study population   
The American Lung Association Airway Clinical Research Centers (ACRC) is a network of clinical centers 
throughout the country dedicated to improving asthma outcomes in diverse populations.  Between 1999 
and 2015, the network completed over ten trials that had a direct impact on the lives of asthma 
participants and the cost of their care.15  As a multicenter network, the ACRC is well poised to conduct 
comparative effectiveness research due to its ability to enroll large numbers of participants from diverse 
populations from different regions of the USA to ensure that the research findings has external 
generalizability and are relevant to large groups of participants.15  All data collected from the clinical 
sites is managed and analyzed by a Data Coordinating Center at Johns Hopkins University.  An overview 
of ACRC studies is reported elsewhere.40  Since 2015, the ACRC was renamed as the Airways Clinical 
Research Centers and its mission was expanded to include other obstructive lung disease such as COPD.  
This change in focus is not relevant to this paper and when discussing the ACRC, it will refer to the 
network as it was between 1999 and 2015. 
 
Study Design  
The Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial was the ACRCs 
second trial that began in 2002 and ran throughout 2003.  It was a multicenter, randomized, double-
blind, parallel design, placebo-controlled trial evaluating whether low-dose theophylline was as effective 
as an add-on therapy in treating asthmatics compared to 1) montelukast and 2) placebo in 488 
participants with poor asthma control.   
 
To be eligible for the study, participants had to be over the age of 15 years, have physician-diagnosed 
asthma, been prescribed daily asthma medication for at least a year, had an FEV1 of 50% or more of 
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predicted values and had a score of 1.5 or greater on the Asthma Control Questionnaire.  Potential 
participants who smoked or used oral corticosteroids, leukotriene antagonists or theophylline with four 
weeks preceding enrollment or had other significant illness were ineligible to participate.  
 
After a one to two week run-in, eligible participants were randomized in a stratified permuted block 
method in a 1:1:1 allocation ratio to 300mg/day theophylline (n=160) or 10mg/day montelukast (n=164) 
or placebo (n=164) – in addition to their existing asthma therapy.  Participants were followed for six 
months (24 weeks), attended three follow-up visits (one, three and six months after randomization) and 
were contacted by phone periodically in between visits to ensure the participant was not experiencing 
any problems associated with study participation (figure 4.2). 
 
For the purposes of this paper, analyses will be restrict to only the theophylline and montelukast groups 




Participants were randomized in equal allocation ratio to one of the following treatment groups:  
 
• Theophylline (Theo-Dur®) 300 mg/capsule (n=160) 
• Montelukast (Singulair®) 10 mg/capsule (n=164) 
 
Subjects were instructed to ingest 1 capsule daily following their evening meal.  All treatments were 
masked by opaque capsules.   
After randomization, the remainder of the study was observation in the sense that participants could 
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discontinue study medication. As such, for the IPW analysis treatment groups consisted of all those who 
were compliant with their respective assigned treatments at each visit compared to those who were not 
compliant for each arm of the original randomization.  This allowed for a participant’s propensity for 
adherence to vary as circumstances changed over the course of the study.   
 
Primary Outcome 
The outcome of interest was the annual rate of acute asthma exacerbations (events/person/time) 
defined as having at least one of the following episodes of poor asthma control (EPACs):    
 
• 30% drop in peak flow for 2 consecutive days; or 
• Increase of 2 or more used of rescue medication (4 puffs MDI, 2 nebulizer uses); or 
• New course of oral steroids for asthma; or 
• Unscheduled health care for asthma symptoms 
 
This composite outcome measure was used to reflect the several dimensions of good asthma control, 
including physiology, symptoms and health care use.  It should be noted that EPACs is not a standardized 
composite measure of asthma control and this definition was created by the ACRC for this and other 
trials.  This measure has been used as an outcome for many of their trials in order to achieve its mission 
to provided evidence to support optimal standards of care into clinical or public health practice for 





ACRC investigators collected data on treatment adherence two different ways – direct measurement of 
venous blood plasma at the 1 and 6 month clinical visit (i.e. blood assay group) and self-report through 
patient diaries over the entire duration of the trial (i.e. self-report group).   
 
Plasma concentrations for theophylline were collected by particle-enhanced turbidimetric inhibition 
immunoassay while montelukast concentrations were collected through reversed-phase liquid 
chromatography. The detection levels for theophylline and montelukast were 2mg/L and 5ng/ml, 
respectively. Persons with plasma concentrations lower than these levels were considered to be non-
adherent.   
 
Self-reported adherence was calculated as the proportion of days an individual reported taking 
medication over the total number of days that the medicine should have been taken, within the 
respective time period.  A person was considered to be adherent to assigned treatment in a time period, 
if they were at least 80% adherent to study medication.  All other cases were considered to be non-
adherent.   
 
Potential Time-Dependent Confounders 
A number of covariates were considered as potential time-dependent confounders. It was assumed that 
these variables were measured prior to deciding whether or not to continue with their assigned 
treatment or the study in general.   
 
Variables that were collected only at baseline and remained static throughout the trial included age 




Covariates considered potential time-vary confounders included: 
 
• FEV1, FVC and PEF volumes - interpreted as percentages of predicted values based on Hankinson 
et al. well-established reference equations for healthy subjects of similar demographic 
characteristics (height, age, sex, race and weight).  A detailed description on how percent 
predicted values based on normal lung function are calculated has been previously 
published.34,41  
  
• Average Asthma Symptom Utility Index (ASUI) was scored from 0 to 1, with 0 indicating severe 
symptoms for at least one week to 1 signifying no symptoms in the two week period.42  The 
items are then weighted according to participant preferences and scored based on a multi-
attribute utility function of ASUI= 1.200 x (S1 Cough * S2 Wheeze * S3 Shortness of Breath * S4 
Awake At Night * S5 Medical Side Effects) - 0.200. 
 
• Medication use was defined as a binary measure.  Participants were asked if they had used any 
of the following medications since their last visit: inhaled corticosteroids, inhaled long-acting 
beta-agonists, inhaled short-acting beta-agonists, inhaled anticholinergic, combination drugs 
such as Advair.   
 
• Adverse effects were also defined as a binary measure.  Participants were asked if they had any 
of the following adverse effects since their last visit – nausea, vomiting, poor appetite, 




• Use of health care services was also defined since their last visit.  Starting with the 1 month visit, 
participants were asked if they visited with their doctor or were hospitalized since their last 
study visit.  
 
All potential time-varying confounders came from participant diary cards except for FEV1 and FVC 
measures which were collected through spirometry at each visit.  It was assumed that these covariates 
fully encompass the loosely associated four domains of asthma, as well as, both the clinician’s and 
participant’s perspective and therefore, was considered good predictors of the outcome (asthma 
exacerbation), treatment adherence and censorship. 
 
Missing Data  
Twenty visits in the plasma group (2.4% of 828 visits) and 28 visits in the self-report group (2.5% of 1,104 
visits) had missing covariate estimates for one or more confounders despite attending visits and 
providing exposure and outcome data.  Missing covariate data were imputed using the mean value for 
current treatment at each time point. These cases were retained for all analyses. 
 
Data were censored at the time of the first missed visit (i.e. exposure), first missed blood draw (for the 
blood assay group) or in cases where the outcome was missing.  Research has indicated that censored at 
first missed visit is generally the least biased across all missingness mechanisms.3,4,43  Censored data was 
higher in the plasma concentration group with 91 participants missing data compared to 75 in the self-
report group.   
 
Out of the 91 participants in the plasma group, 53 were lost to follow-up after the baseline visit – 26 
from theophylline and 27 from montelukast – leaving 271 cases in the plasma group with complete data 
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at the six week visit.  Another 38 patients were lost to follow-up after the six-week visit – 18 from 
theophylline and 20 from montelukast – leaving 233 cases in the plasma group with complete data at 
the six month and final visit.   
 
Out of the 75 participants in the self-report group, 58 cases were lost to follow-up after the baseline visit 
– 33 from the theophylline group and 25 from montelukast - leaving 266 cases with complete data at 
the six week visit.  One case was lost to follow up between six weeks and three months and at the six 
month visit, another 16 were censored – 9 from the theophylline and 7 from montelukast – leaving 249 
cases with complete data at the six month and final visit.   
 
Statistical Analysis  
Inverse Probability Weighting Models 
Pooled logistic regression models were fitted separately for the probability of staying on assigned 
treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment 
arm for both adherence metrics. The dataset for these models was discretized into one observation per 
subject per visit so that 1) time could be fit as a class variable to allow a separate intercept for each time 
and 2) lagged variables for previous treatment and confounder histories would be comparable between 
subjects.   
 
Stabilized treatment weights were created by dividing the baseline probability of selecting a treatment 
(numerator in equation 1) by the probability of selecting treatment given prior treatment history and 
potential confounders up to time t (denominator in equation 1).  The calculation of censored 
probabilities mimicked that of treatment adherence weights but was offset by one visit as censoring 
looked forward i.e. ‘did the subject return for a following visit?’ compared to ‘what was the treatment at 
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the previous visit?’ (equation 2).  Each covariate was entered in the pooled logistic models as a main 
effect only. 
 
Resulting predicted probabilities were then used to construct the final stabilized treatment and 
censoring weights for each subject at each visit.  For the Inverse Probability Treatment Weights, the 
pooled logistic regression models provided the estimated probability of remaining on assigned 
treatment, so the next step was to subtract the propensity score by 1 to get the probability of not 
staying on assigned treatment for those who were non-adherent.  Once all subjects had a stabilized 
weight for each visit, a final stabilized weight per participant was obtained by multiplying the estimated 
probability of their observed treatment at each visit cumulatively over time, i.e. the first score was left 
as is, and for all others, the scores at the current visit was multiplied by the score of the previous visit.  
For the Inverse Probability Censoring Weights, the estimated probabilities of being uncensored for each 
visit were multiplied cumulatively over time.  The final Inverse Probability Weight for each subject was 
the product of the treatment selection weights and the censoring weights.  
 
To determine whether the final stabilized weights resulted in balanced data, distribution plots were 
created to assess central tendency and skewness between the original and weighted data sets. 
 
Outcome Models 
Poisson regression models using PROC GENMOD were fitted for the annual rate of acute asthma 
exacerbations (outcome) as a function of the assigned treatment (theophylline vs. montelukast) using 
the weighted sample and a generalized estimating equation (GEE) with an independent correlation 
matrix for both the blood assay and self-reported groups. GEE accounts for the correlation within-
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subjects typically seen when estimating regression parameters to make valid statistical inferences from 
longitudinal data.44–46 Final models were fit to all uncensored cases with complete data.   
 




Baseline characteristics of the 324 subjects randomized to the LODO study is shown in Table 4.1. 
Assigned treatment groups were balanced with respect to demographics and baseline asthma 
characteristics.  Participants tended to be of middle-aged, predominantly female and white.   
 
On average, participants pre-bronchodilator FEV1 was slightly below that of a normal population 
indicating mild asthma severity.  Post-bronchodilator lung function continued to be mildly reduced on 
average compared to a normal population.  Around 9% of participants were prescribed daily asthma 
medication, but did not use it.  The majority of subjects either took short acting beta-agonists, inhaled 
corticosteroids or a combination of medications.   
  
Adherence over Time 
Table 4.2 provides information on adherence rates over time for both study treatments and methods.  
Adherence was significantly greater in the self-reported group compared with the blood assay group for 
both theophylline and montelukast treatments throughout the trial.  Theophylline adherence ranged 
from 84% in the self-reported group to 79% in the blood assay group (p=<.0001) at 1 month and 86% vs. 
61% (p=<.0001) at six months.  Montelukast adherence ranged from 87% in the self-reported group to 
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70% in the blood assay group at month 1 (p=0.0002).  At six months, adherence to montelukast was 89% 
in the self-reported group vs.  61% in the blood assay group (p=0.015). 
 
According to plasma assays, a total of 125 participants (38.6%) did not adhere to their assigned study 
treatment at some point in the study – 58 in the theophylline and 67 in the montelukast groups, 
respectively.  Thirty-four subjects never seemed to comply after baseline.  At 1 month, 68 participants 
were non-adherent with assigned medication – 27 and 41 in the theophylline and montelukast groups, 
respectively.  At 6 months, an addition 57 patients were non-adherent – 31 in the theophylline and 26 in 
the montelukast groups.   
 
According to patient diaries, 71 participants (21.9%) did not adhere to their assigned study treatment at 
some point in the study – 56 in the theophylline and 51 in the montelukast groups, respectively.  Eleven 
participants were completely non-adherent to study medications.  Thirty nine participants were non-
adherent with assigned medication at 1 month – 21 and 18 in the theophylline and montelukast groups, 
respectively.  Twenty additional subjects were non-adherent at three months – 10 and 10 in the 
theophylline and montelukast groups, respectively.  At the six month visit, an additional 12 participants 
did not adhere to the study medication – 4 in the theophylline group and 8 in the montelukast group.   
 
Inverse Probability Weights 
The model for the denominator of the weights is the most important component for determining the 
predicted probabilities.  Covariates with negative coefficients predict those individuals who would be 
more likely to be non-adherent and be censored, while those with positive coefficients should be more 




For the inverse probability treatment weights, previous treatment was strongest predictor of present 
treatment in all treatment groups regardless of adherence metric used.  However, the coefficients were 
much more pronounced in the self-report analysis than that of the blood assay (-2.58 in the theophylline 
group vs. -1.85 in the montelukast group for self-report and -1.24 vs. -1.36 for blood assay, respectively).  
None of the other time-varying covariates were strong predictors of treatment changes in the blood 
assay group, but being male was significantly associated with the probability of staying on present 
treatment in the self-report group (1.19, p=0.04). Despite this, it does not seem that bias in treatment 
selection over time was particularly strong in these data.  Information on the inverse probability 
treatment weights for both self-report and blood assay can be found in Appendix 4.A and 4.B).    
 
For the inverse probability censoring weights, most of the covariates in the MSM model were not 
associated with censoring.  The exceptions were current treatment with theophylline (1.17; p=0.02) and 
ASUI score (2.23, p=0.005) for the blood assay group and being in the study at time 1 (-1.50, p=<.0001) 
and time 2 (2.74, p=0.009), being black (-0.63, p=0.04) and age (0.03, p=0.006) for the self-report group.  
Similarly to the treatment weights, this indicates that selection bias may not be particularly strong in this 
data (see Appendix 4.C). 
 
The mean of the final stabilized weights (treatment x censoring) was 0.98 (range 0.09-10.4) and 0.99 
(range 0.16-4.43) for the self-reported and blood assay groups, respectively, indicating that both models 
were correctly specified.  Furthermore, the sum of the weights in both the self-reported and blood assay 
pseudo populations matched the number of visits with complete data in the original sample (1104 and 
828, respectively).  Figure 4.3 shows the distribution overlap of the stabilized weights for all groups over 




The distribution of theophylline vs. montelukast was examined through plotting the stabilized weights in 
the treated and untreated groups over time both in the original and in the weighted data sets for both 
the self-reported and blood assay groups.  The central tendency of the covariate values coincided 
between groups indicating that balance was achieved.   The distribution plots for the weighted data sets 
are shown in figure 4.4. 
 
Outcome Models 
Table 4.3 summarizes the outcome using Poisson regression models, looking at asthma control rates 
using EPAC composite events as well as each component individually due to treatment effects.  
 
The results of the MSM self-reported analysis found no significant treatment effect on overall asthma 
exacerbation rates between theophylline and montelukast (RR=1.28, 95% CI: 0.85-1.94, p=0.24) 
However, theophylline was significantly more likely to cause drops in peak flow than in the montelukast 
group (RR = 2.25 p-value= 0.02) in the self-reported group.  No further significant findings were found 
for any of the individual components of asthma control. 
 
The results of the MSM blood assay analysis were nearly identical to that of the MSM self-reported 
analysis, although estimates were closer to the null and to the original results from the ITT results (table 
4.3).  The theophylline group was 24% more likely to have an asthma exacerbation than those in the 
montelukast group, but this was not significant (95% CI: 0.84-1.84, p=0.28).  There were no significant 






Marginal structural models for repeated measures were used to estimate the causal effect of treatment 
on asthma control in the LODO trial of the ALA-ACRC.  This method was used as it was assumed that, 
due to non-adherence and censoring over time, there may have been time-varying covariates that were 
simultaneously confounders and intermediates that could not have been appropriately adjusted for by 
using standard statistical methods. 
 
Despite a significant difference in adherence rates between the self-reported group and the blood assay 
group over time, the adjusted rate ratio, and corresponding 95% confidence intervals, obtained from 
both MSMs were nearly identical.  Using a measure of self-reported adherence, the theophylline group 
had a 28% increased risk of having EPACs compared with the montelukast group.  This was in 
comparison to a 24% increased risk of EPACs in the blood assay group.  None of these findings were 
significant and were nearly identical to the original ITT estimates (table 4.3).   
 
This is the first study to directly compare the effects of different adherence measures using MSMs.  As 
the direction and magnitude of the effect of “assigned” treatment depends on the adherence pattern, it 
was assumed that different levels of adherence would have led to changes in the causal effects of 
treatment on asthma control.  As this was not the case, it indicates that 1) adherence and censoring was 
not a significant problem in this data, 2) adherence levels as low as 60% may not be low enough to 
severely compromise a study’s validity.   
 
These results should be considered in the context of the following limitations. First, has been shown that 
variations in adherence levels distorts the response rate and alter the number of patients required to 
detect a significant difference between treatments.7  As this was a secondary analysis of a clinical trial, 
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power was not calculated and as such, the sample size may not have been large enough to reach 
definite conclusions.  
 
Second, MSMs requires the untestable assumption of no unmeasured confounding; i.e. that subjects are 
exchangeable, conditional on the measured variables.17,20,48,49  It was assumed that all the most 
important confounders were identified using the expert knowledge of the ALA-ACRC investigators and 
were then appropriately measured and included in the analysis.  However, it can never be verified that 
all joint predictors of exposure and outcome were added to the models. 
 
Third, due to the small sample size and the number of potential confounders added to the MSM models, 
finite-sample bias occurred leading to the presence of random zeros in a few of the exposure-covariate 
groups.  Therefore, one can assume that the positivity assumption was not met in this study.  However, 
random zeros are essentially guaranteed because of the infinite number of possible values and a more 
valid assessment of positivity includes looking at extreme values, mean of weights and values of 
exposure-covariate groups adjacent to those with zero.20   Overall, the mean stabilized weights in this 
study were 0.98 in the self-report group and 0.99 in the blood assay and the sample did not have very 
extreme values.  Also, as seen in figure 4.5, many if not all of the exposure-covariate groupings with zero 
were surrounded by non-zero groups.   
 
Fourth, it was also assumed that the models used in this analysis were correctly specified. To explore the 
robustness of the models, linear and quadratic terms of continuous variables were tested to restrict the 
possible values of the propensity scores such that on a logit scale the conditional relation between the 
continuous  covariates and the risk of treatment can be represented by a parabolic curve, and each 
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covariates contributions to the risk is independent of that of the other covariates.18  No significant 
changes to the outcome were noted.   
 
Additionally models were fitted with different groupings of covariates.  For example, models were fitted 
for individual side effects and medications alone, for composite measures of side effects and 
medications and for both composite and individual grouping.  Again, there were no significant changes 
to the outcome.  Finally, the fact that the mean of the final stabilized weights were close to 1 and that 
each of the MSMs and the original ITT results were near identical, gives strength to the assumption that 
the MSM was not mis-specified.  Unfortunately, the assumption of a correctly specified model can never 
be proven. 
 
Lastly, it is impossible to predict the nature of the relationship between adherence and an outcome 
without taking into account the pharmacokinetics and pharmacodynamics of the drug.7,11,12  
Unfortunately, this is beyond the scope of this paper but cannot be ruled out as a reason that results 
were not different between the two adherent groups. 
   
Based on my research, I recommend that if there is a high likelihood or preliminary evidence suggesting 
the presence of time-varying confounders or selection bias in a RCT then the MSMs approach should be 
used, regardless of the length of the study or levels of non-adherence or censorship.  Unfortunately, 
there is no definitive guidance as to the type of adherence metric to use for such an analysis or at what 
level of non-adherence or loss to follow up will lead to bias that severely compromises a study’s validity.  
Therefore, conducting a MSM as a sensitivity analysis of the ITT can only bolster one’s confidence of the 





Despite the complexity of these models, MSMs hold much potential for further analyses of randomized 
clinical trials as it allows adjustment for time-varying confounding and selection bias due to censoring, 
issues more traditional regression based methods cannot account for.  
 
In my analysis, fitting MSMs using two significantly different adherence metrics did not cause the null 
outcomes to change.  This may not have been the case if the LODO trial was longer than six months and 
if the sample size was larger.  However, it seems that despite the present of non-adherence and 
censorship in the LODO trial, theophylline was no more effective than montelukast in preventing EPACs.    
 
In any event, it is my recommendation that MSMs be used, at a minimum, as a sensitivity analysis to the 
ITT approach in RCTs where there is preliminary evidence suggesting the presence of time-varying 












1.  Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in 
epidemiology. Epidemiology. 2000;11(5):550-560. 
http://www.ncbi.nlm.nih.gov/pubmed/10955408. Accessed May 11, 2014. 
2.  Hernán MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count 
with a marginal structural model for repeated measures. Stat Med. 2002;21(12):1689-1709. 
doi:10.1002/sim.1144 
3.  Robins J, Hernan M. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, 
Davidian M, Verbeke G, Molenberghs G, eds. Longitudinal Data Analysis. Boca Raton: Chapman & 
Hall/CRC; 2009:553-599. 
4.  Shortreed SM, Forbes AB. Missing data in the exposure of interest and marginal structural 
models: A simulation study based on the Framingham Heart Study. Stat Med. 2009;29(4):n/a-n/a. 
doi:10.1002/sim.3801 
5.  VanderWeele TJ, Hawkley LC, Thisted RA, Cacioppo JT. A marginal structural model analysis for 
loneliness: implications for intervention trials and clinical practice. J Consult Clin Psychol. 
2011;79(2):225-235. doi:10.1037/a0022610 
6.  Toh S, Hernán MA. Causal inference from longitudinal studies with baseline randomization. Int J 
Biostat. 2008;4(1):Article 22. doi:10.2202/1557-4679.1117 
7.  Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical 
trials and clinical practice. Clin Ther. 1999;21(6):1074-90; discussion 1073. doi:10.1016/S0149-
2918(99)80026-5 
8.  Monnette A, Zhang Y, Shao H, Shi L. Concordance of Adherence Measurement Using Self-
Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review. 
Pharmacoeconomics. 2018;36(1):17-27. doi:10.1007/s40273-017-0570-9 
9.  Toh S, Hernandez-Diaz S, Logan R, Robins J, Hernan M. Estimating absolute risks in the presence 
of nonadherence: an application to a follow-up study with baseline randomization. Epidemiology. 
2010;21:528-539. 
10.  Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: 
concepts and analytical approaches. Annu Rev Public Health. 2000;21:121-145. 
doi:10.1146/annurev.publhealth.21.1.121 
11.  Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med. 2005;353(5):487-497. 
doi:10.1056/NEJMra050100 
12.  Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 
2015;2015:217047. doi:10.1155/2015/217047 
13.  Lee JK, Grace KA, Foster TG, et al. How should we measure medication adherence in clinical trials 
and practice? Ther Clin Risk Manag. 2007;3(4):685-690. 
http://www.ncbi.nlm.nih.gov/pubmed/18472991. Accessed August 26, 2018. 
14.  The American Lung Association Asthma Clinical Research. Clinical trial of low-dose theophylline 
and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med. 
2007;175(3):235-242. doi:10.1164/rccm.200603-416OC 
15.  Lancet E, Holbrook J, Wise R, Hanania N. The American Lung Association: Asthma Clinical 
Research Centers network: addressing real life questions in asthma management. Clin Investig 
(Lond). 2014;4(6):495-499. 
16.  Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA. Marginal Structural Models for Analyzing 
Causal Effects of Time-dependent Treatments: An Application in Perinatal Epidemiology. Am J 
Epidemiol. 2004;159(10):926-934. doi:10.1093/aje/kwh131 
17.  Hernán, MA Robins J. Causal Inference. Boca Raton: Chapman & Hall/CRC, forthcoming; 2018. 




18.  Faries DE, Kadziola ZA. Analysis of Longitudinal Observational Data Using Marginal Structural 
Models. 
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.606.3489&rep=rep1&type=pdf. 
Accessed December 10, 2017. 
19.  Rochon J, Bhapkar M, Pieper CF, Kraus WE. Application of the marginal structural model to 
account for suboptimal adherence in a randomized controlled trial. Contemp Clin Trials Commun. 
2016;4:222-228. doi:10.1016/J.CONCTC.2016.10.005 
20.  Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am 
J Epidemiol. 2008;168(6):656-664. doi:10.1093/aje/kwn164 
21.  Thoemmes F, Ong AD. A Primer on Inverse Probability of Treatment Weighting and Marginal 
Structural Models. doi:10.1177/2167696815621645 
22.  Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of 
zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561-570. 
http://www.ncbi.nlm.nih.gov/pubmed/10955409. Accessed May 14, 2014. 
23.  Crowson CS, Schenck LA, Green AB, Atkinson EJ, Therneau TM. The Basics of Propensity Scoring 
and Marginal Structural Models. 2013. http://www.mayo.edu/research/documents/biostat-84-
pdf/doc-20024406. Accessed December 3, 2017. 
24.  Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness 
research. Clin Trials. 2012;9(1):48-55. doi:10.1177/1740774511420743 
25.  Hernán MA, Hernández-Díaz S, Robins JM. Randomized trials analyzed as observational studies. 
Ann Intern Med. 2013;159(8):560-562. doi:10.7326/0003-4819-159-8-201310150-00709 
26.  Hernan M, Hernandez-Diaz S, Robins J. A Structural Approach to Selection Bias. Epidemiology. 
2004;15(5):615-625. 
27.  Seaman S, White I. Re-analysis using Inverse Probability Weighting and Multiple Imputation of 
Data from the Southampton Women’s Survey. 2008. 
https://pdfs.semanticscholar.org/b3df/514c8bda0d2315fdb8bbf676b696636987fe.pdf. Accessed 
December 3, 2017. 
28.  Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland; 2003. 
http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf?ua=1. Accessed 
August 19, 2018. 
29.  Lee CP, Holmes T, Neri E, Kushida CA. Deception in clinical trials and its impact on recruitment 
and adherence of study participants. Contemp Clin Trials. 2018;72:146-157. 
doi:10.1016/j.cct.2018.08.002 
30.  Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS 
Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 
2000;56(3):779-788. http://www.ncbi.nlm.nih.gov/pubmed/10985216. Accessed May 13, 2014. 
31.  Rand CS, Wright RJ, Cabana MD, et al. Mediators of asthma outcomes. J Allergy Clin Immunol. 
2012;129(3 Suppl):S136-41. doi:10.1016/j.jaci.2011.12.987 
32.  National Asthma Education, and Prevention Program. Expert Panel Report 3:Guidelines for the 
Diagnosis andManagement of Asthma.; 2007. 
http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. 
33.  Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: 
GINA executive summary. Eur Respir J. 2008;31(1):143-178. doi:10.1183/09031936.00138707 
34.  Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European 
Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for 




35.  Busse WW, Morgan WJ, Taggart V, Togias A. Asthma outcomes workshop: Overview. J Allergy 
Clin Immunol. 2012;129(3):S1-S8. 
http://linkinghub.elsevier.com/retrieve/pii/S009167491102954X?showall=true. 
36.  Taylor DR, Bateman ED, Boulet L-P, et al. A new perspective on concepts of asthma severity and 
control. Eur Respir J. 2008;32(3):545-554. doi:10.1183/09031936.00155307 
37.  Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin 
Immunol. 2012;129(3 Suppl):S65-87. doi:10.1016/j.jaci.2011.12.986 
38.  Sheiner LB. Is intent-to-treat analysis always (ever) enough? Br J Clin Pharmacol. 2002;54(2):203-
211. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1874399&tool=pmcentrez&rendert
ype=abstract. Accessed September 2, 2014. 
39.  Textor J, Hardt J KS. DAGitty - drawing and analyzing causal diagrams (DAGs). Epidemiology. 
2011;5(22):745. http://dagitty.net/. Accessed January 28, 2018. 
40.  Sumino K, Holbrook JT, Wise RA, Rogers L. Asthma clinical trials of American Lung 
Association/Asthma Clinical Research Centers (ALA-ACRC): what have we learned in 12 years? 
Curr Respir Care Rep. 2012;1(4):251-258. doi:10.1007/s13665-012-0024-y 
41.  Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: Pulmonary physiology. J Allergy Clin 
Immunol. 2012;129(3):S65-S87. 
http://linkinghub.elsevier.com/retrieve/pii/S0091674911029551?showall=true. 
42.  Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences 
into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest. 
1998;114(4):998-1007. http://www.ncbi.nlm.nih.gov/pubmed/9792568. Accessed December 26, 
2017. 
43.  Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted 
estimators in comparative effectiveness analyses with observational databases. Med Care. 
2007;45(10 Supl 2):S103-7. doi:10.1097/MLR.0b013e31806518ac 
44.  Twisk JWR. Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide. Cambridge 
University Press; 2013. http://books.google.com/books?id=DRSAfYDnZqUC&pgis=1. Accessed 
June 28, 2013. 
45.  Fox J. Applied Regression Analysis and Generalized Linear Models. Second Edi. Thousand Oaks, 
CA: Sage Publications; 2008. 
46.  Dobson A. An Introduction to Generalized Linear Models. Florida: Chapman & Hall/CRC; 2002. 
47.  SAS Institute I. SAS/STAT 9.2 User’s Guide. 2009. 
48.  Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of 
aspirin on cardiovascular mortality in the Physicians’ Health Study. Am J Epidemiol. 
2002;155(11):1045-1053. http://www.ncbi.nlm.nih.gov/pubmed/12034583. Accessed January 
29, 2018. 
49.  Cerdá M, Diez-Roux A V., Tchetgen Tchetgen E, Gordon-Larsen P, Kiefe C. The Relationship 
Between Neighborhood Poverty and Alcohol Use: Estimation by Marginal Structural Models. 




Figure 4.1. Structural relationships over time between treatments and asthma control in the Low Dose 
Theophylline as Add-On Therapy in the Treatment of Asthma (LODO) trial (ACRC, 2002-2003)1  
 
1 Created through Daggity software: Johannes Testor, Juliane Hardt, and Sven Knuppel.  Daggitty: A 
graphical tool for analyzing causal diagrams.  Epidemiology, 22(5): 745, 2011 
-A0, A1, A2, A3 represent observed cumulative treatment exposure to either Theophylline, Montelukast 
or Placebo from baseline randomization (A0), 1 month (A1), 3 months (A2) and 6 months (A3). 
-L1, L2, L3 denote measured confounders (pulmonary function measures, asthma symptoms, 
medications and adverse effects) that may be associated with A(k),respectively. L(0) denotes baseline 
demographic characteristics along with baseline FEV1.  It was assumed that there was no effect of L(0) 
on A(0), because of randomization and full initial compliance.   
-C1, C2, C3 reflects loss to follow up at 1 month (C1), 3 months (C2) and 6 months (C3). 
Y indicates the outcome of annual rate of asthma exacerbations indicating poor asthma control.   If all 
possible confounding paths are blocked, the green arrows into Y represent the remaining causal paths.   
 
 
Figure 4.2. A Schema of the Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma 
(LODO) trial (ACRC, 2002-2003) 
 
 
V1/Run-In: Potentially eligible patients were followed for a 1-2 week run-in period  
V2/M0: Patients who successfully completed the run-in and agreed to be randomized were assigned to 
one of the three treatments shown 
V3: 1 month follow up visit 
V4: 3 month follow up visit 
V5: 6 month follow up visit 
P1-P4: Telephone calls between visits to assess diary card completion and adverse/side effects   
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Table 4.1. Baseline Characteristics of the 324 LODO Participants by Treatment Assignment 
    
      
  Theophylline Montelukast p-value 1       
Number of patients 160 164 ---       
              
Demographics              
Age, mean ± SD 41.5 ± 14.7 39.8 ± 15.0 0.56       
Male, % 25.0 28.1 0.80       
White, % 60.0 62.2 0.88       
Black, % 31.3 25.6 0.48       
Other Race, % 8.8 12.2 0.57       
              
Asthma Symptoms, mean ± SD             
ASUI Average Score 0.66 ± 0.15 0.68 ± 0.15 0.16       
              
Pulmonary Function, mean ± SD             
Pre-BD FEV1, % predicted* 78.3 ± 16.5 77.5 ± 17.5 0.32       
Pre-BD FVC, % predicted* 87.2 ± 14.8 87.1 ± 16.9 0.65       
Post-BD FEV1, % predicted* 84.4 ± 15.6 83.7 ± 17.1 0.18       
Post-BD FVC, % predicted* 91.8 ± 15.7 91.6 ± 16.0 1.00       
Peak Flow, % predicted* 83.4 ± 20.3 83.0 ± 20.3 0.39       
FEV1 Bronchodilator % change 9.2 ± 12.6 9.3 ± 11.7 0.94       
FVC Bronchodilator % change 5.9 ± 10.3 6.6 ± 13.8 0.06       
              
Daily Asthma Treatments, %             
Using asthma medication daily 90.0 92.7 0.51       
Inhaled anticholinergic 2.5 4.9 0.52       
Inhaled long-acting -agonist 22.5 22.6 0.56       
Inhaled short-acting -agonist 58.1 60.4 0.79       
Combination drugs 37.5 40.2 0.78       
Inhaled Corticosteroids 39.4 34.8 0.63       
*Predicted values of Hankinson and colleagues.  
 
      






Table 4.2. Participant Adherence to Assigned Drug by Types of Adherence Metrics at Each Time Period1 
  
           
 
Theophylline  Montelukast  
Time 
Period Self-Report Blood Assay2   Self-Report Blood Assay2   
  N n (%) N n (%) p-value N n (%) N n (%) p-value 
Baseline 160 160 (100%) 160 160 (100%) 1.00 164 164 (100%) 164 164 (100%) 1.00 
1 Month 127 106 (83.5%) 134 107 (79.9%) <.0001 139 121 (87.1%) 137 96 (70.1%) 0.0002 
3 Months 126 106 (84.1%) NA NA NA 139 121 (87.1%) NA NA NA 
6 Months 117 101 (86.3%) 116 71 (61.2%) <.0001 132 117 (88.6%) 117 71 (60.7%) 0.015 
1 P values from Pearson Chi-Square tests  










Figure 4.3a. Distribution Overlap of the Stabilized Inverse Probability Weights for all Treatments Over 
Time, Self-Reported Group 
 
-Stabilized Inverse Probability Weights (SW) in each time period showed a mean (◊)and median (─) close 
to 1 indicating that the model was correctly specified.   
-Overall, the mean and median of the SW was 0.98 and 0.99, respectively, and ranged from 0.9-10.4. 
-Time Period 0: Baseline with 324 participants; Time Period 1: 1 month with 266 participants; Time 
Period 2: 3 months with 265 participants; Time Period 3: 6 months with 249 participants 
 
Figure 4.3b. Distribution Overlap of the Stabilized Inverse Probability Weights for all Treatments Over 
Time, Blood Assay Group 
 
-Stabilized Inverse Probability Weights (SW) in each time period showed a mean (◊) and median (─) close 
to 1 indicating that the model was correctly specified.   
-Overall, the mean and median of the SW was 0.99 and 1.0, respectively, and ranged from 0.16-4.43.  
-Time Period 0: Baseline with 324 participants; Time Period 1: 1 month with 271 participants; Time 




Figure 4.4a. Distribution of Self-Reported Stabilized Inverse Probability Weights in the Treated 
(Theophylline) and Untreated (Montelukast) Groups 
 
Stabilized Inverse Probability Weights (SW) in the theophylline and montelukast groups had means of 1 
and followed a similar distribution indicating balance between both groups. 
 
Figure 4.4b. Distribution of Blood Assay Stabilized Inverse Probability Weights in the Treated 
(Theophylline) and Untreated (Montelukast) Groups 
 
Stabilized Inverse Probability Weights (SW) in the theophylline and placebo groups had means of 1 and 
followed a similar distribution indicating balance between both groups.  
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Table 4.3. Estimated Effects of Treatment on Episodes of Poor Asthma Control (EPACs) in the LODO Trial,  
2002-2003 by Adherence Metric1 
   
 
  
          





Weighting RR                                             
- Self Report  
Inverse 
Probability 
Weighting RR                                    
- Blood Assay  
          
  Theophylline Montelukast           
Number of patients 150 160    
 
          
                     
Asthma EPACs                    
    Events, n 269 236                
    Rate, events/person-year 4.9 4.0 1.22 1.28 1.24           
    95% Confidence Interval 3.6-6.7 3.0-5.4 0.82-1.86 0.85-1.94 0.83-1.85           
    p-value -- -- 0.35 0.24 0.29           
                     
Episode Components                    
Peak flow, 30% drop                    
    Events, n 75 43                
    Rate, events/person-year 1.3 0.7 1.85 2.25 1.78           
    95% Confidence Interval 0.8-2.2 0.5-1.1 0.96-3.54 1.12-4.54 0.90-3.52           
    p-value -- --  0.07 0.02* 0.10           
Increased medication use                    
    Events, n 198 179                
    Rate, events/person-year 3.5 3.0 1.16 1.26 1.19           
    95% Confidence Interval 2.4-5.0 2.2-4.2 0.71-1.90 0.75-2.11 0.71-1.99           
    p-value -- --  0.55 0.39 0.51           
New use of oral 
corticosteroids                    
    Events, n 30 32                
    Rate, events/person-year 0.5 0.5 0.99 1.22 1.19           
    95% Confidence Interval 0.4-0.7 0.3-0.8 0.56-1.75 0.67-2.22 0.67-2.12           
    p-value -- --  0.97 0.51 0.56           
Unscheduled health care                    
    Events, n 41 34                
    Rate, events/person-year 0.7 0.5 1.27 1.32 1.40           
    95% Confidence Interval 0.5-1.0 0.4-0.8 0.72-2.24 0.71-2.47 0.76-2.56           
    p-value -- -- 0.40 0.38 0.28           1 p values for treatment effects on rates of episodes of poor asthma control are based on Poisson  




Chapter 5. Discussion 
The overall goal of this dissertation was to demonstrate the advantages and disadvantages of using 
Marginal Structural Models (MSMs) to 1) control for time-dependent confounding and 2) detect effect 
modification in a RCT with a time-varying exposure, non-adherence and missing data.  
 
Unlike the traditional regression used in the ITT approach, MSMs account for both the joint effects of 
baseline and subsequent treatments as well as the presence of time-dependent confounding influenced 
by prior treatment and selection bias due to censoring.1–4  By modeling exposures at each follow up and 
the final outcome, MSMs are able to measure confounders and/or mediators that may affect either 
adherence to an exposure or loss to follow up (attrition) in an attempt to eliminate all back door 
pathways that may bias the association between the exposure and the outcome.1,3,5–8  In theory this will 
lead to less biased estimates than ITT analyses.  Furthermore, MSMs can detect effect modification by 
the simple addition of a treatment covariate product term to the final logistic model weighted by the 
inverse probability weights.1,9,10  In theory, this enables investigators to assess effect modification 
without having to ensure that sample sizes are large enough for stratified analyses at the conclusion of a 
study when effect modification was not considered a priori.   
 
Despite the theoretical advantages of MSMs, my research found that the approach failed to invalidate 
previous ITT analyses, regardless of adherence level.  This indicates that either 1) MSMs do not 
invalidate ITT analyses; 2) that the LODO trial just didn’t have a significant problem with adherence and 
censoring; or 3) that the study was too short in duration with a sample size too small for time-
dependent confounding to occur and for a difference between MSM and ITT to exist.  There are a 
limited number of studies in the literature that have compared ITT to MSM but those that have, have all 
found similar interpretations to my results.11,12,13 
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In the case of effect modification, the MSM analysis was able to detect effect modification by race in 
only one of the treatment groups (montelukast) but there were many limitations that precluded 
confidence in the results.  Most importantly, more research is needed to determine the most 
appropriate way to calculate inverse probability treatment weights propensity scores as there is no 
consensus in the literature on how best to calculate the propensity scores required for weighting and 
achieve accurate subgroup results.   
 
Summary of Findings 
Chapter 2 - Aim 1 
In aim 1 I used MSMs to check the validity of an ITT analysis in the LODO trial of the ALA-ACRC, a RCT with a 
time-varying exposure, non-adherence and missing data assessing treatment effectiveness on asthma 
control. MSMs were used as it was assumed that, due to non-adherence and censoring over time, there may 
have been time-varying covariates that were simultaneously confounders and intermediates that could not 
have been appropriately adjusted for by using standard statistical methods. 
 
Although non-adherence and censoring occurred over time in the LODO trial, the effect estimates 
obtained from the MSM, using no further adjustments other than the stabilized weights, were nearly 
identical to that of the ITT analysis.  Each method found no significant treatment effect on overall 
episodes of poor asthma control (EPACs) among all three groups.  The results of the ITT analysis found a 
22% increased risk of EPACs for theophylline compared with montelukast (RR=1.22, 95% CI: 0.82-1.86, 
p=0.35), no increased risk between theophylline and placebo (RR=0.99, 95% CI: 0.67-1.50, p=1.00), and 
an 18% decreased risk of EPACs between montelukast and placebo (RR=0.82; 95% CI: 0.55-1.21, p=0.31).  
This is in comparison to a 24% increased risk of EPACs for theophylline compared with montelukast 
(RR=1.24, 95% CI: 0.83-1.84, p=0.28), no increased risk between theophylline and placebo (RR=1.01, 95% 
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CI: 0.70-1.48, p=0.95), and a 17% decreased risk of EPACs between montelukast and placebo (RR=0.83; 
95% CI: 0.57-1.19, p=0.27). 
  
These findings are most likely the result of the short time frame of the study (6 months) and the 
relatively level of overall adherence (84% for theophylline and 88% for both montelukast and placebo) 
and censoring (6%) rather than the use of a mis-specified model.  First, the mean of the final stabilized 
weights (treatment x censoring) was 0.995 and ranged from 0.4 to 4.3, indicating that the model was 
correctly specified.  Furthermore, the sum of the weights in the pseudo population was 1785 which was 
identical to the number of visits with complete data in the original sample.  Second, the inverse 
probability treatment weights indicated that previous treatment was the only strong predictor of being 
non-adherent to treatment assignment for all treatment groups (-5.70 for theophylline, -4.96 for 
montelukast and -18.17 for placebo). Similarly, inverse probability censoring weights found none of the 
covariates to be strongly associated with censoring indicating that time-depending confounding and 
selection bias over time were not particularly strong in these data. 
 
Chapter 3 – Aim 2 
In Aim 2, I used MSMs to detect effect modification by race in the LODO trial of the ALA-ACRC, a 
RCT with a time-varying exposure, non-adherence and missing data assessing treatment effectiveness 
on asthma control. Race was chosen as a potential effect modifier for two reasons.  First, research has 
indicated that certain racial and ethnic groups fare significantly worse than whites when assessing 
asthma control14–21 and that certain first-line asthma treatments were not as effective in improving 
asthma control in African Americans and Puerto Ricans in comparison with other racial and ethnic 
subgroups.22–26 Second, this was a secondary data analysis of a trial that had larger than usual minority 
representation.27,28   
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Inverse probability treatment weights (IPTW) were initially computed for the full cohort and by racial 
strata as a lack of consensus exists as to whether the propensity scores used to calculate the IPTWs 
should be estimated on the full cohort or by strata.29–32  The mean stabilized weight in the full cohort 
was 0.998 and ranged from 0.04 to 4.0, indicating that the model was correctly specified.  In 
comparison, the stratum-specific mean stabilized weights were similar to the full cohort for whites but 
ranged from 0.02 to 10 in the non-white group.  Furthermore, the non-white group had abnormally 
large standard errors and violated the positivity assumption as many exposure-covariate groupings had 
zero cases.  This led to the conclusion that the non-white group was not of sufficient size to obtain 
meaningful estimates.  While it is assumed that strata-propensity scores would lead to better balance 
between treatment groups and therefore, less bias in the treatment-outcome relationship, research has 
indicated that weighting according to the distribution of effect modifiers observed in the full cohort is 
the ideal method when estimating a casual contrast from RCTs.29  As such, the full cohort was used for 
all subsequent analyses. 
 
As hypothesized, qualitative effect modification on the multiplicative scale existed for a number of 
treatment-outcome associations. However, race differences only seemed to exist for patients on 
montelukast.  In the unadjusted analysis, non-whites were twice as likely to have an EPAC on 
montelukast as their white counterparts (5.75 vs. 2.66 episodes per person year, p=0.0034).  Similar 
findings were seen for increased medication use and health care visits.  Results of the MSM also 
indicated the presence of effect modification for overall EPACs, medication use and unscheduled health 
care when treated with montelukast instead of placebo.  Compared with whites, non-whites were more 
than twice as likely to suffer from an EPAC on montelukast as on placebo (RR=2.13, 95% CI: 1.08-4.46, p= 
0.04) and almost 3 times as likely to increase medication use (RR=2.86, 95% CI: 1.10-7.42, p=0.03).  Non-
whites were over 5 times more likely to have unscheduled health care visits than whites while on 
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montelukast compared with placebo (RR=5.01, 95% CI: 1.36-18.97, p=0.02).  Lastly, while only 
borderline significant, it should be noted that compared with whites, non-whites on theophylline were 
66% less likely to have unscheduled health care visits than those on montelukast (RR=0.34, 95% CI: 0.11-
1.01, p=0.05). 
 
These finding may be indicative of potential information bias in adherence levels, which was determined 
in this study by self-report.  Research has shown that minority groups are more likely to be over reliant 
on symptom-driven management rather than daily use of controller medications.33–35  One study found 
that at least a third of black patients claimed to not take their controller medications, with many 
managing symptoms of asthma with short-term beta-agonists alone.35  However, since the significant 
findings only applied to montelukast and not to theophylline, it may be more plausible that the 
difference is due to pharmacogenetics reasons.  Prior research has found that African Americans do not 
respond as well as whites to inhaled corticosteroids and albuterol.23,24  Unfortunately, there have been 
no studies to date that have examined racial differences in pharmacokinetics for montelukast.    
 
Chapter 4 – Aim 3 
In aim 3, I used MSMs to demonstrated whether the use of different adherence metrics had any effect 
on the direction and magnitude of the causal effect of asthma treatments on the rate of episodes of 
poor asthma control in the LODO trial of the ALA-ACRC, a RCT with a time-varying exposure, non-
adherence and missing data assessing treatment effectiveness on asthma control.  As the direction and 
magnitude of the effect of “assigned” treatment depends on the adherence pattern, it was assumed 
that conducting MSMs using two significantly different adherence proportions would result in different 
effect estimates.  In the LODO trial, adherence was measured by both self-report patient diaries and by 
the collection of blood plasma.  Adherence was significantly greater in the self-reported group 
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compared with the blood assay group for both theophylline and montelukast treatments throughout the 
trial.  Theophylline adherence ranged from 84% in the self-reported group to 79% in the blood assay 
group (p=<.0001) at 1 month and 86% vs. 61% (p=<.0001) at six months.  Montelukast adherence ranged 
from 87% in the self-reported group to 70% in the blood assay group at month 1 (p=0.0002).  At six 
months, adherence to montelukast was 89% in the self-reported group vs. 61% in the blood assay group 
(p=0.015).   
 
Despite a significant difference in adherence rates between the self-reported group and the blood assay 
group over time, the adjusted rate ratio, and corresponding 95% confidence intervals, obtained from 
both MSMs were nearly identical. The results of the MSM self-reported analysis found no significant 
treatment effect on overall asthma exacerbation rates between theophylline and montelukast (RR=1.28, 
95% CI: 0.85-1.94, p=0.24).  However, theophylline was significantly more likely to cause drops in peak 
flow than in the montelukast group (RR = 2.25 p-value= 0.02) in the self-reported group.  No further 
significant findings were found for any of the individual components of asthma control.  The results of 
the MSM blood assay analysis were nearly identical to that of the MSM self-reported analysis, although 
estimates were closer to the null and to the original results from the ITT results.  The theophylline group 
was 24% more likely to have an asthma exacerbation than those in the montelukast group, but this was 
not significant (95% CI: 0.84-1.84, p=0.28).  There were no significant findings of treatment effect for any 
of the individual components of asthma control in the blood assay group. 
 
As seen in Aim 1, previous treatment was the strongest predictor of remaining on treatment assigned in 
all treatment groups, regardless of adherence metric used.  However, the coefficients were much more 
pronounced in the self-report analysis than that of the blood assay (-2.58 in the theophylline group vs. -
1.85 in the montelukast group for self-report and -1.24 vs. -1.36 for blood assay, respectively).  None of 
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the other time-varying covariates were strong predictors of treatment changes in the blood assay group, 
but being male was significantly associated with the probability of staying on present treatment in the 
self-report group (1.19, p=0.04).  
 
For the inverse probability censoring weights, most of the covariates in the MSM model were not 
associated with censoring.  The exceptions were current treatment with theophylline (1.17; p=0.02) and 
ASUI score (2.23, p=0.005) for the blood assay group and being in the study at time 1 (-1.50, p=<.0001) 
and time 2 (2.74, p=0.009), being black (-0.63, p=0.04) and age (0.03, p=0.006) for the self-report group.  
Similarly to the treatment weights, this indicates that selection bias may not be particularly strong in this 
data. 
 
Lastly, the mean of the final stabilized weights (treatment x censoring) was 0.98 (range 0.09-10.4) and 
0.99 (range 0.16-4.43) for the self-reported and blood assay groups, respectively, indicating that both 
models were correctly specified.  Furthermore, the sum of the weights in both the self-reported and 
blood assay pseudo populations matched the number of visits with complete data in the original sample 
(1104 and 828, respectively).   
 
As such, it can be assumed that adherence and censoring was not a significant problem in this data and 
that adherence levels as low as 60% may not be low enough to severely compromise a study’s validity.   
 
Limitations 
For all aims, the following limitations should be considered.  First, MSMs requires the untestable 
assumption of no unmeasured confounding; i.e. that subjects are exchangeable, conditional on the 
measured variables.5,9,36,37  It is assumed that all the most important confounders were identified using 
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the expert knowledge of the ALA-ACRC investigators and were then appropriately measured and 
included in the analysis.  However, it can never be verified that all joint predictors of exposure and 
outcome were added to the models. 
 
Second, due to the small sample size and the number of potential confounders added to the MSM 
models ran for all aims, finite-sample bias occurred leading to the presence of random zeros in a few of 
the exposure-covariate groups.  Therefore, one can assume that the positivity assumption was not met 
in any of the aims.  However, random zeros are essentially guaranteed because of the infinite number of 
possible values and a more valid assessment of positivity includes looking at extreme values, mean of 
weights and values of exposure-covariate groups adjacent to those with zero.5  Overall, the mean 
stabilized weight in each study was close to 1 and samples did not have very extreme values.   
 
Third, it was assumed that the models used in all aims are correctly specified. To explore the robustness 
of the models, linear and quadratic terms of continuous variables were tested to restrict the possible 
values of the propensity scores such that on a logit scale the conditional relation between the 
continuous  covariates and the risk of treatment can be represented by a parabolic curve, and each 
covariates contributions to the risk is independent of that of the other covariates.38  No significant 
changes to the outcome were noted.  Additionally models were fitted with different groupings of 
covariates.  For example, models were fitted for individual side effects and medications alone, for 
composite measures of side effects and medications and for both composite and individual grouping.  
Again, there were no significant changes to the outcome.  Finally, the fact that the mean of the final 
stabilized weight was close to 1 and that the MSM and ITT results were near identical, gives strength to 
the assumption that the MSM was not mis-specified.  Unfortunately, the assumption of a correctly 




Aim 2 had two additional limitations.  First, there is lack of consensus as to whether the IPTWs should be 
estimated on the full cohort or by strata when using MSMs to detect effect modification.29–32  It is 
assumed that strata-propensity scores would lead to better balance between treatment groups and 
therefore, less bias in the treatment-outcome relationship when dealing with studies like this with rare 
outcome events.  However, the same research indicates that weighting according to the distribution of 
effect modifiers observed in the full cohort is the ideal method when estimating a casual contrast from 
randomized clinical trials (or any trial where there is well defined inclusion and exclusion criteria and 
everyone has the indication under study).  Unfortunately, there is no guideline as to what constitutes a 
sufficient size for strata-specific IPTWs.29  Due to the small sample size in the non-white group, a full 
cohort was used for aim 2.   
 
Second, while there has been plenty of research published regarding racial disparities on asthma 
morbidity and burden, it is important to note that race may not be the true causal factor but instead 
serves as a proxy or marker for one or more of the complex, multilevel and intertwined environmental 
and cultural factors thought to be associated with asthma control disparities.17,20,39–42  Related to this last 
point, the original LODO study results found that the use of inhaled corticosteroids modified the effect 
of treatment on asthma control. Comparatively, the only significant difference in baseline characteristics 
in this study was the fact that whites were significantly more likely to be taking inhaled corticosteroids 
than their non-white counterparts (p-value= 0.02).  Adding credence to the argument that race is an 
effect modifier by proxy and not a direct effect modifier in this study is the fact that while there was 
significance for effect modification in some treatment-outcome relationships, there was no significant 
relationship found between race and any of the asthma control outcomes.  Having an association with 
the outcome is a prerequisite of being an effect modifier.9,43–45  Unfortunately, effect modification by 
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inhaled corticosteroids was not examined in this paper and it is unknown if it would have impacted the 
results of the MSM analysis.  
 
Aim 3 also had two additional limitations.  First, it has been shown that variations in adherence levels 
distorts the response rate and alter the number of patients required to detect a significant difference 
between treatments.46  As this was a secondary analysis of a clinical trial, power was not calculated and 
as such, the sample size may not have been large enough to reach definite conclusions.  Second, it is 
impossible to predict the nature of the relationship between adherence and an outcome without taking 
into account the pharmacokinetics and pharmacodynamics of the drug.46–48  Unfortunately, this is 
beyond the scope of this paper but cannot be ruled out as a reason that results were not different 
between the two adherent groups. 
 
Strengths and Public Health Significance 
The biggest strength of my dissertation is that it adds to the limited research on using MSMs to analyze 
RCTs with incomplete adherence and/or censorship.  As far as I know, aim 2 and aim 3 are the first 
studies of its kind to use MSMs to detect effect modification and to directly compare the effects of 
different adherence measures in a RCT.  While there is no other studies to compare results of aim 2 and 
aim 3 to, I have confidence that the research was conducted appropriately as my findings from aim 1 
mirror that of other trials conducted with similar proportions of noncompliance and censorship.   
 
Despite my original hypotheses that the use of MSMs would lead to less biased estimates compared to 
ITT due to its ability to account for time-varying exposures, non-adherence and censorship, the results of 
all three aims indicate that in practice, MSMs may not invalidate ITT effect measures.  More research is 
warranted however, as patients and clinicians usually prefer to know what are the benefits and risk of 
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receiving a treatment rather than being assigned to one and my research may have used too small of a 
sample and too short of a trial to see a real difference.  
 
Policy Recommendations and Future Research Directions  
Theoretically, MSMs hold much potential for the analyses of RCTs as it allows adjustment for time-
varying exposures, time-dependent confounding and selection bias due to censoring, issues more 
traditional regression based methods cannot account for.  However, this may not be the case in practice 
as my research in aim 1 mirrors the findings of previously conducted RCT studies which found that 
MSMs do not invalidate effect estimates from ITT analyses.      
 
While some may conclude that concordance between the effect estimates from ITT and MSM indicates 
that the former is still superior for RCT analyses, I caution that more practical guidance on the benefits 
and limitations of MSMs is required before coming to that conclusion.  It would be beneficial to known if 
there are any specific conditions in which MSMs would produce meaningful differences in estimates 
compared to ITT.  This kind of research is extremely limited even for non-experimental study designs.49,50   
 
There is also no definitive guidance as to what level of non-adherence or loss to follow up will lead to 
bias that severely compromises a study’s validity. In my aim 3, a non-adherence level of 60% was still 
not enough to see a change in effect estimates from that of a non-adherence level of close to 90%.  
However, this study was the first of its kind and more studies simulating different levels of adherence 
are needed.  
 
Lastly, while MSMs have been commonly used to adjust for confounding in longitudinal studies with 
time-varying exposures and time-dependent covariates, they have been rarely used for detecting effect 
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modification.  Unfortunately, there is very little information on the appropriate way to accurately assess 
effect modification using MSMs despite the obvious need for ways to combine moderation analysis with 
advanced causal methods.  While I attempted to add to the literature with my aim 2, my results are 
limited due to the inability to calculate strata-specific IPTWs using my sample.  As such, more simulated 
research is needed to determine the best way to calculate IPTWs when assessing effect modification 
using MSMs and what is the minimum strata specific sample size that is required. 
 
Based on my research, I recommend that MSMs be used for sensitivity analyses in RCTs where there is 
preliminary evidence suggesting the presence of time-varying exposures, time-dependent confounding 
and/or selection bias and where MSM’s limitations can be reasonably ignored.   
 
Conclusion 
In theory MSMs hold much potential for further analyses of randomized clinical trials as it allows 
adjustment for time-varying exposures, time-dependent confounding and selection bias, issues more 
traditional regression based methods cannot account for.  However, it remains unclear as to whether 
this is the case in practice.  At the very least, MSMs should be conducted as a sensitivity analysis to the 
ITT approach in RCTs where there is preliminary evidence suggesting the presence of time-varying 
exposures, time-dependent confounding and/or selection bias and when MSM’s limitations can be 
reasonably ignored.  Conducting a MSM as a sensitivity analysis of the ITT can only bolster one’s 
confidence of the estimated effects of treatment on an outcome.  In terms of effect modification, more 
research is needed to determine the most appropriate way to calculate inverse probability treatment 
weights propensity scores as there is no consensus in the literature on how best to calculate the 
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Appendix 2.A: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Theophylline1 
 
Parameter Estimate Std. Error Chi-Square Pr > ChiSq 
Intercept -1.0050 2.7907 0.1297 0.7187 
Time At One Month 2.1844 0.4316 25.6155 <.0001 
Time At Three Months 2.6348 0.4881 29.1382 <.0001 
Previous treatment with theophylline -5.6501 1.3644 17.1494 <.0001 
Age -0.00728 0.0118 0.3810 0.5370 
Male 0.2494 0.4133 0.3642 0.5462 
Black Race 0.1599 0.3752 0.1817 0.6700 
Other Race 0.6954 0.6928 1.0075 0.3155 
Previous ASUI score -0.7728 1.2098 0.4081 0.5230 
Previous Pre-BD FEV1, % predicted 0.00626 0.0330 0.0360 0.8496 
Previous Pre-BD FVC, % predicted -0.0481 0.0356 1.8281 0.1764 
Previous Post-BD FEV1, % predicted -0.0152 0.0334 0.2077 0.6486 
Previous Post-BD FVC, % predicted 0.0480 0.0341 1.9851 0.1589 
Previous Peak Flow, % predicted 0.0227 0.0122 3.4386 0.0637 
Previous use of anticholinergics 0.8856 0.8551 1.0726 0.3004 
Previous use of long-acting beta agonists -0.1052 0.4603 0.0523 0.8192 
Previous use of short-acting beta agonists 0.2742 0.3389 0.6549 0.4184 
Previous use of combination drugs 0.0186 0.3904 0.0023 0.9621 
Previous use of inhaled corticosteroids 0.0303 0.4056 0.0056 0.9405 
Previous complaint of nausea -0.6625 1.1931 0.3083 0.5787 
Previous complaint of vomiting 2.0315 1.5873 1.6379 0.2006 
Previous complaint of poor appetite 0.3431 0.7953 0.1861 0.6662 
Previous complaint of heartburn -0.6842 0.6526 1.0994 0.2944 
Previous complaint of headaches -0.0391 0.4545 0.0074 0.9314 
Previous complaint of insomnia 0.3158 0.4608 0.4696 0.4932 
Previous complaint of anxiety 0.8114 0.5663 2.0527 0.1519 
Previous complaint of tremors -0.4519 1.2770 0.1252 0.7234 
Previous complaint of heart palpitations -1.0438 1.0718 0.9485 0.3301 
Previous complaint of skin rash -0.3170 1.1658 0.0740 0.7857 
Previous visit to the hospital -0.3782 0.9440 0.1605 0.6887 
Previous visit to a doctor 0.1166 0.4186 0.0775 0.7806 
1) Positive coefficients represent factors that increased the probability of receiving theophylline while negative coefficients denote factors that 
decreased the probability of receiving theophylline, i.e. previous treatment  
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Appendix 2.B: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Montelukast1 
 
Parameter Estimate Std. Error Chi-Square Pr > ChiSq 
Intercept 1.1615 3.1357 0.1372 0.7111 
Time At One Month 2.8209 0.4745 35.3434 <.0001 
Time At Three Months 3.1624 0.5661 31.2123 <.0001 
Previous treatment with montelukast -4.9230 1.3204 13.9014 0.0002 
Age -0.00656z 0.0136 0.2322 0.6299 
Male 0.3919 0.4113 0.9079 0.3407 
Black Race -0.5415 0.4179 1.6789 0.1951 
Other Race 0.2028 0.5720 0.1258 0.7229 
Previous ASUI score 1.8411 1.1225 2.6898 0.1010 
Previous Pre-BD FEV1, % predicted -0.0245 0.0305 0.6429 0.4226 
Previous Pre-BD FVC, % predicted 0.0121 0.0263 0.2122 0.6450 
Previous Post-BD FEV1, % predicted 0.0206 0.0325 0.4012 0.5265 
Previous Post-BD FVC, % predicted -0.0246 0.0250 0.9698 0.3247 
Previous Peak Flow, % predicted -0.0201 0.0112 3.2289 0.0723 
Previous use of anticholinergics 0.4357 0.9027 0.2330 0.6293 
Previous use of long-acting beta agonists -0.2981 0.5019 0.3527 0.5526 
Previous use of short-acting beta agonists -0.2553 0.3835 0.4432 0.5056 
Previous use of combination drugs -0.5382 0.4367 1.5193 0.2177 
Previous use of inhaled corticosteroids -0.6370 0.4333 2.1618 0.1415 
Previous complaint of nausea -0.1704 1.2911 0.0174 0.8950 
Previous complaint of vomiting 0.3640 1.5882 0.0525 0.8187 
Previous complaint of poor appetite 1.3875 1.2115 1.3118 0.2521 
Previous complaint of heartburn -0.6652 0.7724 0.7417 0.3891 
Previous complaint of headaches 0.5969 0.4298 1.9291 0.1649 
Previous complaint of insomnia -0.4719 0.5463 0.7459 0.3878 
Previous complaint of anxiety 0.6391 0.6528 0.9585 0.3276 
Previous complaint of tremors -1.4015 2.1850 0.4114 0.5213 
Previous complaint of heart palpitations 0.2659 1.2046 0.0487 0.8253 
Previous complaint of skin rash 1.7337 1.0743 2.6043 0.1066 
Previous visit to the hospital -0.3368 1.0004 0.1133 0.7364 
Previous visit to a doctor 0.2892 0.4202 0.4737 0.4913 
1) Positive coefficients represent factors that increased the probability of receiving montelukast while negative coefficients denote factors that 




Appendix 2.C: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Placebo1 
Parameter Estimate Std. Error Chi-Square Pr > ChiSq 
Intercept -7.9301 3.5402 5.0177 0.0251 
Time At One Month 4.9187 0.8473 33.7029 <.0001 
Time At Three Months 4.5387 0.8561 28.1041 <.0001 
Previous treatment with placebo -18.3575 750.7 0.0006 0.9805 
Age 0.00191 0.0154 0.0155 0.9010 
Male -0.3968 0.4991 0.6320 0.4266 
Black Race 0.1006 0.4766 0.0446 0.8328 
Other Race 0.7361 0.8404 0.7672 0.3811 
Previous ASUI score 3.8638 1.5649 6.0957 0.0136 
Previous Pre-BD FEV1, % predicted -0.0186 0.0472 0.1557 0.6931 
Previous Pre-BD FVC, % predicted 0.0677 0.0413 2.6836 0.1014 
Previous Post-BD FEV1, % predicted 0.00449 0.0477 0.0089 0.9249 
Previous Post-BD FVC, % predicted -0.0577 0.0391 2.1769 0.1401 
Previous Peak Flow, % predicted -0.0118 0.0138 0.7300 0.3929 
Previous use of anticholinergics -0.1018 1.4251 0.0051 0.9430 
Previous use of long-acting beta agonists -0.1683 0.6246 0.0726 0.7876 
Previous use of short-acting beta agonists -0.0264 0.4037 0.0043 0.9479 
Previous use of combination drugs 1.0359 0.5637 3.3765 0.0661 
Previous use of inhaled corticosteroids 1.2569 0.5719 4.8295 0.0280 
Previous complaint of nausea 0.8391 0.8205 1.0459 0.3064 
Previous complaint of vomiting 0.9931 1.1198 0.7865 0.3752 
Previous complaint of poor appetite 0.3595 1.3219 0.0740 0.7856 
Previous complaint of heartburn 0.8371 0.7812 1.1481 0.2840 
Previous complaint of headaches 0.2046 0.5879 0.1211 0.7278 
Previous complaint of insomnia 0.2979 0.5498 0.2937 0.5879 
Previous complaint of anxiety 1.1212 0.7537 2.2130 0.1369 
Previous complaint of tremors 1.2217 1.1341 1.1605 0.2814 
Previous complaint of heart palpitations -0.4847 1.6485 0.0864 0.7687 
Previous complaint of skin rash -0.5512 1.3232 0.1735 0.6770 
Previous visit to the hospital 0.4389 1.0379 0.1789 0.6723 
Previous visit to a doctor 0.9318 0.5077 3.3689 0.0664 
1) Positive coefficients represent factors that increased the probability of receiving placebo while negative coefficients denote factors that 





Appendix 2.D:  Coefficients Obtained from the Denominator of the Pooled Logistic Censoring Model1 
Parameter Estimate Std. Error Chi-Square Pr > ChiSq 
Intercept 23.8525 334.3 0.0051 0.9431 
Time At Baseline 12.5669 73.9229 0.0289 0.8650 
Time At One Month 0.3140 0.3190 0.9686 0.3250 
Time At Three Months -0.0355 0.2995 0.0141 0.9056 
Assigned to theophylline -12.2756 216.2 0.0032 0.9547 
Assigned to montelukast -11.4687 216.2 0.0028 0.9577 
Currently on theophylline  0.1481 0.5447 0.0739 0.7857 
Currently on montelukast 0.6640 0.6715 0.9776 0.3228 
Currently on placebo 12.4110 216.2 0.0033 0.9542 
Age 0.0284 0.00954 8.8338 0.0030 
Male -0.2037 0.2726 0.5583 0.4550 
Black -0.5365 0.2590 4.2892 0.0384 
Other Race -0.6405 0.3676 3.0355 0.0815 
ASUI score 1.6982 0.8028 4.4746 0.0344 
Pre-BD FEV1, % predicted -0.0451 0.0205 4.8521 0.0276 
Pre-BD FVC, % predicted 0.0469 0.0203 5.3440 0.0208 
Post-BD FEV1, % predicted 0.0312 0.0213 2.1511 0.1425 
Post-BD FVC, % predicted -0.0316 0.0162 3.8178 0.0507 
Peak Flow, % predicted -0.0125 0.00793 2.4877 0.1147 
Use of anticholinergics -11.1890 203.8 0.0030 0.9562 
Use of long-acting beta agonists -0.3967 0.4010 0.9785 0.3226 
Use of short-acting beta agonists 0.1123 0.2451 0.2100 0.6467 
Use of combination drugs -0.1834 0.2848 0.4147 0.5196 
Use of inhaled corticosteroids 0.0224 0.3117 0.0052 0.9427 
Complaint of nausea -0.3521 0.6622 0.2826 0.5950 
Complaint of vomiting -11.9122 265.0 0.0020 0.9641 
Complaint of poor appetite  0.0164 0.6767 0.0006 0.9807 
Complaint of heartburn 0.4928 0.3831 1.6545 0.1983 
Complaint of headaches 0.0977 0.3111 0.0986 0.7535 
Complaint of insomnia -0.2728 0.3555 0.5890 0.4428 
Complaint of anxiety 0.5425 0.4169 1.6938 0.1931 
Complaint of tremors -0.3890 0.7971 0.2381 0.6256 
Complaint of heart palpitations -0.6081 0.6950 0.7653 0.3817 
Complaint of skin rash 0.9618 0.4706 4.1768 0.0410 
Visit to the hospital -0.5784 0.8912 0.4213 0.5163 
Visit to a doctor 0.1741 0.3041 0.3278 0.5670 
1) Positive coefficients represent factors that increased the probability of remaining in the study while negative coefficients denote factors that 





Appendix 3.A: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Theophylline1 
 
 Full-Cohort Propensity Score Subgroup-Specific Propensity Scores  
  Overall White Non-White 
Parameter Estimate Std. Error p Estimate 
Std. 
Error p Estimate 
Std. 
Error  p 
Intercept -0.72 2.75 0.79 -1.43 3.74 0.70 51.48 997.40 0.96 
Non-White 0.27 0.35 0.44 -- -- -- -- -- -- 
Time At One Month 2.18 0.43 <.0001 2.11 0.53 <.0001 3.56 1.19 0.00 
Time At Three Months 2.63 0.49 <.0001 3.64 0.82 <.0001 2.42 0.81 0.00 
Previous treatment with  -5.72 1.38 <.0001 -5.72 1.53 0.00 -30.27 400.90 0.94 
Age -0.01 0.01 0.51 -0.03 0.02 0.03 0.05 0.03 0.07 
Male 0.26 0.41 0.52 0.16 0.55 0.76 -0.70 0.92 0.45 
Previous ASUI score -0.75 1.21 0.53 -0.36 1.72 0.84 -2.25 2.81 0.42 
Previous Pre-BD FEV1, % predicted 0.01 0.03 0.86 0.06 0.05 0.26 -0.10 0.07 0.13 
Previous Pre-BD FVC, % predicted -0.05 0.04 0.17 -0.10 0.06 0.08 -0.01 0.06 0.86 
Previous Post-BD FEV1, % predicted -0.02 0.03 0.63 -0.06 0.05 0.23 0.08 0.08 0.27 
Previous Post-BD FVC, % predicted 0.05 0.03 0.15 0.10 0.06 0.08 0.01 0.05 0.87 
Previous Peak Flow, % predicted 0.02 0.01 0.05 0.01 0.02 0.71 0.04 0.03 0.11 
Previous use of anticholinergics 0.92 0.86 0.28 0.85 1.14 0.46 2.52 1.82 0.17 
Previous use of long-acting beta agonists -0.12 0.46 0.80 0.23 0.58 0.69 -1.06 1.10 0.34 
Previous use of short-acting beta agonists 0.24 0.33 0.48 0.18 0.45 0.68 0.86 0.77 0.26 
Previous use of combination drugs 0.00 0.39 1.00 0.58 0.52 0.26 -0.68 0.89 0.45 
Previous use of inhaled corticosteroids 0.05 0.41 0.89 -0.22 0.53 0.68 0.75 0.76 0.32 
Previous complaint of nausea -0.72 1.19 0.55 0.38 1.33 0.78 -9.14 151.70 0.95 
Previous complaint of vomiting 2.08 1.59 0.19 1.29 1.93 0.50 2.05 926.70 1.00 
Previous complaint of poor appetite 0.34 0.79 0.66 0.89 1.06 0.40 -10.47 168.40 0.95 
Previous complaint of heartburn -0.67 0.65 0.30 -0.53 0.81 0.51 -10.25 177.80 0.95 
Previous complaint of headaches -0.08 0.45 0.86 0.14 0.59 0.81 -0.75 1.14 0.51 
Previous complaint of insomnia 0.32 0.46 0.48 -0.06 0.59 0.91 1.44 1.14 0.21 
Previous complaint of anxiety 0.79 0.56 0.16 0.98 0.71 0.17 0.41 1.36 0.76 
Previous complaint of tremors -0.53 1.24 0.67 0.11 1.76 0.95 -10.36 156.20 0.95 
Previous complaint of heart palpitations -1.08 1.06 0.31 -0.83 1.41 0.56 -10.65 156.00 0.95 
Previous complaint of skin rash -0.40 1.16 0.73 0.24 1.41 0.87 -10.41 224.20 0.96 
Previous visit to the hospital -0.39 0.94 0.68 -0.93 1.22 0.45 2.15 1.60 0.18 
Previous visit to a doctor 0.11 0.42 0.80 0.30 0.57 0.59 -0.03 0.96 0.97 
1) Positive coefficients represent factors that increased the probability of receiving theophylline while negative coefficients denote factors that 




Appendix 3.B: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Montelukast1 
 
 Full-Cohort Propensity Score Subgroup-Specific Propensity Scores  
  Overall White Non-White 
Parameter Estimate Std. Error p Estimate 
Std. 
Error p Estimate 
Std. 
Error p 
Intercept 0.80 3.14 0.80 6.08 1201.6 1.00 19.93 1488.0 0.99 
Non-White -0.28 0.36 0.43 -- -- -- -- -- -- 
Time At One Month 2.78 0.47 <.0001 3.52 0.73 <.0001 2.98 0.89 0.00 
Time At Three Months 3.16 0.57 <.0001 3.25 0.72 <.0001 4.13 1.21 0.00 
Previous treatment with -4.97 1.31 0.00 -4.26 1.52 0.01 -25.08 423.1 0.95 
Age 0.00 0.01 0.77 -0.01 0.02 0.51 0.03 0.03 0.31 
Male 0.32 0.40 0.42 0.32 0.59 0.59 1.23 0.85 0.15 
Previous ASUI score 1.72 1.11 0.12 2.30 1.50 0.13 1.48 2.18 0.50 
Previous Pre-BD FEV1, % predicted -0.03 0.03 0.39 -0.03 0.04 0.49 -0.03 0.07 0.62 
Previous Pre-BD FVC, % predicted 0.01 0.03 0.59 0.01 0.04 0.83 0.03 0.05 0.59 
Previous Post-BD FEV1, % predicted 0.02 0.03 0.47 0.04 0.05 0.45 0.05 0.06 0.39 
Previous Post-BD FVC, % predicted -0.03 0.02 0.28 -0.04 0.05 0.45 -0.05 0.04 0.24 
Previous Peak Flow, % predicted -0.02 0.01 0.08 -0.02 0.02 0.30 -0.04 0.02 0.11 
Previous use of anticholinergics 0.62 0.88 0.48 0.43 1.28 0.74 0.87 1.67 0.60 
Previous use of long-acting beta agonists -0.27 0.50 0.59 -0.97 0.70 0.17 0.75 1.13 0.51 
Previous use of short-acting beta agonists -0.30 0.38 0.43 0.10 0.51 0.85 -0.63 0.78 0.42 
Previous use of combination drugs -0.56 0.44 0.20 -0.89 0.60 0.13 -0.33 0.85 0.69 
Previous use of inhaled corticosteroids -0.66 0.43 0.12 -0.85 0.62 0.17 -1.03 0.90 0.26 
Previous complaint of nausea -0.10 1.28 0.94 -0.29 1.60 0.86 -7.32 323.7 0.98 
Previous complaint of vomiting 0.39 1.57 0.80 -0.93 1.97 0.64 32.11 1485.3 0.98 
Previous complaint of poor appetite 1.35 1.19 0.26 1.70 1.55 0.27 -9.33 351.5 0.98 
Previous complaint of heartburn -0.85 0.76 0.26 -1.06 1.16 0.36 -0.53 1.42 0.71 
Previous complaint of headaches 0.57 0.43 0.18 1.00 0.61 0.10 1.65 0.92 0.07 
Previous complaint of insomnia -0.49 0.55 0.38 -0.71 0.80 0.37 -0.18 1.06 0.87 
Previous complaint of anxiety 0.60 0.65 0.36 0.18 0.91 0.84 0.89 1.36 0.51 
Previous complaint of tremors -1.05 2.21 0.64 -9.99 1201.6 0.99 0.43 388.9 1.00 
Previous complaint of heart palpitations 0.25 1.19 0.83 4.59 2.08 0.03 -12.55 175.5 0.94 
Previous complaint of skin rash 1.81 1.04 0.08 1.70 1.59 0.28 -12.14 295.0 0.97 
Previous visit to the hospital -0.45 1.01 0.66 1.53 1.46 0.29 -12.89 183.1 0.94 
Previous visit to a doctor 0.32 0.42 0.44 0.10 0.55 0.85 0.61 0.87 0.48 
1) Positive coefficients represent factors that increased the probability of receiving montelukast while negative coefficients denote factors that 





Appendix 3.C: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Model for Placebo1 
 
 Full-Cohort Propensity Score Subgroup-Specific Propensity Scores  
  Overall White Non-White 
Parameter Estimate Std. Error p Estimate 
Std. 
Error p Estimate 
Std. 
Error p 
Intercept -8.04 3.52 0.02 -13.14 5.18 0.01 13.84 271.1 0.96 
Non-White 0.24 0.44 0.58 -- -- -- -- -- -- 
Time At One Month 4.88 0.84 <.0001 5.38 1.16 <.0001 8.76 2.95 0.00 
Time At Three Months 4.50 0.85 <.0001 4.12 1.00 <.0001 15.82 24.06 0.51 
Previous treatment with -18.43 736.1 0.98 -15.21 665.4 0.98 -23.31 1068.3 0.98 
Age 0.00 0.02 0.90 -0.01 0.02 0.67 0.06 0.04 0.14 
Male -0.31 0.48 0.52 -0.81 0.68 0.24 1.97 1.61 0.22 
Previous ASUI score 3.88 1.56 0.01 3.47 2.21 0.12 5.65 5.06 0.26 
Previous Pre-BD FEV1, % predicted -0.02 0.05 0.74 -0.05 0.07 0.46 0.04 0.13 0.74 
Previous Pre-BD FVC, % predicted 0.07 0.04 0.11 0.09 0.05 0.10 0.00 0.15 0.98 
Previous Post-BD FEV1, % predicted 0.00 0.05 0.98 0.03 0.06 0.67 -0.09 0.14 0.53 
Previous Post-BD FVC, % predicted -0.06 0.04 0.15 -0.07 0.05 0.15 -0.01 0.13 0.94 
Previous Peak Flow, % predicted -0.01 0.01 0.42 0.02 0.02 0.44 -0.09 0.04 0.03 
Previous use of anticholinergics -0.02 1.42 0.99 -0.29 2.31 0.90 -10.73 56.44 0.85 
Previous use of long-acting beta agonists -0.16 0.62 0.80 0.22 0.79 0.78 -2.19 2.26 0.33 
Previous use of short-acting beta agonists -0.03 0.40 0.93 -0.65 0.54 0.23 1.51 1.15 0.19 
Previous use of combination drugs 0.99 0.56 0.08 1.93 0.83 0.02 0.55 1.40 0.69 
Previous use of inhaled corticosteroids 1.25 0.57 0.03 1.83 0.86 0.03 1.35 1.49 0.36 
Previous complaint of nausea 0.81 0.82 0.32 1.68 1.09 0.12 1.41 10.09 0.89 
Previous complaint of vomiting 0.99 1.11 0.38 1.14 1.30 0.38 2.32 168.30 0.99 
Previous complaint of poor appetite 0.47 1.30 0.72 -0.70 1.91 0.71 2.19 3.80 0.57 
Previous complaint of heartburn 0.77 0.77 0.32 0.27 0.93 0.77 2.40 2.52 0.34 
Previous complaint of headaches 0.11 0.57 0.85 -0.09 0.75 0.91 1.51 1.71 0.38 
Previous complaint of insomnia 0.25 0.54 0.64 0.11 0.74 0.88 2.02 1.77 0.25 
Previous complaint of anxiety 1.11 0.75 0.14 0.98 0.98 0.31 0.70 2.49 0.78 
Previous complaint of tremors 1.18 1.11 0.29 3.00 1.80 0.10 1.61 3.97 0.69 
Previous complaint of heart palpitations -0.33 1.63 0.84 2.02 2.69 0.45 -8.74 106.4 0.93 
Previous complaint of skin rash -0.58 1.33 0.66 -0.72 1.32 0.59 -1.91 175.3 0.99 
Previous visit to the hospital 0.46 1.04 0.66 0.12 1.34 0.93 -2.53 3.39 0.46 
Previous visit to a doctor 0.97 0.50 0.05 1.58 0.69 0.02 2.29 1.70 0.18 
1) Positive coefficients represent factors that increased the probability of receiving placebo while negative coefficients denote factors that 





Appendix 4.A: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Models Using Self-
Reported Adherence1 
 
Analysis of Maximum Likelihood Estimates 














Intercept 2.604 3.052 0.728 0.394 14.405 925.4 0.000 0.988 
Time At One Month -0.595 0.484 1.515 0.218 -0.460 0.465 0.977 0.323 
Time At Three Months 0.321 0.473 0.459 0.498 -0.365 0.448 0.664 0.415 
Previous treatment with -2.580 0.483 28.581 <.0001 -1.854 0.505 13.501 0.000 
Age -0.015 0.013 1.403 0.236 -0.024 0.014 2.943 0.086 
Male 1.186 0.574 4.275 0.039 0.439 0.467 0.882 0.348 
Black Race 0.217 0.414 0.273 0.601 -0.001 0.495 0.000 0.998 
Other Race 1.328 0.872 2.320 0.128 -0.462 0.467 0.978 0.323 
Previous ASUI score 1.493 1.146 1.699 0.193 0.978 1.132 0.746 0.388 
Previous Pre-BD FEV1, % predicted -0.037 0.034 1.179 0.278 -0.045 0.038 1.384 0.239 
Previous Pre-BD FVC, % predicted 0.037 0.031 1.412 0.235 0.032 0.031 1.098 0.295 
Previous Post-BD FEV1, % predicted 0.024 0.033 0.509 0.476 0.065 0.038 2.861 0.091 
Previous Post-BD FVC, % predicted -0.051 0.027 3.493 0.062 -0.060 0.028 4.663 0.031 
Previous Peak Flow, % predicted 0.017 0.012 1.931 0.165 -0.003 0.011 0.069 0.793 
Previous use of anticholinergics -1.030 1.192 0.747 0.388 0.574 0.689 0.695 0.405 
Previous use of long-acting beta agonists 0.441 0.507 0.756 0.385 -0.190 0.486 0.153 0.696 
Previous use of short-acting beta agonists 0.313 0.370 0.715 0.398 0.124 0.386 0.103 0.748 
Previous use of combination drugs -0.026 0.425 0.004 0.952 -0.296 0.452 0.429 0.512 
Previous use of inhaled corticosteroids -0.380 0.439 0.749 0.387 -0.153 0.439 0.121 0.728 
Previous complaint of nausea 1.317 0.671 3.854 0.050 -0.663 1.049 0.400 0.527 
Previous complaint of vomiting -0.172 1.331 0.017 0.897 0.592 1.475 0.161 0.688 
Previous complaint of poor appetite -0.567 0.906 0.392 0.531 0.526 1.164 0.204 0.651 
Previous complaint of heartburn 0.149 0.620 0.058 0.810 -0.071 0.566 0.016 0.901 
Previous complaint of headaches -0.114 0.450 0.064 0.800 0.465 0.424 1.200 0.273 
Previous complaint of insomnia 0.246 0.452 0.295 0.587 -0.789 0.576 1.874 0.171 
Previous complaint of anxiety 0.728 0.553 1.733 0.188 1.147 0.626 3.361 0.067 
Previous complaint of tremors 1.278 1.140 1.257 0.262 -13.590 925.4 0.000 0.988 
Previous complaint of heart palpitations -0.910 1.126 0.654 0.419 0.651 0.940 0.480 0.489 
Previous complaint of skin rash 0.352 1.443 0.060 0.807 0.249 1.025 0.059 0.808 
Previous visit to the hospital -1.278 0.954 1.793 0.181 0.715 0.811 0.777 0.378 
Previous visit to a doctor -0.160 0.419 0.146 0.703 0.256 0.418 0.374 0.541 
1) Positive coefficients represent factors that increased the probability of receiving their assigned treatment while negative coefficients denote 
factors that decreased the probability of receiving their assigned treatment, i.e. previous treatment  
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Appendix 4.B: Coefficients Obtained from the Denominator of the Pooled Logistic Treatment Models Using Blood 
Assay Adherence1  
 Analysis of Maximum Likelihood Estimates 














Intercept -6.011 3.075 3.823 0.051 13.696 526.4 0.001 0.979 
Time At One Month 1.031 0.378 7.424 0.006 0.062 0.366 0.029 0.866 
Previous treatment with -1.238 0.585 4.475 0.034 -1.355 0.512 7.013 0.008 
Age 0.026 0.012 4.543 0.033 0.002 0.012 0.023 0.881 
Male 0.054 0.407 0.017 0.895 0.537 0.375 2.054 0.152 
Black Race 0.220 0.377 0.341 0.559 -0.189 0.391 0.235 0.628 
Other Race 1.051 0.726 2.092 0.148 0.078 0.470 0.028 0.868 
Previous ASUI score 2.019 1.064 3.597 0.058 0.412 1.118 0.136 0.712 
Previous Pre-BD FEV1, % predicted 0.057 0.031 3.349 0.067 -0.038 0.023 2.758 0.097 
Previous Pre-BD FVC, % predicted -0.018 0.032 0.310 0.578 0.026 0.022 1.390 0.238 
Previous Post-BD FEV1, % predicted -0.059 0.033 3.091 0.079 0.005 0.026 0.031 0.859 
Previous Post-BD FVC, % predicted 0.017 0.030 0.305 0.581 -0.010 0.022 0.209 0.648 
Previous Peak Flow, % predicted 0.002 0.012 0.036 0.849 0.007 0.010 0.598 0.440 
Previous use of anticholinergics 0.540 0.879 0.378 0.539 -0.655 0.882 0.552 0.458 
Previous use of long-acting beta agonists 0.739 0.470 2.475 0.116 -0.234 0.425 0.303 0.582 
Previous use of short-acting beta agonists 0.178 0.350 0.259 0.611 -0.020 0.349 0.003 0.954 
Previous use of combination drugs -0.046 0.399 0.013 0.909 -0.294 0.368 0.638 0.424 
Previous use of inhaled corticosteroids -0.676 0.412 2.693 0.101 -0.445 0.389 1.312 0.252 
Previous complaint of nausea 0.354 0.661 0.286 0.593 0.446 1.190 0.141 0.708 
Previous complaint of vomiting -0.512 1.475 0.121 0.728 0.455 1.848 0.061 0.805 
Previous complaint of poor appetite -0.505 1.084 0.217 0.642 -0.607 1.452 0.175 0.676 
Previous complaint of heartburn -0.496 0.657 0.570 0.450 -0.481 0.562 0.732 0.392 
Previous complaint of headaches 0.561 0.409 1.879 0.171 0.243 0.393 0.381 0.537 
Previous complaint of insomnia -0.246 0.468 0.276 0.600 -1.192 0.481 6.141 0.013 
Previous complaint of anxiety 0.590 0.619 0.910 0.340 0.380 0.701 0.294 0.588 
Previous complaint of tremors 2.086 1.498 1.940 0.164 -0.188 1.890 0.010 0.921 
Previous complaint of heart palpitations 0.299 1.076 0.077 0.781 0.485 1.307 0.138 0.711 
Previous complaint of skin rash 1.197 1.107 1.169 0.280 2.524 1.462 2.981 0.084 
Previous visit to the hospital 0.512 0.843 0.369 0.544 -13.712 526.4 0.001 0.979 
Previous visit to a doctor 0.024 0.396 0.004 0.952 0.107 0.379 0.080 0.778 
1) Positive coefficients represent factors that increased the probability of receiving assigned treatment while negative coefficients denote factors 






Appendix 4.C:  Coefficients Obtained from the Denominator of the Pooled Logistic Censoring Models1 
 Analysis of Maximum Likelihood Estimates – Censoring for All Groups 














Intercept 12.192 730.3 0.000 0.987 -2.142 2.433 0.776 0.379 
Time At Baseline 14.187 203.4 0.005 0.944 15.132 185.4 0.007 0.935 
Time At One Month -1.502 0.348 18.626 <.0001 0.052 0.255 0.042 0.839 
Time At Three Months 2.743 1.052 6.803 0.009 --- --- --- --- 
Assigned to theophylline -0.537 1.020 0.277 0.599 0.552 0.565 0.954 0.329 
Currently on theophylline 0.507 0.642 0.625 0.429 1.175 0.502 5.487 0.019 
Currently on montelukast 0.619 0.861 0.516 0.473 0.760 0.401 3.589 0.058 
Age 0.033 0.012 7.530 0.006 0.016 0.010 2.821 0.093 
Male -0.086 0.341 0.064 0.801 0.085 0.290 0.085 0.771 
Black -0.628 0.318 3.889 0.049 -0.396 0.279 2.014 0.156 
Other Race -0.255 0.480 0.281 0.596 0.003 0.424 0 0.995 
ASUI score 0.472 0.952 0.245 0.620 2.226 0.797 7.797 0.005 
Pre-BD FEV1, % predicted -0.016 0.022 0.530 0.467 -0.027 0.025 1.128 0.288 
Pre-BD FVC, % predicted 0.035 0.024 2.207 0.137 0.022 0.024 0.832 0.362 
Post-BD FEV1, % predicted 0.002 0.025 0.004 0.951 0.016 0.026 0.398 0.528 
Post-BD FVC, % predicted -0.011 0.023 0.241 0.623 -0.004 0.023 0.023 0.879 
Peak Flow, % predicted -0.013 0.009 1.993 0.158 -0.006 0.008 0.536 0.464 
Use of anticholinergics -0.544 1.104 0.243 0.622 -1.367 1.085 1.587 0.208 
Use of long-acting beta agonists -0.127 0.422 0.090 0.764 -0.335 0.386 0.754 0.385 
Use of short-acting beta agonists 0.138 0.309 0.199 0.656 0.322 0.260 1.537 0.215 
Use of combination drugs 0.198 0.346 0.326 0.568 0.061 0.302 0.041 0.839 
Use of inhaled corticosteroids 0.210 0.378 0.308 0.579 0.361 0.315 1.319 0.251 
Complaint of nausea -1.630 1.072 2.312 0.128 0.107 0.555 0.037 0.848 
Complaint of vomiting -12.346 730.3 0.000 0.987 -0.686 1.267 0.293 0.588 
Complaint of poor appetite 0.796 0.733 1.179 0.278 0.487 0.692 0.495 0.482 
Complaint of heartburn 0.469 0.499 0.886 0.347 0.031 0.427 0.005 0.942 
Complaint of headaches -0.125 0.386 0.105 0.746 0.235 0.302 0.607 0.436 
Complaint of insomnia -0.256 0.386 0.437 0.508 -0.424 0.341 1.547 0.214 
Complaint of anxiety -0.074 0.551 0.018 0.894 0.323 0.484 0.446 0.504 
Complaint of tremors -0.662 1.163 0.324 0.569 -0.378 0.764 0.244 0.621 
Complaint of heart palpitations 1.161 0.876 1.760 0.185 0.093 0.758 0.015 0.903 
Complaint of skin rash 1.202 0.645 3.473 0.062 0.927 0.583 2.531 0.112 
Visit to the hospital 0.197 0.862 0.052 0.819 0.256 0.736 0.121 0.728 
Visit to a doctor 1.367 0.317 18.552 <.0001 0.162 0.304 0.285 0.594 
1) Positive coefficients represent factors that increased the probability of being censored while negative coefficients denote factors that decreased 
the probability of being censored 
 
